Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.25.1 - proteasome endopeptidase complex

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abnormalities, Multiple
Role of the deubiquitylating enzyme DmUsp5 in coupling ubiquitin equilibrium to development and apoptosis in Drosophila melanogaster.
Abortion, Spontaneous
Proteomic analysis on the alteration of protein expression in the placental villous tissue of early pregnancy loss.
Acidosis
Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle.
Acidosis and glucocorticoids interact to provoke muscle protein and amino acid catabolism.
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Metabolic acidosis as a uremic toxin.
Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes.
Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle.
The search for the uremic toxin: the case for metabolic acidosis.
TSS-Seq analysis of low pH-induced gene expression in intercalated cells in the renal collecting duct.
Acne Vulgaris
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Acquired Immunodeficiency Syndrome
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Protein degradation and apoptotic death in lymphocytes during Fiv infection: activation of the ubiquitin-proteasome proteolytic system.
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.
The proteasome: a new target for novel drug therapies.
Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients.
Acute Coronary Syndrome
Assessing performance of prediction rules in machine learning.
Acute Kidney Injury
Different roles of bortezomib and ONX 0914 in acute kidney injury.
Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity.
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats.
Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats.
Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.
Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.
Proteasome participates in the pathogenesis of ischemic acute renal failure in rats.
Thrombotic microangiopathy associated with proteasome inhibitors.
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Acute Lung Injury
Age influences inflammatory responses, hemodynamics, and cardiac proteasome activation during acute lung injury.
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury.
Adenocarcinoma
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition.
A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
An Investigation Into the Prognostic Significance of High Proteasome PSB7 Protein Expression in Colorectal Cancer.
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib.
Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia.
Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells.
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Genetic and epigenetic changes in stomach cancer.
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy.
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Targeting NF-?B in mouse models of lung adenocarcinoma.
Uncovering growth-suppressive MicroRNAs in lung cancer.
Adenocarcinoma of Lung
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Expression pattern of parkin isoforms in lung adenocarcinomas.
Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.
Response and resistance to NF-?B inhibitors in mouse models of lung adenocarcinoma.
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
The Silence of PSMC6 Inhibits Cell Growth and Metastasis in Lung Adenocarcinoma.
Adenoma
Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo.
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Adenomatous Polyposis Coli
New helpers in TF dependent migration.
Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines.
Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein.
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
Adenoviridae Infections
Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
Adrenocortical Carcinoma
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Adrenoleukodystrophy
Adrenoleukodystrophy: subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations.
Airway Obstruction
Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.
Alexander Disease
Adaptive autophagy in Alexander disease-affected astrocytes.
In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.
Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.
Alzheimer Disease
18?-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures.
20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.
20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients.
4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease.
?-Secretase 1's Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice.
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
Alzheimer's disease associated presenilin 1 interacts with HC5 and ZETA, subunits of the catalytic 20S proteasome.
Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome.
Amyloid-? Secretion, Generation, and Lysosomal Sequestration in Response to Proteasome Inhibition: Involvement of Autophagy.
Analysis of gene expression in neural cells subject to chronic proteasome inhibition.
Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms?
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.
Binding of amyloid beta protein to the 20 S proteasome.
Characterization of chronic low-level proteasome inhibition on neural homeostasis.
Characterization of proteasome inhibition on astrocytes cell cycle.
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Contribution of the proteasome to the alpha-secretase pathway in Alzheimer's disease.
Copper: from neurotransmission to neuroproteostasis.
Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer's disease.
Divergent effect of proteasome inhibition on interleukin-1beta and tumor necrosis factor alpha signaling in human astroglial cells.
Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease?
Effects of tau phosphorylation on proteasome activity.
Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease.
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation.
Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: Association with neurofibrillary tangle pathology.
Impaired proteasome function in Alzheimer's disease.
Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.
Lactacystin Stimulates Stellation of Cultured Rat Cortical Astrocytes.
LMP2 inhibitors as a potential treatment for Alzheimer's disease.
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis?
Molecular Basis of Etiological Implications in Alzheimer's Disease: Focus on Neuroinflammation.
Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer's disease.
Optimization of in vitro measurement of proteasome activity in mammalian cells using fluorogenic substrates.
Oxidative inactivation of the proteasome in Alzheimer's disease.
Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome.
Peptidase activities of the 20/26S proteasome and a novel protease in human brain.
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction.
Physiology of the Alzheimer's disease.
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
Presenilin 1 forms aggresomal deposits in response to heat shock.
Production of active glycosylation-deficient ?-secretase complex for crystallization studies.
Proteasome Assay in Cell Lysates.
Proteasome degradation of brain cytosolic tau in Alzheimer's disease.
Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover.
Proteasome inhibition and Tau proteolysis: an unexpected regulation.
Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.
Proteasome inhibition increases tau accumulation independent of phosphorylation.
Proteasome inhibition induces stress kinase dependent transport deficits--implications for Alzheimer's disease.
Proteasome modulator 9 (PSMD9) gene rs14259 polymorphism in Alzheimer's disease.
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site.
Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.
Protein ubiquitination, degradation and the proteasome in neuro-degenerative disorders: no clear evidence for a significant pathogenetic role of proteasome failure in Alzheimer disease and related disorders.
Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from ?-Amyloid Toxicity.
Reactive glia show increased immunoproteasome activity in Alzheimer's disease.
Regulation of aberrant proteasome activity re-establishes plasticity and long-term memory in an animal model of Alzheimer's disease.
Review: Unchained maladie - a reassessment of the role of Ubb(+1) -capped polyubiquitin chains in Alzheimer's disease.
Role of the proteasome in Alzheimer's disease.
Role of the ubiquitin proteasome system in Alzheimer's disease.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Soluble a? promotes wild-type tau pathology in vivo.
Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators.
The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.
The Proteasome and Oxidative Stress in Alzheimer's Disease.
The Proteasome Function Reporter GFPu Accumulates in Young Brains of the APPswe/PS1dE9 Alzheimer's Disease Mouse Model.
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
The role of the ubiquitin proteasome system in Alzheimer's disease.
Transcriptome sequencing (RNA-seq) analysis of the effects of metal nanoparticle exposure on the transcriptome of Chlamydomonas reinhardtii.
Ubiquitin binds the amyloid ? peptide and interferes with its clearance pathways.
Unexpected beta-amyloid production by middle doses of resveratrol through stabilization of APP protein and AMPK-mediated inhibition of trypsin-like proteasome activity in a cell model of Alzheimer's disease.
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Amebiasis
The effect of peptidic and non-peptidic proteasome inhibitors on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype.
aminopeptidase i deficiency
Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.
Amnesia, Retrograde
The ubiquitin-proteasome cascade is required for mammalian long-term memory formation.
Amyloidosis
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients.
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
Functional proteasome complex is required for turnover of islet amyloid polypeptide in pancreatic ?-cells.
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Neuropathy Associated with Systemic Amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Systemic Amyloidosis: a Contemporary Overview.
The proteasome in terminal plasma cell differentiation.
Amyotrophic Lateral Sclerosis
Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways.
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Biological and Pathological Implications of an Alternative ATP-Powered Proteasomal Assembly With Cdc48 and the 20S Peptidase.
Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons.
Expression of ubiquitin and proteasome in motorneurons and astrocytes of spinal cords from patients with amyotrophic lateral sclerosis.
Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis.
Impaired proteasome function in sporadic amyotrophic lateral sclerosis.
Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
Proteasome Activation is a Mechanism for Pyrazolone Small Molecules Displaying Therapeutic Potential in Amyotrophic Lateral Sclerosis.
Proteasome Assay in Cell Lysates.
Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis.
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Tdp-25 Routing to Autophagy and Proteasome Ameliorates its Aggregation in Amyotrophic Lateral Sclerosis Target Cells.
Anemia
Budding of equine infectious anemia virus is insensitive to proteasome inhibitors.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
Late domain-dependent inhibition of equine infectious anemia virus budding.
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Retroviruses have differing requirements for proteasome function in the budding process.
Anemia, Diamond-Blackfan
Study of the effects of proteasome inhibitors on ribosomal protein S19 (RPS19) mutants, identified in patients with Diamond-Blackfan anemia.
Anemia, Hemolytic
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Anemia, Sickle Cell
Proteasome Inhibition Induces Both Antioxidant and Hb F Responses in Sickle Cell Disease Via the Nrf2 Pathway.
Angelman Syndrome
Angelman syndrome-associated point mutations in the Zn-binding N-terminal (AZUL) domain of UBE3A ubiquitin ligase inhibit binding to the proteasome.
Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome.
Angiomyolipoma
Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Anhedonia
[Signs of anhedonia and destructive changes in the ventral tegmental area of the midbrain in the model of the preclinical Parkinson's disease stage in experiment].
Anthrax
Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome.
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Heat shock inhibits caspase-1 activity while also preventing its inflammasome-mediated activation by anthrax lethal toxin.
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Proteasome activity is required for anthrax lethal toxin to kill macrophages.
Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin.
Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay.
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis.
Aortic Aneurysm, Abdominal
Effect of Bortezomib on Angiotensin ?-induced Abdominal Aortic Aneurysm in ApoE
Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.
Appendicitis
Concentration of Proteasome in the Blood Plasma of Children with Acute Appendicitis, Before and After Surgery, and Its Correlation with CRP.
Determination of the concentration of cathepsin B by SPRI biosensor in children with appendicitis, and its correlation with proteasomes.
Immunoproteasome in the of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.
Arrhythmias, Cardiac
MG132 proteasome inhibitor upregulates the expression of connexin 43 in rats with adriamycin-induced heart failure.
Reducing treatment toxicity in Waldenström macroglobulinemia.
Arrhythmogenic Right Ventricular Dysplasia
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Arthritis
Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132.
Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262.
Juvenile Idiopathic Arthritis Subtype- and Sex-specific Associations with Genetic Variants in the PSMA6/PSMC6/PSMA3 Gene Cluster.
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis.
Proteasome inhibition aggravates TNF-mediated bone resorption.
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Arthritis, Experimental
Proteasome inhibitor MG132 modulates inflammatory pain by central mechanisms in adjuvant arthritis.
Arthritis, Juvenile
Juvenile Idiopathic Arthritis Subtype- and Sex-specific Associations with Genetic Variants in the PSMA6/PSMC6/PSMA3 Gene Cluster.
Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis.
Arthritis, Psoriatic
Anti-20S Proteasome Antibodies in Psoriatic Arthritis.
Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
Arthritis, Rheumatoid
Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis.
Cardiac complications may be higher with use of proteasome inhibitors in patients with rheumatoid arthritis.
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis.
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
Proteasome inhibition: a new anti-inflammatory strategy.
Regulation of synovial cell apoptosis by proteasome inhibitor.
Response to abatacept is associated with the inhibition of proteasome ?1i expression in T cells of patients with rheumatoid arthritis.
Role of ADAM17, p38 MAPK, cathepsins, and proteasome pathway in the synthesis and shedding of fractalkine/CX3CL1 in rheumatoid arthritis.
The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Asthenozoospermia
Proteomics-based study on asthenozoospermia: differential expression of proteasome alpha complex.
Asthma
Long-Term Bortezomib Treatment Reduces Allergen-Specific IgE but Fails to Ameliorate Chronic Asthma in Mice.
Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion.
Proteasome inhibition: A novel mechanism to combat asthma.
Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice.
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Astrocytoma
Decreased proteasomal cleavage at nitrotyrosine sites in proteins and peptides.
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
Ataxia
Are Huntington's and polyglutamine-based ataxias proteasome storage diseases?
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly.
Ataxia Telangiectasia
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks.
The Role of the Nuclear Factor ?B Pathway in the Cellular Response to Low and High Linear Energy Transfer Radiation.
Atherosclerosis
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
A Practical Review of Proteasome Pharmacology.
Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis.
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Changes in expression of proteasome in rats at different stages of atherosclerosis.
Chronic proteasome inhibition contributes to coronary atherosclerosis.
Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262.
Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients.
Efficacy of Qingre Huayu Fang on atherosclerotic vulnerable plaque in apolipoprotein E knockout mice: proteasome pathway involvement.
Integrated analysis of microarray data of atherosclerotic plaques: modulation of the ubiquitin-proteasome system.
New advances in drug discovery.
On to the Road to Degradation - Atherosclerosis and the Proteasome.
Physiological and pathological role of the ubiquitin-proteasome system in the vascular smooth muscle cell.
Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis.
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Relationship of the 20S proteasome and the proteasome activator PA28 to atherosclerosis and intimal hyperplasia in the human vascular system.
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
Targeting proteasome worsens atherosclerosis.
Targeting the Ubiquitin-Proteasome System in Atherosclerosis: Status Quo, Challenges, and Perspectives.
The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice.
The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes.
The proteasome: a central regulator of inflammation and macrophage function.
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
The ubiquitin-proteasome system and cardiovascular disease.
[Proteasome activity changes in the aorta, heart tissues, and blood leucocytes in modelling of cholesterol atherosclerosis]
Atrial Fibrillation
Genetic ablation and pharmacological inhibition of immunosubunit ?5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice.
Autoimmune Diseases
A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.
A Minimal ?-Lactone Fragment for Selective ?5c or ?5i Proteasome Inhibitors.
A Practical Review of Proteasome Pharmacology.
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells.
Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells.
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
Bladder cancer detection using a peptide substrate of the 20S proteasome.
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.
Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
Celastrol causes apoptosis and cell cycle arrest in rat glioma cells.
Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond.
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases.
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Development of proteasome inhibitors in oncology and autoimmune diseases.
Diagnostic importance of anti-proteasome antibodies.
Drug discovery and assay development in the ubiquitin-proteasome system.
Heightened levels of circulating 20S proteasome in critically ill patients.
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
Peptide-Based Proteasome Inhibitors in Anticancer Drug Design.
Polymorphisms of TAP, LMP and HLA-DM genes in the Chinese.
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice.
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Proteasome antibodies in paraneoplastic cerebellar degeneration.
Proteasome Immunosubunits Protect against the Development of CD8 T Cell-Mediated Autoimmune Diseases.
Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren's syndrome.
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Proteolytic dynamics of human 20S thymoproteasome.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site.
Selective proteasome inhibitors: modulators of antigen presentation?
Significance of increased circulating proteasome in autoimmune disease.
Small-molecule inhibitors of proteasome activity.
Subunit specific inhibitors of proteasomes and their potential for immunomodulation.
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
The capture proteasome assay: A method to measure proteasome activity in vitro.
The proteasome - victim or culprit in autoimmunity.
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Azoospermia
Ehrlichia chaffeensis TRP32 interacts with host cell targets that influence intracellular survival.
Babesiosis
Validation of Babesia proteasome as a drug target.
Bacterial Infections
Pathogen-associated Molecular Pattern-triggered Immunity Involves Proteolytic Degradation of Core Nonsense-mediated mRNA Decay Factors During the Early Defense Response.
Subunit-selective proteasome activity profiling uncovers uncoupled proteasome subunit activities during bacterial infections.
The 11S Proteasome Subunit PSME3 Is a Positive Feedforward Regulator of NF-?B and Important for Host Defense against Bacterial Pathogens.
Behcet Syndrome
The proteasome is a major autoantigen in multiple sclerosis.
Biliary Tract Neoplasms
A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers.
Blepharitis
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.
Blindness
Temperature sensitive retinoid isomerase activity of RPE65 mutants associated with Leber congenital amaurosis.
Blister
Apoptosis in steroidogenic cells: structure-function analysis.
Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Bone Diseases
Advances in the biology and treatment of myeloma bone disease.
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1.
Effects of proteasome inhibitors on bone cancer.
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Myeloma bone disease and proteasome inhibition therapies.
Pain Management in Patients with Multiple Myeloma: An Update.
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease.
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
Proteasome inhibitors and bone disease.
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1; A Potential Therapeutic Strategy for Myeloma Bone Disease.
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
The Proteasome and Myeloma-Associated Bone Disease.
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
[Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].
[The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease].
Bone Neoplasms
Effects of proteasome inhibitors on bone cancer.
Bone Resorption
Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
Current Controversies in the Management of Myeloma Bone Disease.
ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation.
HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
Myeloma bone disease and proteasome inhibition therapies.
Proteasome inhibition aggravates TNF-mediated bone resorption.
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
[Pathophysiological and therapeutic aspects of bone lesions in patients with multiple myelomas]
Brain Concussion
Circulating proteasome activity following mild head injury in children.
Brain Diseases
Differential hippocampal gene expression and pathway analysis in an etiology-based mouse model of major depressive disorder.
Recent progress of imaging agents for Parkinson's disease.
Report of the first patient with a homozygous OTUD7A variant responsible for epileptic encephalopathy and related proteasome dysfunction.
Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.
Brain Edema
Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Brain Infarction
The role of the ubiquitin proteasome system in ischemia and ischemic tolerance.
Brain Injuries
Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition.
Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration.
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.
Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration.
Recovery from ischemic brain injury in the rat following a 10 h delayed injection with MLN519.
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Temporal Profiles of Stress Protein Inductions after Focal Transient Ischemia in Mice Brain.
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Voluntary exercise may engage proteasome function to benefit the brain after trauma.
Brain Injuries, Traumatic
Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model.
Mutation of a Ubiquitin Carboxy Terminal Hydrolase L1 Lipid Binding Site Alleviates Cell Death, Axonal Injury, and Behavioral Deficits After Traumatic Brain Injury in Mice.
Nrf2-ARE signaling provides neuroprotection in traumatic brain injury via modulation of the ubiquitin proteasome system.
Proteasome and Autophagy-Mediated Impairment of Late Long-Term Potentiation (l-LTP) after Traumatic Brain Injury in the Somatosensory Cortex of Mice.
Voluntary exercise may engage proteasome function to benefit the brain after trauma.
Brain Ischemia
Associations between Huwe1 and autophagy in rat cerebral neuron oxygen?glucose deprivation and reperfusion injury.
Excitotoxic stimulation downregulates the ubiquitin-proteasome system through activation of NMDA receptors in cultured hippocampal neurons.
Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia.
Inhibition of immunoproteasome promotes angiogenesis via enhancing hypoxia-inducible factor-1? abundance in rats following focal cerebral ischaemia.
Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.
Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation.
Possible contribution of proteins of Bcl-2 family in neuronal death following transient global brain ischemia.
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Proteasomal activity in brain tissue following ischemic stroke in Wistar rats.
Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia.
Protein aggregation and proteasome dysfunction after brain ischemia.
Proteolysis of oxidized proteins after oxygen-glucose deprivation in rat cortical neurons is mediated by the proteasome.
PSD-93 Interacts with SynGAP and Promotes SynGAP Ubiquitination and Ischemic Brain Injury in Mice.
Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
Suppression of proteasome C2 contralateral to ischemic lesions in rat brain.
The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Brain Neoplasms
Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients.
Enzymatic activity of extracellular circulating proteasome in the CSF of patients with malignant intrinsic and metastatic brain tumors: proof of concept.
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts.
Proteasome inhibition for the treatment of glioblastoma.
Proteasome inhibition-a new target for brain tumours.
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
Breast Neoplasms
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition.
A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.
A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells.
Advancing the Role of Gamma-Tocotrienol as Proteasomes Inhibitor: A Quantitative Proteomic Analysis of MDA-MB-231 Human Breast Cancer Cells.
An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells.
Anticancer activity and computational modeling of ternary copper (II) complexes with 3-indolecarboxylic acid and 1,10-phenanthroline.
Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/?-Catenin/ABCG2 Axis.
Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer.
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a pro-apoptotic unfolded protein response.
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
Breast Cancer Anti-Estrogen Resistance-3 inhibits transforming growth factor-ß/Smad signaling and associates with favorable breast cancer disease outcomes.
Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3? dependent mechanism.
Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation.
Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.
BU-32: a novel proteasome inhibitor for breast cancer.
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells.
Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells.
Circulating 20S proteasome in patients with non-metastasized breast cancer.
Cks1 proteasomal turnover is a predominant mode of regulation in breast cancer cells: role of key tyrosines and lysines.
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome.
Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes.
Cytotoxicity and Proteasome Inhibition by Alkaloid Extract from Murraya koenigii Leaves in Breast Cancer Cells-Molecular Docking Studies.
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway.
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary adenocarcinoma cells.
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Down-regulation of estrogen receptor-alpha in MCF-7 human breast cancer cells after proteasome inhibition.
Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells.
Dynamic interplay between breast cancer cells and normal endothelium mediates the expression of matrix macromolecules, proteasome activity and functional properties of endothelial cells.
Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells.
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.
Engineering Single Pan-Specific Ubiquibodies for Targeted Degradation of All Forms of Endogenous ERK Protein Kinase.
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Estrogen-Dependent Gene Transcription in Human Breast Cancer Cells Relies upon Proteasome-Dependent Monoubiquitination of Histone H2B.
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Expression of heme oxygenase-1 in response to proteasomal inhibition.
Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions.
Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.
Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.
Flavopiridol Induces Cellular FLICE-Inhibitory Protein Degradation by the Proteasome and Promotes TRAIL-Induced Early Signaling and Apoptosis in Breast Tumor Cells.
Gel-based chemical cross-linking analysis of 20S proteasome subunit-subunit interactions in breast cancer.
Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.
Growth factor regulation of a 26S proteasomal subunit in breast cancer.
GSK-3? signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
HERC1 Regulates Breast Cancer Cells Migration and Invasion.
Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells.
I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
In Vitro and In Vivo Antitumor Activities and DNA Binding Mode of Five Coordinated Cyclometalated Organoplatinum(II) Complexes Containing Biphosphine Ligands.
In vivo imaging, tracking, and targeting of cancer stem cells.
In Vivo Inhibition of Proteasome Activity and Tumour Growth by Murraya koenigii Leaf Extract in Breast Cancer Xenografts and by its active flavonoids in breast cancer cells.
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Increasing intratumor C/EBP-? LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation.
Inhibition of catechol-Omicron-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Inhibition of Paclitaxel-Induced Proteasome Activation Influences Paclitaxel Cytotoxicity in Breast Cancer Cells in a Sequence-Dependent Manner.
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes.
Interaction with Pyruvate Kinase M2 Destabilizes Tristetraprolin by Proteasome Degradation and Regulates Cell Proliferation in Breast Cancer.
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell.
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
LXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition.
Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening.
Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition.
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REG?.
Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.
Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ER? in Cells Modeling Primary and Metastatic Breast Cancer.
Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.
Oxygen levels do not determine radiation survival of breast cancer stem cells.
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.
Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation.
Proteasome affects the expression of aryl hydrocarbon receptor-regulated proteins.
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome functioning in breast cancer: connection with clinical-pathological factors.
Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs.
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-?B Signaling.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.
Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.
Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry.
PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
PSMD12 promotes glioma progression by upregulating the expression of Nrf2.
PSMD9 expression predicts radiotherapy response in breast cancer.
PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer.
RAC1B Induces SMAD7 via USP26 to Suppress TGF?1-Dependent Cell Migration in Mesenchymal-Subtype Carcinoma Cells.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response.
Regulation of cyclin D1 by calpain protease.
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells.
Resveratrol fuels HER2 and ER?-positive breast cancer behaving as proteasome inhibitor.
Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism.
Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells.
Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif containing 21.
Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Shotgun proteomics and network analysis of ubiquitin-related proteins from human breast carcinoma epithelial cells.
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Silencing Hsp25/Hsp27 gene expression augments proteasome activity and increases CD8+ T-cell-mediated tumor killing and memory responses.
Spiropyran-Based Nanocarrier: A New Zn2+ -Responsive Delivery System with Real-Time Intracellular Sensing Capabilities.
Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin.
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression.
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
Targeting the ubiquitin-proteasome pathway in breast cancer.
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
The proteasome as a novel target for the treatment of breast cancer.
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-? gene.
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.
The UPS: a promising target for breast cancer treatment.
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.
Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells.
Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
Treatment of breast cancer cells with proteasome inhibitor lactacystin increases the level of sensitivity to cell death induced by human immunodeficiency virus type 1.
Ubiquitin-Conjugating Enzyme UBE2C Is Highly Expressed in Breast Microcalcification Lesions.
Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer.
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.
Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Bronchiolitis Obliterans
Repetitive diacetyl vapor exposure promotes ubiquitin proteasome stress and precedes bronchiolitis obliterans pathology.
Bronchitis
Interplay of the ubiquitin proteasome system and the innate immune response is essential for the replication of infectious bronchitis virus.
Bulbo-Spinal Atrophy, X-Linked
Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy.
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.
The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor.
Burkitt Lymphoma
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Epstein-Barr virus lytic cycle activation alters proteasome subunit expression in Burkitt's lymphoma cells.
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Selective Cytotoxicity of Amidinopiperidine Based Compounds Towards Burkitt's Lymphoma Cells Involves Proteasome Inhibition.
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine.
The presence or absence of latent Epstein-Barr virus does not alter the sensitivity of Burkitt's lymphoma cell lines to proteasome inhibitors.
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
calpain-3 deficiency
Down-regulation of genes in the lysosomal and ubiquitin-proteasome proteolytic pathways in calpain-3-deficient muscle.
Carcinogenesis
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Antitumor Effect of Inula viscosa Extracts on DMBA-Induced Skin Carcinoma Are Mediated by Proteasome Inhibition.
Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: Recent Patents Review.
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
Cell cycle-dependent localization of the proteasome to chromatin.
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Combining Genomics To Identify the Pathways of Post-Transcriptional Nongenotoxic Signaling and Energy Homeostasis in Livers of Rats Treated with the Pregnane X Receptor Agonist, Pregnenolone Carbonitrile.
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Current status of treatment for primary effusion lymphoma.
DEPTOR ubiquitination and destruction by SCF(?-TrCP).
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Discovery, Development, and clinical applications of bortezomib.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Epigenetic silencing of serine protease HTRA1 drives polyploidy.
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.
Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin.
GRP75 modulates oncogenic Dbl-driven endocytosis derailed via the CHIP-mediated ubiquitin degradation pathway.
Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer.
Identifying reproducible cancer-associated highly expressed genes with important functional significances using multiple datasets.
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-?B and the proteasome.
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.
Inhibition of beta-TrCP function potentiates UVB-induced apoptosis in hTERT-immortalized normal human keratinocytes.
Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
INT6--a link between the proteasome and tumorigenesis.
Isolation of the Schizosaccharomyces pombe Proteasome Subunit Rpn7 and a Structure-Function Study of the Proteasome-COP9-Initiation Factor Domain.
MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
Modeling tumor progression via the comparison of stage-specific graphs.
Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REG?
Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.
Negatively Charged Metal Oxide Nanoparticles Interact with the 20S Proteasome and Differentially Modulate Its Biologic Functional Effects.
p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.
Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
Phosphorylation regulates cullin-based ubiquitination in tumorigenesis.
Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
Proteasome activity is required for the initiation of precancerous pancreatic lesions.
Proteasome expression and activity in cancer and cancer stem cells.
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Proteasome-Rich PaCS as an Oncofetal UPS Structure Handling Cytosolic Polyubiquitinated Proteins. In Vivo Occurrence, in Vitro Induction, and Biological Role.
PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration.
PSMC2 is Up-regulated in Pancreatic Cancer and Promotes Cancer Cell Proliferation and Inhibits Apoptosis.
Regulation of FOXO protein stability via ubiquitination and proteasome degradation.
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Role of E3 ubiquitin ligases in gastric cancer.
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism.
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
The 26S proteasome complex: An attractive target for cancer therapy.
The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors.
The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.
The significance of PA28? and U2AF1 in oral mucosal carcinogenesis.
The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis.
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma.
Trial Watch: Proteasomal inhibitors for anticancer therapy.
TRIB2 desensitizes ferroptosis via ?TrCP-mediated TFRC ubiquitiantion in liver cancer cells.
UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme.
UBE2C promotes the progression of head and neck squamous cell carcinoma.
UBE2D3 gene overexpression increases radiosensitivity of EC109 esophageal cancer cells in vitro and in vivo.
UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer.
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Ubiquitin-Proteasome System in Neurodegenerative Disorders.
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
Carcinoid Tumor
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype.
Pathophysiology of Gastric NETs: Role of Gastrin and Menin.
Carcinoma
15,16-Dihydrotanshinone I, a Compound of Salvia miltiorrhiza Bunge, Induces Apoptosis through Inducing Endoplasmic Reticular Stress in Human Prostate Carcinoma Cells.
A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer.
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the eastern cooperative oncology group (E1303).
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
Antitumor Effect of Inula viscosa Extracts on DMBA-Induced Skin Carcinoma Are Mediated by Proteasome Inhibition.
Apoptotic effect of MG-132 on human tongue squamous cell carcinoma.
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Basic science and research in renal cell carcinoma: from workbench to bedside.
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Bortezomib.
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells.
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Correction for Ye et al., Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition.
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.
Dual degradation signals control Gli protein stability and tumor formation.
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431.
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Expression of Proteasome Activator REG? in Human Laryngeal Carcinoma and Associations with Tumor Suppressor Proteins.
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
Heparan sulfate degradation products can associate with oxidized proteins and proteasomes.
Identification of an EGCG oxidation derivative with proteasome modulatory activity.
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression.
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Inhibition of proteasome activity in Gleditsia sinensis fruit extract-mediated apoptosis on human carcinoma cells.
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Loss of promyelocytic leukemia protein in human gastric cancers.
Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition.
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.
N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation.
NF-kappaB in carcinoma therapy and prevention.
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group.
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4.
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells.
Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo.
Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo.
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.
Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells.
Proteasome Inhibitors Sensitize Colon Carcinoma Cells to TRAIL-Induced Apoptosis via Enhanced Release of Smac/DIABLO from the Mitochondria.
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
Role of heparanase 2 (Hpa2) in gastric cancer.
Role of the ubiquitin proteasome system in renal cell carcinoma.
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Silencing of the proteasome and oxidative stress impair endoplasmic reticulum targeting and signal cleavage of a prostate carcinoma antigen.
Spiropyran-Based Nanocarrier: A New Zn2+ -Responsive Delivery System with Real-Time Intracellular Sensing Capabilities.
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA.
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Targeting transcription factor NFB: comparative analysis of proteasome and IKK inhibitors.
The molecular mechanisms of XBP-1 gene silencing on IRE1?-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation.
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma.
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
[Effect of EGF on ubiquitination and proteasome-dependent degradation of phospholipase C gamma1 in A431 cells]
[Exclusion of immune proteasomes from mouse ascitic carcinoma Krebs-II cells]
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Carcinoma, Adenoid Cystic
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the eastern cooperative oncology group (E1303).
Carcinoma, Basal Cell
Dual degradation signals control Gli protein stability and tumor formation.
Carcinoma, Ductal
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Carcinoma, Hepatocellular
A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome.
Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3.
ATP-based cell viability assay is superior to trypan blue exclusion and XTT assay in measuring cytotoxicity of anticancer drugs Taxol and Imatinib, and proteasome inhibitor MG-132 on human hepatoma cell line HepG2.
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
cDNA cloning of rat proteasome subunit RC7-I, a homologue of yeast PRE1 essential for chymotrypsin-like activity.
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.
Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia.
Endoplasmic Reticulum Stress Induced Synthesis of a Novel Viral Factor Mediates Efficient Replication of Genotype-1 Hepatitis E Virus.
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Hepatitis B virus X protein stimulates cell growth by downregulating p16 levels via PA28?-mediated proteasomal degradation.
Hepatitis C virus core protein activates proteasomal activator 28 gamma to downregulate p16 levels via ubiquitin-independent proteasomal degradation.
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
Identification of proteasome subunit alpha type-1 as a novel biomarker in HBV-associated hepatocellular carcinoma tissue interstitial fluid by proteomic analysis.
Impaired methylation as a novel mechanism for proteasome suppression in liver cells.
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes.
Involvement of the proteasome and antizyme in ornithine decarboxylase degradation by a reticulocyte lysate.
Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2.
MG132 inhibits the expression of PBX3 through miRNAs by targeting Argonaute2 in hepatoma cells.
mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression.
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Notch1 signaling sensitizes TRAIL-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glycoprotein for degradation by the proteasome.
Oxidative stress and activation of proteasome protease during serum deprivation-induced apoptosis in rat hepatoma cells; inhibition of cell death by melatonin.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Pattern RT1A and proteasome expression in cellular fractions of Zajdela ascitic hepatoma.
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib.
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Proteasome inhibition induces differential heat shock protein response but not unfolded protein response in HepG2 cells.
Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus.
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells.
Proteomic analysis of hepatitis C virus (HCV) core protein transfection and host regulator PA28? knockout in HCV pathogenesis: a network-based study.
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Proteomic signatures in thapsigargin-treated hepatoma cells.
Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.
Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells.
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker.
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
The intracellular stability of DLC1 is regulated by the 26S proteasome in human hepatocellular carcinoma cell line Hep3B.
The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.
The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice.
Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.
Turnover of hepatitis B virus X protein is facilitated by Hdj1, a human Hsp40/DnaJ protein.
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
[Features of the immune proteasome expression in ascite Zajdela hepatoma after implantation into Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis].
Carcinoma, Intraductal, Noninfiltrating
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Carcinoma, Medullary
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition.
Carcinoma, Neuroendocrine
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Carcinoma, Non-Small-Cell Lung
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Lovastatin overcomes gefitinib resistance through TNF-? signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Proteasome inhibitors diminish c-Met expression and induce cell death in non-small cell lung cancer cells.
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
SPOP promotes FADD degradation and inhibits NF-?B activity in non-small cell lung cancer.
Sulforaphane Induced Apoptosis via Promotion of Mitochondrial Fusion and ERK1/2-Mediated 26S Proteasome Degradation of Novel Pro-survival Bim and Upregulation of Bax in Human Non-Small Cell Lung Cancer Cells.
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
The role of proteasome inhibition in nonsmall cell lung cancer.
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Carcinoma, Ovarian Epithelial
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer.
Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer.
Carcinoma, Renal Cell
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.
Basic science and research in renal cell carcinoma: from workbench to bedside.
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Role of the ubiquitin proteasome system in renal cell carcinoma.
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Carcinoma, Squamous Cell
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
Apoptotic effect of MG-132 on human tongue squamous cell carcinoma.
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431.
Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities.
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group.
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
Cardiomegaly
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Deubiquitinase Inhibitor Auranofin Attenuated Cardiac Hypertrophy by Blocking NF-?B Activation.
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy.
Gambogic acid suppresses pressure overload cardiac hypertrophy in rats.
Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload.
MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals.
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
New frontiers in heart hypertrophy during pregnancy.
Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22.
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.
Proteasome inhibitors and cardiac cell growth.
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells.
Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system.
The mammalian target of rapamycin modulates the immunoproteasome system in the heart.
The proteasome activator REG? accelerates cardiac hypertrophy by declining PP2Ac?-SOD2 pathway.
The role of the proteasome in heart disease.
The ubiquitin-proteasome system and cardiovascular disease.
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy.
Cardiomyopathies
A substitution mutation in cardiac ubiquitin ligase, FBXO32, is associated with an autosomal recessive form of dilated cardiomyopathy.
Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.
Concepts in cardiac oncology.
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Inadequate ubiquitination-proteasome coupling contributes to myocardial ischemia-reperfusion injury.
Lysine ubiquitination and acetylation of human cardiac 20S proteasomes.
p62 Stages an Interplay Between the Ubiquitin-Proteasome System and Autophagy in the Heart of Defense Against Proteotoxic Stress.
Proteasome dysfunction in cardiomyopathies.
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Proteasome inhibition promotes regression of left ventricular hypertrophy.
Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond.
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective.
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Ubiquitin-proteasome system and hereditary cardiomyopathies.
VCP and PSMF1: Antagonistic regulators of proteasome activity.
Cardiomyopathy, Dilated
Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis.
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention.
Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy.
The Ubiquitin Proteasome System in Ischemic and Dilated Cardiomyopathy.
TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy.
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Cardiomyopathy, Hypertrophic
Corrigendum: Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Effects of a Proteasome Inhibitor on Cardiomyocytes in a Pressure-Overload Hypertrophy Rat Model: An Animal Study.
Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Cardiomyopathy, Restrictive
Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.
Cardiotoxicity
A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress.
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts.
Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells.
Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity.
Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload.
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Personalized Approach to Cancer Treatment-Related Cardiomyopathy.
Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-?B, Hypertrophic Gene Expression and Oxidative Stress.
Surviving Cancer without a Broken Heart.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Cardiovascular Diseases
Age-dependent declines in proteasome activity in the heart.
Basic mechanisms in endoplasmic reticulum stress and relation to cardiovascular diseases.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Deficiency of the Immunoproteasome LMP10 Subunit Attenuates Angiotensin II-Induced Cardiac Hypertrophic Remodeling via Autophagic Degradation of gp130 and IGF1R.
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Exercise Modulates Oxidative Stress and Inflammation in Aging and Cardiovascular Diseases.
Genetics of Proteasome Diseases.
Homogeneous, bioluminescent proteasome assays.
Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis.
Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner.
Nutritional Supplement-5 with a Combination of Proteasome Inhibitors (Resveratrol, Quercetin, ?-Tocotrienol) Modulate Age-Associated Biomarkers and Cardiovascular Lipid Parameters in Human Subjects.
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Preliminary comments on proteasome inhibition and cardiovascular disease.
Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins.
Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.
The ubiquitin proteasome pathway and endothelial (dys)function.
The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended.
The ubiquitin-proteasome system--micro target for macro intervention?
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Carpal Tunnel Syndrome
Proteasome modulator 9 and carpal tunnel syndrome.
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Cataract
Age-dependent protein modifications and declining proteasome activity in the human lens.
Comprehensive Profiling of Proteome and Ubiquitome Changes in Human Lens Epithelial Cell Line after Ultraviolet-B Irradiation.
Differential gene expression in male and female rat lenses undergoing cataract induction by transforming growth factor-beta (TGF-beta).
H2O2-induced cataract as a model of age-related cataract: Lessons learned from overexpressing the proteasome activator PA28?? in mouse eye lens.
Increased O-GlcNAc causes disrupted lens fiber cell differentiation and cataracts.
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population.
Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats.
Proteasome activity in human lens nuclei and correlation with age, gender and severity of cataract.
Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6.
Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress.
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Proteolytic cleavage of N-Succ-Leu-Leu-Val-Tyr-AMC by the proteasome in lens epithelium from clear and cataractous human lenses.
Role of the proteasome in TGF-beta signaling in lens epithelial cells.
Sustained oxidative stress inhibits NF-kappaB activation partially via inactivating the proteasome.
The apoptosis of bovine lens epithelial cells induced by proteasome inhibitor MG132.
[Compare the proteasome activity in the epithelium of human age-related cataract and normal lens]
Cell Transformation, Neoplastic
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
Central Nervous System Diseases
Immunoproteasome in cancer and neuropathologies: a new therapeutic target?
Is PROTAC technology really a game changer for central nervous system drug discovery?
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Cerebral Hemorrhage
Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.
Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.
Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats.
Cerebral Small Vessel Diseases
Cerebral Small Vessel Disease Is Associated with Dysregulation in the Ubiquitin Proteasome System and Other Major Cellular Pathways in Specific Brain Regions.
Cerebrovascular Disorders
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Chagas Disease
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Chalazion
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.
Charcot-Marie-Tooth Disease
Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.
Inducible HSP70 is critical in preventing the aggregation and enhancing the processing of PMP22.
Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.
Chickenpox
Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Pain Management in Patients with Multiple Myeloma: An Update.
Studying protein complexes by the yeast two-hybrid system.
Cholangiocarcinoma
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells.
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.
Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker.
Cholelithiasis
Proteasome Activity and C-Reactive Protein Concentration in the Course of Inflammatory Reaction in Relation to the Type of Abdominal Operation and the Surgical Technique Used.
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Chondrosarcoma
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
Choroidal Neovascularization
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization.
Chronic Urticaria
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Ciliopathies
Dishevelled stabilization by the ciliopathy protein Rpgrip1l is essential for planar cell polarity.
Interplay between primary cilia, ubiquitin-proteasome system and autophagy.
The cilia-regulated proteasome and its role in the development of ciliopathies and cancer.
Classical Swine Fever
MG132 Attenuates the Replication of Classical Swine Fever Virus in vitro.
Coinfection
Comparative analysis of transcriptomic and hormonal responses to compatible and incompatible plant-virus interactions that lead to cell death.
HIV-1 burden influences host response to co-infection with Neisseria gonorrhoeae in vitro.
The proteasome acts as a hub for plant immunity and is targeted by Pseudomonas type-III effectors.
Colitis
Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis.
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Enhanced inflammatory potential of CD4+ T-cells that lack proteasome immunosubunit expression, in a T-cell transfer-based colitis model.
Glutamine enema regulates colonic ubiquitinated-proteins but not proteasome activities during TNBS-induced colitis leading to increased mitochondrial activity.
Proteasome activator REG? promotes inflammation in Leydig cells via IkB? signaling.
Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis.
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
The application and relevance of ex vivo culture systems for assessment of IBD treatment in murine models of colitis.
Colitis, Ulcerative
Increased Levels of Survivin, via Association With Heat Shock Protein 90, in Mucosal T Cells From Patients With Crohn's Disease.
Colitis-Associated Neoplasms
The REG?-proteasome forms a regulatory circuit with I?B? and NF?B in experimental colitis.
Colonic Neoplasms
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
ADRM1-amplified metastasis gene in gastric cancer.
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
ANXA1?derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Changes in spatio-temporal localization of tripeptidyl peptidase II (TPPII) in murine colon adenocarcinoma cells during aggresome formation: a microscopy study based on a novel fluorescent proteasome inhibitor.
Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway.
Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.
Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing ?-catenin mRNA expression.
Correction: Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Development of the proteasome inhibitor Velcade (Bortezomib).
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line.
Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA Screening.
Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.
Fem1b, a proapoptotic protein, mediates proteasome inhibitor-induced apoptosis of human colon cancer cells.
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells.
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Indirect participation of Hsp90 in the regulation of the cyclin E turnover.
Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells.
Inhibition of metalloproteinase and proteasome activities in colon cancer cells by citrus peel extracts.
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo.
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Proteasome Inhibitors-Mediated TRAIL Resensitization and Bik Accumulation.
Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells.
Responses of Porcupine and Wntless proteins to oxidative, hypoxic and endoplasmic reticulum stresses.
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
Role of apoptosis in colon cancer biology, therapy, and prevention.
Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors.
Single-cell imaging of the heat-shock response in colon cancer cells suggests that magnitude and length rather than time of onset determines resistance to apoptosis.
Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase.
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Synthesis and Inhibitory Activities against Colon Cancer Cell Growth and Proteasome of Alkylresorcinols.
The calpain system is involved in the constitutive regulation of beta-catenin signaling functions.
The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage.
The potential of proteasome inhibition in the treatment of colon cancer.
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Wheat sprout extract induces changes on 20S proteasomes functionality.
[Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis].
Colorectal Neoplasms
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
An Investigation Into the Prognostic Significance of High Proteasome PSB7 Protein Expression in Colorectal Cancer.
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: Recent Patents Review.
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy.
Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function.
Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy.
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration.
Downregulation of Siah1 promotes colorectal cancer cell proliferation and migration by regulating AKT and YAP ubiquitylation and proteasome degradation.
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Expression of TMEM207 in Colorectal Cancer: Relation between TMEM207 and Intelectin-1.
Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester.
Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis.
Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.
Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors.
Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity.
Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines.
NRF3-POMP-20S proteasome assembly axis promotes cancer development via ubiquitin-independent proteolysis of p53 and Rb.
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Peroxisome proliferator activated receptor-? and the ubiquitin-proteasome system in colorectal cancer.
Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
PSMA7 directly interacts with NOD1 and regulates its function.
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Targeted therapies for cancer 2004.
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.
The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer.
The ubiquitin-proteasome system in colorectal cancer.
The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation.
Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
[High expression of proteasome subunit PSMA7 in colorectal cancer is significantly correlated with liver metastasis]
[Silencing of Adrm1 by RNA interference suppresses proliferation of colorectal cancer cells]
Communicable Diseases
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors.
Impairment of immunoproteasome function by ?5i/LMP7 subunit deficiency results in severe enterovirus myocarditis.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Connective Tissue Diseases
Autoimmune response to proteasome activator 28alpha in patients with connective tissue diseases.
Contracture
Proteasome inhibition preserves longitudinal growth of denervated muscle and prevents neonatal neuromuscular contractures.
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Timing of proteasome inhibition as a pharmacologic strategy for prevention of muscle contractures in neonatal brachial plexus injury.
Corneal Dystrophies, Hereditary
A novel proteotoxic stress associated mechanism for macular corneal dystrophy.
Coronary Artery Disease
Chronic proteasome inhibition contributes to coronary atherosclerosis.
Genetics of Proteasome Diseases.
Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk.
Coronary Occlusion
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
Coronary Vasospasm
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.
Coronavirus Infections
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.
Corticobasal Degeneration
Clinicopathological correlations in behavioural variant frontotemporal dementia.
COVID-19
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets.
Proteasome activator PA28?-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein.
Coxsackievirus Infections
Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells.
Craniocerebral Trauma
Circulating proteasome activity following mild head injury in children.
Glucocorticoids do not regulate the expression of proteolytic genes in skeletal muscle from Cushing's syndrome patients.
The comparison of C-proteasome activity in the plasma of children after burn injury, mild head injury and blunt abdominal trauma.
Crohn Disease
Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease.
Increased Levels of Survivin, via Association With Heat Shock Protein 90, in Mucosal T Cells From Patients With Crohn's Disease.
Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.
Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis.
Cryopyrin-Associated Periodic Syndromes
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Cryptorchidism
20S proteasome in the blood plasma of boys with cryptorchidism.
cystathionine beta-synthase deficiency
Correction of cystathionine ?-synthase deficiency in mice by treatment with proteasome inhibitors.
Cystic Fibrosis
A Practical Review of Proteasome Pharmacology.
A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator.
Activation of DeltaF508 CFTR in an epithelial monolayer.
BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP.
Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia.
Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation.
Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.
The forced aggresome formation of a bovine anion exchanger 1 (AE1) mutant through association with deltaF508-cystic fibrosis transmembrane conductance regulator upon proteasome inhibition in HEK293 cells.
The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary.
The role of doxorubicin in non-viral gene transfer in the lung.
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Cysts
A reduced VWA domain-containing proteasomal ubiquitin receptor of Giardia lamblia localizes to the flagellar pore regions in microtubule-dependent manner.
Acanthamoeba castellanii: Gene profile of encystation by ESTs analysis and KOG assignment.
Proteasome-dependent cyst formation and stage-specific ubiquitin mRNA accumulation in Entamoeba invadens.
The effect of peptidic and non-peptidic proteasome inhibitors on the biological properties of Acanthamoeba castellanii belonging to the T4 genotype.
Ubiquitination dynamics in the early-branching eukaryote Giardia intestinalis.
Cytomegalovirus Infections
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription.
Deafness
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress.
Dehydration
COST1 regulates autophagy to control plant drought tolerance.
Gene expression changes governing extreme dehydration tolerance in an Antarctic insect.
Dementia
Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: Association with neurofibrillary tangle pathology.
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome.
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.
Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia.
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.
T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model.
TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Demyelinating Diseases
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelination.
Dengue
Host gene expression profiling of dengue virus infection in cell lines and patients.
Inhibitory effects of curcumin on dengue virus type 2-infected cells in vitro.
K48-linked polyubiquitination of dengue virus NS1 protein inhibits its interaction with the viral partner NS4B.
Papers of note in Science 355 (6323).
Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue.
Production of Infectious Dengue Virus in Aedes aegypti Is Dependent on the Ubiquitin Proteasome Pathway.
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.
West nile virus and Dengue virus capsid protein negates the antiviral activity of human Sec3 protein Through The Proteasome Pathway.
Dental Pulp Calcification
Choniomyzon inflatus n. sp. (Crustacea: Copepoda: Nicothoidae) associated with Ibacus novemdentatus (Crustacea: Decapoda: Scyllaridae) from Japanese waters.
Dermatitis
Inhibition of NF-kappaB Signaling Retards Eosinophilic Dermatitis in SHARPIN-Deficient Mice.
Dermatitis, Atopic
Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression.
The Role of Proteasome Inhibitor MG132 in 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis in NC/Nga Mice.
Dermatitis, Contact
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Diabetes Complications
High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications.
Diabetes Insipidus, Nephrogenic
The proteasome is involved in the degradation of different aquaporin-2 mutants causing nephrogenic diabetes insipidus.
Diabetes Mellitus
Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus.
Downregulation of type II diabetes mellitus and maturity onset diabetes of young pathways in human pancreatic islets from hyperglycemic donors.
Enhancement of 26S Proteasome Functionality Connects Oxidative Stress and Vascular Endothelial Inflammatory Response in Diabetes Mellitus.
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Increased 4-hydroxy-2-nonenal-induced proteasome dysfunction is correlated with cardiac damage in streptozotocin-injected rats with isoproterenol infusion.
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene.
Renal gene expression in embryonic and newborn diabetic mice.
Signals regulating accelerated muscle protein catabolism in uremia.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetes Mellitus, Type 1
Increased 4-hydroxy-2-nonenal-induced proteasome dysfunction is correlated with cardiac damage in streptozotocin-injected rats with isoproterenol infusion.
Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme.
Involvement of the proteasome in IL-1beta induced suppression of islets of Langerhans in the rat.
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.
Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene.
The balance between glucocorticoids and insulin regulates muscle proteolysis via the ubiquitin-proteasome pathway.
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.
The regulation of muscle protein turnover in diabetes.
Diabetes Mellitus, Type 2
An Extract of Artemisia dracunculus L. Inhibits Ubiquitin-Proteasome Activity and Preserves Skeletal Muscle Mass in a Murine Model of Diabetes.
Downregulation of type II diabetes mellitus and maturity onset diabetes of young pathways in human pancreatic islets from hyperglycemic donors.
Genetics of Proteasome Diseases.
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Proteasome modulator 9 and carpal tunnel syndrome.
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
PSMD9 is linked to type 2 diabetes neuropathy.
Significant improvement of stress and aging biomarkers using a novel stress management program with the cognitive restructuring method "Pythagorean Self-Awareness Intervention" in patients with type 2 diabetes mellitus and healthy adults.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
The inducible ?5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient ?-cells and is overexpressed in type 2 diabetes pancreatic islets.
The ubiquitin proteasome system regulates the stability and activity of the glucose sensor glucokinase in pancreatic beta cells.
The UPS in diabetes and obesity.
Diabetic Cardiomyopathies
Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.
Targeting the ubiquitin proteasome system in diabetic cardiomyopathy.
Diabetic Nephropathies
Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.
Correction: Proteasome subunit-? type-6 protein is post-transcriptionally repressed by the microRNA-4490 in diabetic nephropathy.
MG132 ameliorates kidney lesions by inhibiting the degradation of Smad7 in streptozotocin-induced diabetic nephropathy.
Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome.
Proteasome Activators, PA28? and PA28?, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.
Proteasome subunit alpha type-6 protein is posttranscriptionally repressed by the microRNA-4490 in diabetic nephropathy.
The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro.
Diabetic Neuropathies
PSMD9 is linked to type 2 diabetes neuropathy.
Diabetic Retinopathy
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Proteasome Modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2D.
Diphtheria
Clinical Trials and Treatment of ATL.
[Adult T cell leukemia-lymphoma (ATL)].
Disorders of Excessive Somnolence
TNF-NF-kappaB signaling mediates excessive somnolence in hemiparkinsonian rats.
DNA Virus Infections
USP44 positively regulates innate immune response to DNA viruses through deubiquitinating MITA.
Down Syndrome
Decreased expression of thymus-specific proteasome subunit ?5t in Down syndrome patients.
Oxidized SOD1 alters proteasome activities in vitro and in the cortex of SOD1 overexpressing mice.
Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome.
Drug-Related Side Effects and Adverse Reactions
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
The Importance of CYP2E1 in the Pathogenesis of Alcoholic Liver Disease and Drug Toxicity and the Role of the Proteasome.
Dysautonomia, Familial
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Dyslipidemias
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors.
Dystonia
Dystonia-associated mutations cause premature degradation of torsinA protein and cell-type-specific mislocalization to the nuclear envelope.
Eczema
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
Edema, Cardiac
Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation.
Embolism
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Encephalitis
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.
Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis.
Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
Persistent hijacking of brain proteasomes in HIV-associated dementia.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Encephalomyelitis
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis.
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Encephalomyelitis, Autoimmune, Experimental
Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis.
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Encephalomyelitis, Venezuelan Equine
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
West Nile virus genome amplification requires the functional activities of the proteasome.
Endocrine Gland Neoplasms
Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study.
Endometrial Neoplasms
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REG?
Proteasome activity and their subunit composition in endometrial cancer tissue: correlations with clinical morphological parameters.
Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants.
[Proteasome activity in tumors of female reproductive system].
Endometriosis
Bufalin suppresses endometriosis progression by inducing pyroptosis and apoptosis.
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
Combating endometriosis by blocking proteasome and nuclear factor-{kappa}B pathways.
Disulfiram, as a candidate NF-?B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosis.
Endotoxemia
Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers.
The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.
Up-regulation of the proteasome subunit LMP7 in tissues of endotoxemic rats.
Epilepsy
Dysregulation of the (immuno)proteasome pathway in malformations of cortical development.
Increased expression of (immuno)proteasome subunits during epileptogenesis is attenuated by inhibition of the mammalian target of rapamycin pathway.
Long-noncoding RNA Peg13 alleviates epilepsy progression in mice via the miR-490-3p/Psmd11 axis to inactivate the Wnt/?-catenin pathway.
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Targeting the proteasome in epilepsy.
Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy.
Epilepsy, Post-Traumatic
[The quantitative analysis of Ub and UbE1 in focus of traumatic epilepsy]
Epstein-Barr Virus Infections
The current proteomic landscape of the porcine liver.
Equine Infectious Anemia
Budding of equine infectious anemia virus is insensitive to proteasome inhibitors.
Late domain-dependent inhibition of equine infectious anemia virus budding.
Retroviruses have differing requirements for proteasome function in the budding process.
Esophageal Neoplasms
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Exanthema
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Exfoliation Syndrome
Altered unfolded protein response and proteasome impairment in pseudoexfoliation pathogenesis.
Eye Diseases
Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan-Based Peptides as 20S Proteasome Inhibitors.
Familial Mediterranean Fever
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Fanconi Anemia
Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
The PI3K/Akt1 pathway enhances steady-state levels of FANCL.
Fatty Liver
Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice.
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Proteasome inhibitor treatment in alcoholic liver disease.
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal.
The REG? Proteasome Regulates Hepatic Lipid Metabolism through Inhibition of Autophagy.
Feline Infectious Peritonitis
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Fetal Growth Retardation
Altered expression of p97/Valosin containing protein and impaired autophagy in preeclamptic human placenta.
Fibroma
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Fibrosarcoma
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation.
Peripheral Endoplasmic Reticulum Localization of Gp78 Ubiquitin Ligase Activity.
Systemic analysis of heat shock response induced by heat shock and a proteasome inhibitor MG132.
Food Hypersensitivity
Bortezomib treatment diminishes hazelnut-induced intestinal anaphylaxis in mice.
Foot-and-Mouth Disease
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Frontotemporal Dementia
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders.
Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43.
The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair.
Frontotemporal Lobar Degeneration
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Gallbladder Neoplasms
PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
Gallstones
Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Gastritis
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Gastrointestinal Neoplasms
Ubiquitin proteasome system research in gastrointestinal cancer.
Gastrointestinal Stromal Tumors
Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Genetic Diseases, Inborn
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Proteasome protease mediated regulation of cytokine induction and inflammation.
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Gingival Overgrowth
Therapeutic potential of proteasome inhibitors for dihydropyridine-induced gingival overgrowth.
Glaucoma
Changes in ocular aquaporin-4 (AQP4) expression following retinal injury.
Effects of donor age on proteasome activity and senescence in trabecular meshwork cells.
Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study.
Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells.
Glioblastoma
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Anticancer drugs exert differential apoptotic and cytotoxic effects on glioblastoma primary cultures with various EGFR and bcl-2 profiles.
Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells.
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Characterization of the 20S proteasome in human glioblastomas.
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Effects of thymoquinone on isolated and cellular proteasomes.
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation.
Expression profile of parkin isoforms in human gliomas.
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK cell activity.
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.
Paeoniflorin inhibits glioblastoma growth in vivo and in vitro: a role for the Triad3A-dependent ubiquitin proteasome pathway in TLR4 degradation.
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Proteasome inhibition for the treatment of glioblastoma.
Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells.
Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling.
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Proteasome inhibitors in glioblastoma.
Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.
Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth.
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo.
Targeting the Ubiquitin System in Glioblastoma.
The degradation (by distinct pathways) of human D-amino acid oxidase and its interacting partner pLG72--two key proteins in D-serine catabolism in the brain.
The emerging role of m-TOR up-regulation in brain Astrocytoma.
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
Tumor cells can evade dependence on autophagy through adaptation.
Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib.
Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells.
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response.
Glioma
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Arginylated Calreticulin Increases Apoptotic Response Induced by Bortezomib in Glioma Cells.
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Celastrol causes apoptosis and cell cycle arrest in rat glioma cells.
Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome.
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
Effects of thymoquinone on isolated and cellular proteasomes.
Enzymatic activity of extracellular circulating proteasome in the CSF of patients with malignant intrinsic and metastatic brain tumors: proof of concept.
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Hydrogen Peroxide-Induced Oxidative Stress Activates Proteasomal Trypsin-Like Activity in Human U373 Glioma Cells.
Identification of Survival Genes in Human Glioblastoma Cells Using siRNA Screening.
Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis.
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
In vivo imaging, tracking, and targeting of cancer stem cells.
Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells.
Innervation-dependent phosphorylation and accumulation of alphaB-crystallin and Hsp27 as insoluble complexes in disused muscle.
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Marizomib for central nervous system-multiple myeloma.
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1).
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation.
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma.
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress.
Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.
Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells.
Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells.
Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKC?-dependent downregulation of AKT and XIAP expressions.
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Proteasome-dependent degradation of p27/kip1 in gliomas.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta.
Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma.
SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo.
SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.
The Bmi-1/NF-?B/VEGF story: another hint for proteasome involvement in glioma angiogenesis?
The proteasome inhibitor lactacystin exerts its therapeutic effects on glioma via apoptosis: an in vitro and in vivo study.
The Proteasome Inhibitor MG-132 Induces AIF Nuclear Translocation Through Down-Regulation of ERK and Akt/mTOR Pathway.
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
Transient nuclear factor kappaB (NF-kappaB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IkappaBalpha molecule, in C6 glioma cells. Regulation of NF-kappaB linked to chemokine production.
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Visualization of stem cell features in human hepatocellular carcinoma enlightened in vivo significance of tumor-host interaction and clinical implication.
[The intracellular mechanism of NF-kappa B activation involved in iNOS and chemokine induction in C6 glioma cells]
Glomerulonephritis
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Glomerulonephritis, IGA
Bortezomib for Reduction of Proteinuria in IgA Nephropathy.
The ubiquitin-proteasome pathway and IgA nephropathy: a novel link?
Glomerulonephritis, Membranous
Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy.
Glomerulosclerosis, Focal Segmental
A case of nephrotic syndrome, showing evidence of response to saquinavir.
Glycogen Storage Disease Type II
Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal ?-Glucosidase in Pompe Disease.
Proteasome inhibitors improve the function of mutant lysosomal ?-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
Goiter
Aberrant apoptosis in thyroid epithelial cells from goiter nodules.
Goiter, Nodular
Aberrant apoptosis in thyroid epithelial cells from goiter nodules.
Graft vs Host Disease
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
IL-1? and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
[What's new in internal medicine?].
Granulosa Cell Tumor
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Graves Disease
Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501.
Head and Neck Neoplasms
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Hearing Loss
A small molecule mitigates hearing loss in a mouse model of Usher syndrome III.
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
The effect and mechanism of 19S proteasome PSMD11/Rpn6 subunit in D-Galactose induced mimetic aging models.
Hearing Loss, Bilateral
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Heart Arrest
Proteasome Biology Is Compromised in White Matter After Asphyxic Cardiac Arrest in Neonatal Piglets.
Heart Diseases
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Age-dependent declines in proteasome activity in the heart.
Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Heterogeneous cardiac proteasomes: mandated by diverse substrates?
Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.
p62 Stages an Interplay Between the Ubiquitin-Proteasome System and Autophagy in the Heart of Defense Against Proteotoxic Stress.
Proteasomal and lysosomal protein degradation and heart disease.
Proteasome biology and therapeutics in cardiac diseases.
Proteasome functional insufficiency in cardiac pathogenesis.
Proteasome malfunction activates macroautophagy in the heart.
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
Role of proteasomes in disease.
Role of the ubiquitin proteasome system in the heart.
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Targeting proteasomes for cardioprotection.
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
The role of the proteasome in heart disease.
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
The ubiquitin-proteasome system: focus on the heart.
Heart Failure
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.
Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart.
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Cytokine-induced oxidative stress in cardiac inflammation and heart failure-how the ubiquitin proteasome system targets this vicious cycle.
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.
Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.
Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy.
Impaired Assembly and Post-Translational Regulation of 26S Proteasome in Human End Stage Heart Failure.
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
MG132 proteasome inhibitor upregulates the expression of connexin 43 in rats with adriamycin-induced heart failure.
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition.
Pathophysiology and pathological remodelling associated with dilated cardiomyopathy in broiler chickens predisposed to heart pump failure.
Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil.
Proteasome dysfunction in cardiomyopathies.
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression.
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.
Proteasome inhibition improves diaphragm function in congestive heart failure rats.
Proteasome Inhibitors as a Potential Cause of Heart Failure.
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells.
Proteomic remodeling of proteasome in right heart failure.
The role of the proteasome in heart disease.
The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure.
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
Hematologic Diseases
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Proteasome inhibition: a new approach to the treatment of hematologic diseases.
Hematologic Neoplasms
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies.
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Activity-based probes for the multicatalytic proteasome.
An historic perspective of proteasome inhibition.
An inhibitor of ubiquitin conjugation and aggresome formation.
Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Bortezomib as a potential treatment for prostate cancer.
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Bortezomib represses HIF-1? protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Chimeric antigen receptor T cell therapies for multiple myeloma.
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NF?B recruitment to IL-1? and TNF? gene promoters in human macrophages.
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Clinical development of novel proteasome inhibitors for cancer treatment.
Clinical trials with anti-angiogenic agents in hematological malignancies.
Clinical update: proteasome inhibitors in hematologic malignancies.
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Comparative mechanisms of action of proteasome inhibitors.
Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Development of peptidomimetic boronates as proteasome inhibitors.
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Histone deacetylase inhibitors: clinical implications for hematological malignancies.
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
Inducible nitric oxide synthase mediates MG132 lethality in leukemic cells through mitochondrial depolarization.
Inhibitors of the Immunoproteasome: Current Status and Future Directions.
Interferon-?-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Measurement of the Multiple Activities of 26S Proteasomes.
Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Molecular pathogenesis of multiple myeloma.
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.
Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies.
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Peripheral neuropathy in hematologic malignancies - Past, present and future.
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Positioning of proteasome inhibitors in therapy of solid malignancies.
Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Proteasome inhibition for the treatment of glioblastoma.
Proteasome inhibition in hematologic malignancies.
Proteasome inhibition in hematologic malignancies: clinical update and practical applications.
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Proteasome inhibition: a new approach for the treatment of malignancies.
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Proteasome inhibitors in acute leukemia.
Proteasome inhibitors in cancer therapy.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Proteasome inhibitors: structure and function.
Proteasomes and immunoproteasomes.
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Reporter-Based Screens for the Ubiquitin/Proteasome System.
Role of the ubiquitin proteasome system in hematologic malignancies.
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Targeting proteasome inhibition in hematologic malignancies.
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Targeting the ubiquitin+proteasome system in solid tumors.
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
The aggresome pathway as a target for therapy in hematologic malignancies.
The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes.
The immunoproteasome as a target in hematologic malignancies.
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
The potential of proteasome inhibitors in cancer therapy.
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
The role of the proteasome in AML.
The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options.
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.
The vital link between the ubiquitin-proteasome pathway and DNA repair: Impact on cancer therapy.
Therapeutic strategies within the ubiquitin proteasome system.
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Toward Understanding Induction of Oxidative Stress and Apoptosis by Proteasome Inhibitors.
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.
[CAR Technology and Its Application in Treatment of Multiple Myeloma].
Hemophilia A
Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application.
Hepatitis
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Proteasome activity deregulation in LEC rat hepatitis: following the insights of transcriptomic analysis.
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis.
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry.
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo.
Hepatitis A
Degradation of the encephalomyocarditis virus and hepatitis A virus 3C proteases by the ubiquitin/26S proteasome system in vivo.
Hepatitis B
Chromatin remodelling factor BAF155 protects hepatitis B virus X protein (HBx) from ubiquitin-independent proteasomal degradation.
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome.
Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity?
Effect of a conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway.
Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy.
HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome alpha-subunit.
Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4/MC6 subunit.
Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system.
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.
Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53.
Hepatitis B virus X protein in the proteasome of mammalian cells: defining the targeting domain.
Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex.
Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo.
Inhibition of Hepatitis B Virus Production In Vitro by Proteasome Inhibitor MG132.
Inhibition of hepatitis B virus replication by interferon requires proteasome activity.
Proteasome complex as a potential cellular target of hepatitis B virus X protein.
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex.
The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis.
The X-Linked Tumor Suppressor TSPX Interacts and Promotes Degradation of the Hepatitis B Viral Protein HBx via the Proteasome Pathway.
Hepatitis C
?-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients.
Activity-based profiling of the proteasome pathway during hepatitis C virus infection.
Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.
Ethanol and Hepatitis C Virus Suppress Peptide-MHC Class I Presentation in Hepatocytes by Altering Proteasome Function.
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity.
Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome.
High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.
Involvement of PA28gamma in the propagation of hepatitis C virus.
Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.
Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress.
Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver.
Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein.
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Upregulation of nuclear PA28? expression in cirrhosis and hepatocellular carcinoma.
Hepatitis C, Chronic
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Hepatitis E
Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Hepatitis, Chronic
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis.
The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model.
Hepatoblastoma
Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3.
cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p.
cDNA cloning of p40, a regulatory subunit of the human 26S proteasome, and a homolog of the Mov-34 gene product.
Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes).
Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells.
Herpes Simplex
Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells.
Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB.
Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy.
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Enhanced Over-Representation Analysis for the Differential Regulation of Birc5a and HIF2?-Knockdown Approaches.
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
Hsc70 Focus Formation at the Periphery of HSV-1 Transcription Sites Requires ICP27.
Zinc ionophores pyrithione inhibits herpes simplex virus replication through interfering with proteasome function and NF-?B activation.
Herpes Zoster
Comparative analysis of proteomes between diabetic and normal human sperm: Insights into the effects of diabetes on male reproduction based on the regulation of mitochondria-related proteins.
Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Involvement of multimeric protein complexes in mediating the capacitation-dependent binding of human spermatozoa to homologous zonae pellucidae.
Pain Management in Patients with Multiple Myeloma: An Update.
Participation of the sperm proteasome in human fertilization.
Posttranslational modifications of zona pellucida proteins.
Proteasomal interference prevents zona pellucida penetration and fertilization in mammals.
Proteasomes in human spermatozoa.
Proteomic profile of pre-implantational ovine embryos produced in vivo.
Role of the sperm proteasome during fertilization and gamete interaction in the mouse.
Sperm Proteasomes Degrade Sperm Receptor on the Egg Zona Pellucida during Mammalian Fertilization.
Studying protein complexes by the yeast two-hybrid system.
Targeted salmon gene array (SalArray): a toxicogenomic tool for gene expression profiling of interactions between estrogen and aryl hydrocarbon receptor signalling pathways.
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
Herpesviridae Infections
A surprising role for the proteasome in the regulation of herpesvirus infection.
HIV Infections
A role for the proteasome in HIV infection.
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks.
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.
Transcriptome analysis of monocyte-HIV interactions.
Hodgkin Disease
Bortezomib down-modulates the survival factor IRF4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-Associated Fibroblasts.
Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma.
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma.
Proteasome inhibitors in the treatment of B-cell malignancies.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Homocystinuria
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Correction of cystathionine ?-synthase deficiency in mice by treatment with proteasome inhibitors.
Huntington Disease
20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.
A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.
Co-expression network-based analysis of hippocampal expression data associated with Alzheimer's disease using a novel algorithm.
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin.
Enhanced proteasome degradation extends Caenorhabditis elegans lifespan and alleviates aggregation-related pathologies.
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Gene therapy by proteasome activator, PA28?, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
Generalized brain and skin proteasome inhibition in Huntington's disease.
Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease.
Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.
Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction.
Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington's disease knock-in striatal cell model STHdhQ111/Q111.
Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones.
Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism.
Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation.
Proteasome activator enhances survival of huntington's disease neuronal model cells.
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
Proteasome regulators: activators and inhibitors.
Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Sequence- and species-dependence of proteasomal processivity.
Strategies to Investigate Ubiquitination in Huntington's Disease.
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue?
Widespread remodeling of proteome solubility in response to different protein homeostasis stresses.
Hyalinosis, Systemic
Hyaline Fibromatosis Syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.
Hydatidiform Mole
Low molecular mass polypeptide-2 in human trophoblast: over-expression in hydatidiform moles and possible role in trophoblast cell invasion.
Hyperalgesia
A role of the ubiquitin-proteasome system in neuropathic pain.
Control of chronic pain by the ubiquitin proteasome system in the spinal cord.
The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms.
Hypercalcemia
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Hypercholesterolemia
Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia.
Global gene expression changes in the prefrontal cortex of rabbits with hypercholesterolemia and/or hypertension.
Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis.
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Hyperglycemia
Effect of Dietary Silk Peptide on Obesity, Hyperglycemia, and Skeletal Muscle Regeneration in High-Fat Diet-Fed Mice.
Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice.
Functional proteasome complex is required for turnover of islet amyloid polypeptide in pancreatic ?-cells.
Hyperglycemia impairs proteasome function by methylglyoxal.
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Mechanism and Consequences of The Impaired Hif-1? Response to Hypoxia in Human Proximal Tubular HK-2 Cells Exposed to High Glucose.
Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose.
Proteasome Activators, PA28? and PA28?, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.
Proteasome inhibitors, including curcumin, improve pancreatic ?-cell function and insulin sensitivity in diabetic mice.
Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia.
Hyperhomocysteinemia
Hyperhomocysteinemia-induced oxidative stress differentially alters proteasome composition and activities in heart and aorta.
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Hyperlipidemias
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
LDL suppresses angiogenesis through disruption of the HIF pathway via NF-?B inhibition which is reversed by the proteasome inhibitor BSc2118.
Hypersensitivity
Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Multiubiquitin chain binding and protein degradation are mediated by distinct domains within the 26 S proteasome subunit Mcb1.
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.
Proteasomal Control of Cytokinin Synthesis Protects Mycobacterium tuberculosis against Nitric Oxide.
Proteasome inhibition: A novel mechanism to combat asthma.
Proteasome involvement in the repair of DNA double-strand breaks.
Proteasome nuclear import mediated by Arc3 can influence efficient DNA damage repair and mitosis in Schizosaccharomyces pombe.
Proteasome regulation, plant growth and stress tolerance.
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
The RPT2 subunit of the 26S proteasome directs complex assembly, histone dynamics, and gametophyte and sporophyte development in Arabidopsis.
Hypertension
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
Aerobic exercise training improves oxidative stress and ubiquitin proteasome system activity in heart of spontaneously hypertensive rats.
Antihypertensive effect of a proteasome inhibitor in DOCA-salt hypertensive rats.
Arterial hypertension and multiple myeloma: physiopathology and cardiovascular risk and 'practical' indications in patients receiving carfilzomib.
Arterial hypertension in patients under antineoplastic therapy: a systematic review.
Bortezomib, a proteasome inhibitor, attenuates Angiotensin II-induced hypertension and aortic remodeling in rats.
Concepts in cardiac oncology.
Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury.
Etiology and management of hypertension in patients with cancer.
Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.
Global gene expression changes in the prefrontal cortex of rabbits with hypercholesterolemia and/or hypertension.
Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-?B/TGF?1 pathway.
Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.
Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Proteasome Modulator 9 SNPs are linked to Hypertension in Type 2 Diabetes Families.
Tyrosine hydroxylase is short-term regulated by the ubiquitin-proteasome system in PC12 cells and hypothalamic and brainstem neurons from spontaneously hypertensive rats: possible implications in hypertension.
Tyrosine nitration of PA700 activates the 26S proteasome to induce endothelial dysfunction in mice with angiotensin II-induced hypertension.
Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors.
[Allele polymorphism of genes coding proteasome subunits is associated with an enhanced risk for arterial hypertension in adolescents]
[Effect of quercetin on proteasome activity in the aorta and heart tissues of spontaneously hypertensive rats].
Hypertension, Pulmonary
Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis.
Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells.
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Hypertension, Renovascular
Changes in proteasome activity in the ischemic kidney of rat with experimental renovascular hypertension.
Hypertensive Retinopathy
Proteasome Modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2D.
Hyperthyroidism
Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.
Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism.
Hypertrophy, Left Ventricular
Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy.
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.
Proteasome inhibition promotes regression of left ventricular hypertrophy.
Hypertrophy, Right Ventricular
Altered proteasome function in right ventricular hypertrophy.
Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-?B pathway.
Hypesthesia
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Hypopharyngeal Neoplasms
MG132 reverse the malignant characteristics of hypopharyngeal cancer.
Hypophosphatasia
Molecular Genetics of Hypophosphatasia and Phenotype-Genotype Correlations.
Hypoxia-Ischemia, Brain
Oleuropein Activates Neonatal Neocortical Proteasomes, but Proteasome Gene Targeting by AAV9 Is Variable in a Clinically Relevant Piglet Model of Brain Hypoxia-Ischemia and Hypothermia.
Ichthyosis
129-Derived Mouse Strains Express an Unstable but Catalytically Active DNA Polymerase Iota Variant.
Ichthyosis, Lamellar
siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis.
Idiopathic Pulmonary Fibrosis
Regulation of 26S Proteasome Activity in Pulmonary Fibrosis.
Immune System Diseases
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Non-Covalent Proteasome Inhibitors.
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
The proteasome and its inhibitors in immune regulation and immune disorders.
Immunoglobulin Light-chain Amyloidosis
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.
How we treat systemic light-chain amyloidosis.
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Neuropathy Associated with Systemic Amyloidosis.
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib.
Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Infarction, Middle Cerebral Artery
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome.
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Infections
20S proteasome as a drug target in Trichomonas vaginalis.
A bacterial virulence protein suppresses host innate immunity to cause plant disease.
A luminescence assay for natural product inhibitors of the Mycobacterium tuberculosis proteasome.
A Pathogen and a Non-pathogen Spotted Fever Group Rickettsia Trigger Differential Proteome Signatures in Macrophages.
Age-Dependent Effects of Immunoproteasome Deficiency on Mouse Adenovirus Type 1 Pathogenesis.
Alteration of copper-zinc superoxide dismutase 1 expression by influenza A virus is correlated with virus replication.
Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth.
An adenosine triphosphate-independent proteasome activator contributes to the virulence of Mycobacterium tuberculosis.
Analysis of cotton (Gossypium hirsutum) root proteomes during a compatible interaction with the black root rot fungus Thielaviopsis basicola.
Anti- and pro-microbial roles of autophagy in plant-bacteria interactions.
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Antiparasitic drugs: Proteasome inhibition combats kinetoplastid infections.
Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB.
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus entry and replication.
Bacteria exploit autophagy for proteasome degradation and enhanced virulence in plants.
Biotyping of IRE/CTVM19 tick cell line infected by tick-borne encephalitis virus.
Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis.
Brain-derived neurotrophic factor and the course of experimental cerebral malaria.
Carica papaya microRNAs are responsive to Papaya meleira virus infection.
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses.
CHYR1 ubiquitinates the phosphorylated WRKY70 for degradation to balance immunity in Arabidopsis thaliana.
Comparative transcriptome analysis reveals distinct gene expression profiles in Brachypodium distachyon infected by two fungal pathogens.
Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.
Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection.
Cyclophilin A potentiates TRIM5? inhibition of HIV-1 nuclear import without promoting TRIM5? binding to the viral capsid.
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction.
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
Dengue Virus Genome Uncoating Requires Ubiquitination.
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Early events during BK virus entry and disassembly.
Early responses given distinct tactics to infection of Peronophythora litchii in susceptible and resistant litchi cultivar.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Effector-triggered immunity blocks pathogen degradation of an immunity-associated vesicle traffic regulator in Arabidopsis.
Emerging cellular targets for influenza antiviral agents.
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Enhanced Over-Representation Analysis for the Differential Regulation of Birc5a and HIF2?-Knockdown Approaches.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors.
Evidence against a direct antiviral activity of the proteasome during the early steps of HIV-1 replication.
Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.
Functional analysis of a DNA-shuffled movement protein reveals that microtubules are dispensable for the cell-to-cell movement of tobacco mosaic virus.
Functional genomic studies of tick cells in response to infection with the cattle pathogen, Anaplasma marginale.
Grass carp reovirus capsid protein interacts with cellular proteasome subunit beta-type 7: Evidence for the involvement of host proteasome during aquareovirus infection.
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
HcPro, a multifunctional protein encoded by a plant RNA virus, targets the 20S proteasome and affects its enzymic activities.
Heat shock perturbs TRIM5alpha restriction of human immunodeficiency virus type 1.
Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1?.
Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.
Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection.
High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.
HopZ4 from Pseudomonas syringae, a member of the HopZ type III effector family from the YopJ superfamily, inhibits the proteasome in plants.
Host cell interactome of PA protein of H5N1 influenza A virus in chicken cells.
Host gene expression profiling of dengue virus infection in cell lines and patients.
Host Interaction Analysis of PA-N155 and PA-N182 in Chicken Cells Reveals an Essential Role of UBA52 for Replication of H5N1 Avian Influenza Virus.
Human Antiviral Protein IFIX Suppresses Viral Gene Expression during Herpes Simplex Virus 1 (HSV-1) Infection and Is Counteracted by Virus-induced Proteasomal Degradation.
Human Cytomegalovirus Tegument Protein pp65 (pUL83) Dampens Type I Interferon Production by Inactivating the DNA Sensor cGAS without Affecting STING.
Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect.
Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells.
Immunomodulation of lambs following treatment with a proteasome preparation from infective larvae of Trichostrongylus colubriformis.
Immunoproteasome activation enables human TRIM5? restriction of HIV-1.
Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection.
Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.
Impairment of Immunoproteasome Function by Cigarette Smoke and in COPD.
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice.
Infection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome.
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Infection with Salmonella typhimurium has no effect on the composition and cleavage specificity of the 20S proteasome in human lymphoid cells.
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.
Inhibitory effects of curcumin on dengue virus type 2-infected cells in vitro.
Innate Multigene Family Memories Are Implicated in the Viral-Survivor Zebrafish Phenotype.
Internal deletions of IE2 86 and loss of the late IE2 60 and IE2 40 proteins encoded by human cytomegalovirus affect the levels of UL84 protein but not the amount of UL84 mRNA or the loading and distribution of the mRNA on polysomes.
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Involvement of JNK and NF-?B pathways in lipopolysaccharide (LPS)-induced BAG3 expression in human monocytic cells.
iTRAQ-based quantitative proteomic analysis of peripheral blood serum in piglets infected with Actinobacillus pleuropneumoniae.
JAV1 controls jasmonate-regulated plant defense.
Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells.
Linkage of bacterial protein synthesis and presentation of MHC class I-restricted Listeria monocytogenes-derived antigenic peptides.
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
Medicago Plants Control Nodulation by Regulating Proteolysis of the Receptor-Like Kinase DMI2.
MG-132 interferes with iron cellular homeostasis and alters virulence of bovine herpesvirus 1.
MG-132 reduces virus release in Bovine herpesvirus-1 infection.
MG132 exerts anti-viral activity against HSV-1 by overcoming virus-mediated suppression of the ERK signaling pathway.
MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.
Mining the Active Proteome of Arabidopsis thaliana.
Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis.
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
Mycobacterium tuberculosis proteasomal ATPase Mpa has a ?-grasp domain that hinders docking with the proteasome core protease.
Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1.
Nanoluciferase-Based Method for Detecting Gene Expression in Caenorhabditis elegans.
New insights into host-parasite ubiquitin proteome dynamics in P. falciparum infected red blood cells using a TUBEs-MS approach.
Oligomerization of ICP4 and rearrangement of heat shock proteins may be important for herpes simplex virus type 1 prereplicative site formation.
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.
Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo.
Plant Virus Infection and the Ubiquitin Proteasome Machinery: Arms Race along the Endoplasmic Reticulum.
Platelet Proteasome Activity and Metabolism Is Upregulated during Bacterial Sepsis.
Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue.
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions.
Presentation of a new H-2D(k)-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin.
Promyelocytic Leukemia Restricts Enterovirus 71 Replication by Inhibiting Autophagy.
Proteasome activator REGgamma enhances coxsackieviral infection by facilitating p53 degradation.
Proteasome activity in a naïve mosquito cell line infected with Wolbachia pipientis wAlbB.
Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice.
Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo.
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Proteasome subunit beta type-8 from sevenband grouper negatively regulates cytokine responses by interfering NF-?B signaling upon nervous necrosis viral infection.
Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Proteasome-independent degradation of HIV-1 in naturally non-permissive human placental trophoblast cells.
Proteolytic enzymes involved in MHC class I antigen processing: A guerrilla army that partners with the proteasome.
Proteomic analysis of papaya (Carica papaya L.) displaying typical sticky disease symptoms.
Proteomics of the 26S proteasome in Spodoptera frugiperda cells infected with the nucleopolyhedrovirus, AcMNPV.
Proteotoxic stress induced by Autographa californica nucleopolyhedrovirus infection of Spodoptera frugiperda Sf9 cells.
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway.
Recruitment and Dynamics of Proteasome Association with rhTRIM5? Cytoplasmic Complexes During HIV-1 Infection.
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.
Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection.
Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB.
Respiratory syncytial virus induces ?2-adrenergic receptor dysfunction in human airway smooth muscle cells.
Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency.
Rice stripe Tenuivirus nonstructural protein 3 hijacks the 26S proteasome of the small brown planthopper, via direct interaction with regulatory-particle non-ATPase subunit 3.
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.
Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.
Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription.
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.
Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression.
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.
Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21.
Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Subunit-selective proteasome activity profiling uncovers uncoupled proteasome subunit activities during bacterial infections.
SUMO-1 modification of the major immediate-early (IE) 1 and 2 proteins of human cytomegalovirus is regulated by different mechanisms and modulates the intracellular localization of the IE1, but not IE2, protein.
The 19S proteasome activator promotes human cytomegalovirus immediate early gene expression through proteolytic and nonproteolytic mechanisms.
The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunity.
The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.
The Major Immediate-Early Protein IE2 of Human Cytomegalovirus Is Sufficient to Induce Proteasomal Degradation of CD83 on Mature Dendritic Cells.
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
The pathogenic potential of Campylobacter concisus strains associated with chronic intestinal diseases.
The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion.
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
The proteasome system in infection: impact of ?5 and LMP7 on composition, maturation and quantity of active proteasome complexes.
The Pup-Proteasome System of Mycobacterium tuberculosis.
The role of Src protein in the process formation of PC12 cells induced by the proteasome inhibitor MG-132.
The Tomato yellow leaf curl virus V2 protein forms aggregates depending on the cytoskeleton integrity and binds viral genomic DNA.
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice.
The ubiquitin-proteasome pathway in viral infections.
The ubiquitin-proteasome system is necessary for the replication of duck Tembusu virus.
The ubiquitin-proteasome system is required for the early stages of porcine circovirus type 2 replication.
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
The ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells.
Toxoplasma gondii infection of activated J774-A1 macrophages causes inducible nitric oxide synthase degradation by the proteasome pathway.
Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB.
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection.
Trypanosoma cruzi: effect of the infection on the 20S proteasome in non-immune cells.
Ubiquitin-Independent Proteasomal Degradation of Tumor Suppressors by Human Cytomegalovirus pp71 Requires the 19S Regulatory Particle.
Ubiquitin-Like protein 5 interacts with the silencing suppressor p3 of rice stripe virus and mediates its degradation through the 26S proteasome pathway.
Ubiquitin-Proteasome System Is Required for Efficient Replication of Singapore Grouper Iridovirus.
Ubiquitination and degradation of the ORF34 gene product of equine herpesvirus type 1 (EHV-1) at late times of infection.
Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases.
Ubiquitination is required for effective replication of coxsackievirus B3.
Ubiquitylation and autophagy in the control of bacterial infections and related inflammatory responses.
Up-regulation of the proteasome subunit LMP7 in tissues of endotoxemic rats.
Up-regulation of the ubiquitin-conjugating and proteolytic systems in murine acquired immunodeficiency syndrome.
VacA promotes CagA accumulation in gastric epithelial cells during Helicobacter pylori infection.
West Nile virus genome amplification requires the functional activities of the proteasome.
Why hasn't there been more progress in new Chagas disease drug discovery?
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
[Systemic varicella-zoster infection during ixazomib-containing multiagent chemotherapy for multiple myeloma].
[Transcriptome Analysis of Rabbit Spleen with Hog Cholera Lapinized Virus Infection Based on High-throughput Sequencing Technology].
Infertility
Proteasome localization and ultrastructure of spermatozoa from patients with varicocele--immunoelectron microscopic study.
Infertility, Male
FBXO7 sensitivity of phenotypic traits elucidated by a hypomorphic allele.
The REG?-Proteasome Regulates Spermatogenesis Partially by P53-PLZF Signaling.
Inflammatory Bowel Diseases
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease.
Evaluation of ubiquitinated proteins by proteomics reveals the role of the ubiquitin proteasome system in the regulation of Grp75 and Grp78 chaperone proteins during intestinal inflammation.
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease.
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease.
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Skeletal muscle catabolism in trinitrobenzene sulfonic acid-induced murine colitis.
The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease.
Influenza, Human
A particle-filter framework for robust cryo-EM 3D reconstruction.
Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Apolipoprotein E in macrophages and hepatocytes is eegraded via the proteasomal pathway.
CHD6, a Cellular Repressor of Influenza Virus Replication, Is Degraded in Human Alveolar Epithelial Cells and Mice Lungs during Infection.
Comparative Profiling of Ubiquitin Proteasome System Interplay with Influenza A Virus PB2 Polymerase Protein Recapitulating Virus Evolution in Humans.
Comparative transcriptome analysis of Ethiopian indigenous chickens from low and high altitudes under heat stress condition reveals differential immune response.
Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.
Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
Identification of a membrane targeting and degradation signal in the p42 protein of influenza C virus.
Influenza A virus (H1N1) triggers a hypoxic response by stabilizing hypoxia-inducible factor-1? via inhibition of proteasome.
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.
Proteasomes raise the microtubule dynamics in influenza A (H1N1) virus-infected LLC-MK2 cells.
Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope.
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen.
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.
Insulin Resistance
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity.
Curcumin Improves Palmitate-Induced Insulin Resistance in Human Umbilical Vein Endothelial Cells by Maintaining Proteostasis in Endoplasmic Reticulum.
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1.
Icariin Ameliorates Palmitate-Induced Insulin Resistance Through Reducing Thioredoxin-Interacting Protein (TXNIP) and Suppressing ER Stress in C2C12 Myotubes.
Identification of intracellular peptides in rat adipose tissue: Insights into insulin resistance.
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Nutritional influences on age-related skeletal muscle loss.
Palmitate induces insulin resistance in human HepG2 hepatocytes by enhancing ubiquitination and proteasomal degradation of key insulin signaling molecules.
PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes.
PROTEASOME DYSFUNCTION ASSOCIATED TO OXIDATIVE STRESS AND PROTEOTOXICITY IN ADIPOCYTES COMPROMISE INSULIN SENSITIVITY IN HUMAN OBESITY.
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Proteasome inhibitors, including curcumin, improve pancreatic ?-cell function and insulin sensitivity in diabetic mice.
[The metabolic syndrome and type-2 diabetes mellitus as conditions predisposing for malignant tumors]
Insulinoma
Antitumorigenic effect of proteasome inhibitors on insulinoma cells.
Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis.
Intellectual Disability
A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.
Biallelic variants in PSMB1 encoding the proteasome subunit ?6 cause impairment of proteasome function, microcephaly, intellectual disability, developmental delay and short stature.
Cowden syndrome-related mutations in PTEN associate with enhanced proteosome activity.
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome.
PSMD12 haploinsufficiency in a neurodevelopmental disorder with autistic features.
Intestinal Pseudo-Obstruction
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Intracranial Aneurysm
Nocardia intracranial mycotic aneurysm associated with proteasome inhibitor.
Iritis
Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals.
Iron Deficiencies
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle.
Phosphorylation and Proteasome Recognition of the mRNA-Binding Protein Cth2 Facilitates Yeast Adaptation to Iron Deficiency.
Processes underlying the nutritional programming of embryonic development by iron deficiency in the rat.
Irritable Bowel Syndrome
Evaluation of ubiquitinated proteins by proteomics reveals the role of the ubiquitin proteasome system in the regulation of Grp75 and Grp78 chaperone proteins during intestinal inflammation.
Isaacs Syndrome
Inhibition of ubiquitin proteasome system rescues the defective sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA1) protein causing Chianina cattle pseudomyotonia.
Ischemic Attack, Transient
Altered expression levels of SEF-2 and p112 in the rat hippocampus after transient cerebral ischemia: identification by mRNA differential display.
Protein aggregation and proteasome dysfunction after brain ischemia.
Ischemic Stroke
Genetic association between inflammatory genes (IL-1?, CD14, LGALS2, PSMA6) and risk of ischemic stroke: A meta-analysis.
Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia.
Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation.
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response.
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
[Frequency of allele polymorphism of immune proteasome catalytic subunits in patients with ischemic stroke].
Jet Lag Syndrome
Molecular analysis of sleep: wake cycles in Drosophila.
Keratosis
siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis.
Kidney Diseases
Monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with bortezomib.
Kidney Failure, Chronic
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD.
Renal cytoplasmic proteasome proteinase activities are altered in chronic renal failure.
Kidney Neoplasms
Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Development of interferon ?-based immunocytokines targeting renal cancer.
Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.
Emetine promotes VHL-independent degradation of hypoxia inducible factor-2{alpha} in clear cell renal carcinoma.
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.
Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells.
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.
Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1?-Mediated Glycolysis.
Lafora Disease
Lafora disease fibroblasts exemplify the molecular interdependence between thioredoxin 1 and the proteasome in mammalian cells.
Lambert-Eaton Myasthenic Syndrome
Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.
Laryngeal Neoplasms
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Leber Congenital Amaurosis
Temperature sensitive retinoid isomerase activity of RPE65 mutants associated with Leber congenital amaurosis.
Leiomyoma
Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasome-mediated degradation and an alteration of its transcriptional activity.
Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Leiomyosarcoma
Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.
Leishmaniasis
An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases.
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Functional role of lysine 12 in Leishmania major AQP1.
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Leishmaniasis, Visceral
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Leprosy
The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion.
Leukemia
(Immuno)proteasomes as therapeutic target in acute leukemia.
A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous.
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions.
Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System.
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia.
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex.
Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
Bcl-2 antibodies induce hemoglobin release by red blood cells loaded with in vitro translated Bcl-2 and its cleaved fragment.
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir.
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma.
Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.
Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006;107(1):232-240.
Detection of O-propargyl-puromycin with SUMO and ubiquitin by click chemistry at PML-nuclear bodies during abortive proteasome activities.
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.
Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.
Down-modulation of poly(ADP-ribose) polymerase-1 (PARP-1) in human TUR leukemia cells restores transcriptional responsiveness for differentiation and cell cycle arrest.
Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells.
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Establishment of a human cell line stably overexpressing mouse Nip45 and characterization of Nip45 subcellular localization.
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.
Extracellular polyphosphate signals through Ras and Akt to prime Dictyostelium discoideum cells for development.
Gambogic acid enhances proteasome inhibitor-induced anticancer activity.
Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.
Hemidesmus indicus induces apoptosis via proteasome inhibition and generation of reactive oxygen species.
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis.
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Inhibition of 20 S and 26 S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans retinoic acid.
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Intracellular localization of proteasomal degradation of a viral antigen.
Lithium chloride inactivates the 20S proteasome from WEHI-3B D+ leukemia cells.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53.
Molecular Approaches to Treating Pediatric Leukemias.
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia.
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Novel targeted drug therapies for the treatment of childhood acute leukemia.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65.
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Positive feedback between NF-?B and TNF-? promotes leukemia-initiating cell capacity.
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-kappab activation.
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.
Proteasome inhibitors abolish cell death downstream of caspase activation during anti-microtubule drug-induced apoptosis in leukemia cells.
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Proteasome inhibitors in acute leukemia.
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome.
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment.
Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells.
Retroviruses have differing requirements for proteasome function in the budding process.
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma.
Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome.
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition.
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Ubash3b promotes TPA-mediated suppression of leukemogenesis through accelerated downregulation of PKC? protein.
Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable?
Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification.
Update on developmental therapeutics for acute lymphoblastic leukemia.
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
WITHDRAWN: Evidence for the critical roles of NF-?B p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells.
[Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism.]
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and icam-1 mRNA expression of k562 cells.]
[Effects of proteasome inhibitors on leukemias]
[Inhibition of 8-chloroadenosine on proteasome activity of HL-60 cells]
[Mechanism of G2/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132]
[Proteomic analysis of G2/M arrest of HL-60 cells induced by MG132]
[Rabdocoetsin B, a diterpenoid isolated from Isodon coetsa, is a potential proteasome inhibitor and induced apoptosis of t(8;21) leukemia cells]
[Role of MG132, a proteasome inhibitor, in inducing expression of costimulatory molecules CD86 in leukemic cells and its effect on allogeneic mixed lymphocyte reaction]
[Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Leukemia L1210
Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Leukemia P388
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Leukemia, Erythroblastic, Acute
26S multicatalytic proteinase complexes decrease during the differentiation of murine erythroleukemia cells.
A novel ATP-requiring protease from skeletal muscle that hydrolyzes non-ubiquitinated proteins.
EKLF/KLF1 is ubiquitinated in vivo and its stability is regulated by activation domain sequences through the 26S proteasome.
Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors.
Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail.
[Induction of apoptosis by proteasome inhibitor MG-132 in human erythroleukemia cell line K562.]
Leukemia, Large Granular Lymphocytic
Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.
TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
?-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
Development of the proteasome inhibitor Velcade (Bortezomib).
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells.
RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
The Proteasome Inhibitor Carfilzomib Functions Independently of p53 To Induce Cytotoxicity and an Atypical NF-?B Response in Chronic Lymphocytic Leukemia Cells.
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
[Effect of nuclear transcription factor RelB on the proteasome inhibitor-sensitivity of chronic lymphocytic leukemia cells].
[Effects of proteasome inhibitors on leukemias]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions.
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Proteasome proteolytic profile is linked to Bcr-Abl expression.
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
Targeted therapies for cancer 2004.
[Effect of Bortezomib on Reverse Multidrug Resistance and XIAP Expression in Imatinib-resistant Primary Cells of Chronic Myeloid Leukemia in Blastic Crisis].
[Effects of proteasome inhibitors on leukemias]
Leukemia, Myeloid
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor]
[Knockdown of proteasome subunit ?7 with small interfering RNA inhibits cell proliferation of K562 cell line].
Leukemia, Myeloid, Acute
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-?B and the accumulation of MCL-1.
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Emerging targeted therapies for pediatric acute myeloid leukemia.
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Human Telomerase Reverse Transcriptase (hTERT) Positively Regulates 26S Proteasome Activity.
Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia.
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Proteasome Inhibition Specifically Sensitizes Leukemic Cells to Anthracyclin-Induced Apoptosis through the Accumulation of Bim and Bax Pro-Apoptotic Proteins.
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment.
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G(0)/G(1) phase arrest and transition into granulocytic differentiation.
TRIB3 destabilizes tumor suppressor PPAR? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
[Effects of proteasome inhibitors on leukemias]
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Leukemia, Plasma Cell
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
[Effects of proteasome inhibitors on leukemias]
[Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Leukemia, Promyelocytic, Acute
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Leukemia, T-Cell
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-Cell leukemia.
Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia.
Outfoxing FoxO transcription factors: HTLV-1 Tax oncoprotein inactivates FoxO4 via the ubiquitin-proteasome pathway.
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding.
The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome.
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
[Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells]
Leukocytosis
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
Leukoencephalopathies
Myelin under stress.
Lewy Body Disease
Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains.
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture.
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.
T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model.
Lipodystrophy
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
CANDLE Syndrome: a report of a novel mutation and review of the literature.
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
The human immunodeficiency virus (HIV1) protease inhibitor sanquinavir activates autophagy and removes lipids deposited in lipid droplets.
Liposarcoma
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
Liver Cirrhosis
Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Role of CYP2E1 activity in endoplasmic reticulum ubiquitination, proteasome association, and the unfolded protein response.
Liver Cirrhosis, Biliary
Proteasome is required for class I-restricted presentation by Fcgamma receptor-mediated endocytosis in primary biliary cirrhosis.
Liver Diseases
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity.
NF-kappaB signaling, liver disease and hepatoprotective agents.
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Regulation of stathmin phosphorylation in mouse liver progenitor-29 cells during proteasome inhibition.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Liver Diseases, Alcoholic
Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease.
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease.
Effects of ethanol on the proteasome interacting proteins.
Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically.
Implication of altered proteasome function in alcoholic liver injury.
Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes.
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease.
Proteasome inhibitor treatment in alcoholic liver disease.
Proteasome inhibitor up regulates liver antioxidative enzymesin rat model of alcoholic liver disease.
The effect of CYP2E1-dependent oxidant stress on activity of proteasomes in HepG2 cells.
The Importance of CYP2E1 in the Pathogenesis of Alcoholic Liver Disease and Drug Toxicity and the Role of the Proteasome.
[An experimental study on the relationship between proteasome LMP7 subunit and alcoholic liver disease]
Liver Failure, Acute
Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
Liver Neoplasms
A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer.
Activation of the ubiquitin proteasome pathway by silk fibroin modified chitosan nanoparticles in hepatic cancer cells.
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
Core and specific network markers of carcinogenesis from multiple cancer samples.
Gankyrin: an intriguing name for a novel regulator of p53 and RB.
Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
ONX0912, a selective oral proteasome inhibitor, triggering mitochondrial apoptosis and mitophagy in liver cancer.
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs.
TRIB2 modulates proteasome function to reduce ubiquitin stability and protect liver cancer cells against oxidative stress.
Lung Diseases
Dissecting the molecular effects of cigarette smoke on proteasome function.
Proteasome inhibition promotes autophagy and protects from endoplasmic reticulum stress in rat alveolar macrophages exposed to hypoxia-reoxygenation injury.
Proteasome inhibition: A novel mechanism to combat asthma.
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
The emerging role of the ubiquitin proteasome in pulmonary biology and disease.
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Lung Diseases, Interstitial
Proteasome dysfunction inhibits surfactant protein gene expression in lung epithelial cells: mechanism of inhibition of SP-B gene expression.
Lung Injury
Extracellular alveolar proteasome: possible role in lung injury and repair.
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells.
Proteasome inhibition attenuates lung injury induced by intestinal ischemia reperfusion in rats.
Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats.
[Effect of the proteasome inhibitor MG-132 on hyperoxic lung injury and its mechanism in rats]
[Protective effect of proteasome inhibitor MG-132 in rats with severe acute pancreatitis and lung injury]
Lung Neoplasms
26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.
4-Nitroquinoline-1-oxide effects human lung adenocarcinoma A549 cells by regulating the expression of POLD4.
A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea.
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the Proteasome Inhibitor PS-341 in Human Lung Cancer Cells.
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.
Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids.
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting ?1 subunit expression and disrupting proteasome assembly.
c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity.
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ.
Cytochalasin E increased the sensitivity of human lung cancer A549?cells to bortezomib via inhibition of autophagy.
Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-?B inhibition and p53 reactivation in human lung cancer cells.
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51.
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
Expression and purification of a rapidly degraded protein, TMEM8B-a, in mammalian cell line.
Expression level is a key determinant of E2F1-mediated cell fate.
Fucoidan inhibition of lung cancer in vivo and in vitro : role of the Smurf2-dependent ubiquitin proteasome pathway in TGF? receptor degradation.
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer.
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells: A NOVEL ANTIPROLIFERATIVE AGENT WITH A POTENTIAL THERAPEUTIC IMPLICATION.
Incorporating bortezomib into the treatment of lung cancer.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Lovastatin overcomes gefitinib resistance through TNF-? signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level.
MG132, a proteasome inhibitor decreased the growth of Calu-6 lung cancer cells via apoptosis and GSH depletion.
MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
Mitogen-activated protein kinase inhibitors differently affect the growth inhibition and death of a proteasome inhibitor, carbobenzoxy-Leu-Leu-leucinal-treated human pulmonary fibroblast cells.
Modeling tumor progression via the comparison of stage-specific graphs.
Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Novel Agents in the Management of Lung Cancer.
Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.
Proteasome inhibition by MG132 induces growth inhibition and death of human pulmonary fibroblast cells in a caspase-independent manner.
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.
Proteasome Inhibitor-Induced I?B/NF-?B Activation is Mediated by Nrf2-Dependent Light Chain 3B Induction in Lung Cancer Cells.
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Proteasome inhibitors diminish c-Met expression and induce cell death in non-small cell lung cancer cells.
Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
Proteasome inhibitors in lung cancer.
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis.
Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma.
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.
Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy.
SPOP promotes FADD degradation and inhibits NF-?B activity in non-small cell lung cancer.
Sulforaphane Induced Apoptosis via Promotion of Mitochondrial Fusion and ERK1/2-Mediated 26S Proteasome Degradation of Novel Pro-survival Bim and Upregulation of Bax in Human Non-Small Cell Lung Cancer Cells.
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras.
The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner.
The effects of N-acetyl cysteine on the MG132 proteasome inhibitor-treated lung cancer cells in relation to cell growth, reactive oxygen species and glutathione.
The potential role of proteasome inhibitors in the treatment of lung cancer.
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
The role of proteasome inhibition in nonsmall cell lung cancer.
The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death.
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Treatment with p38 inhibitor partially prevents Calu-6 lung cancer cell death by a proteasome inhibitor, MG132.
Uncovering growth-suppressive MicroRNAs in lung cancer.
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Use of proteasome inhibition in the treatment of lung cancer.
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
[REGgamma promotes malignant behaviors of lung cancer cells].
Lupus Erythematosus, Systemic
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.
Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus.
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
Bioinformatics analysis of the CDK2 functions in neuroblastoma.
Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.
Detection of antibodies to the 20s proteasome by ELISA.
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
New evidence for the role of proteasome inhibitors in systemic lupus erythematosus.
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
The proteasome is a major autoantigen in multiple sclerosis.
Lupus Nephritis
The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture.
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man.]
Lymphocytic Choriomeningitis
CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting.
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver.
Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.
The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope.
Lymphohistiocytosis, Hemophagocytic
A Novel Model for IFN-?-Mediated Autoinflammatory Syndromes.
Lymphoma
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model.
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
A new large proteolytic complex distinct from the proteasome is present in the cytosol of fission yeast.
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma.
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Altering chemosensitivity by modulating translation elongation.
Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
Anti-body building: The exercise of advancing immune based myeloma therapies.
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Boronic Esters in Asymmetric Synthesis.
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I?B? kinase downregulation.
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of epstein-barr virus infection.
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy.
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Cloning and expression of a human pro(tea)some beta-subunit cDNA: a homologue of the yeast PRE4-subunit essential for peptidylglutamyl-peptide hydrolase activity.
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Comparative mechanisms of action of proteasome inhibitors.
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Corrigendum to <'The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis'> [Cellular Signalling 59 (2019) 76-84].
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Deubiquitinating enzymes as Therapeutic Targets in Cancer.
Development of Proteasome Inhibitors as Therapeutic Drugs.
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Differential impact of bortezomib on HL-60 and K562 cells.
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Dissecting bortezomib: development, application, adverse effects and future direction.
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Focal adhesion kinase as a therapeutic target of bortezomib.
From Bortezomib to Other Inhibitors of the Proteasome and Beyond.
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Identification of a new series of amides as non-covalent proteasome inhibitors.
Identification of proteasome inhibitors using analysis of gene expression profiles.
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Inhibitors of the AAA+ Chaperone p97.
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects.
Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.
Mantle cell lymphoma and its management: where are we now?
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Mechanisms of proteasome inhibitor action and resistance in cancer.
Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas.
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Molecular pathways: targeting proteasomal protein degradation in cancer.
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
New proteasome inhibitors in myeloma.
Non-Covalent Proteasome Inhibitors.
Novel proteasome inhibitors to overcome bortezomib resistance.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.
Patented small molecule inhibitors in the ubiquitin proteasome system.
Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Proteasome Inhibitor Drugs.
Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Proteasome inhibitors as therapeutics.
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Proteasome inhibitors in mantle cell lymphoma.
Proteasome inhibitors in the treatment of B-cell malignancies.
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Proteasome inhibitors: structure and function.
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
Rational approaches to design of therapeutics targeting molecular markers.
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment.
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.
Regulated Cell Death of Lymphoma Cells after Graded Mitochondrial Damage is Differentially Affected by Drugs Targeting Cell Stress Responses.
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
SCF E3 Ubiquitin Ligases as Anticancer Targets.
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Targeting the ubiquitin E1 as a novel anti-cancer strategy.
Targeting the ubiquitin proteasome system in haematological malignancies.
Targeting ubiquitin specific proteases for drug discovery.
The 26S proteasome complex: An attractive target for cancer therapy.
The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
The emerging role of lenalidomide in the management of lymphoid malignancies.
The epigenetics of mantle cell lymphoma.
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
The immunoproteasome as a target in hematologic malignancies.
The Immunoproteasome: An Emerging Therapeutic Target.
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
The molecular mechanisms of acquired proteasome inhibitor resistance.
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
The proteasome and its inhibitors in immune regulation and immune disorders.
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
The role of bortezomib in the treatment of lymphoma.
The role of the proteasome in AML.
The role of the ubiquitin proteasome system in lymphoma.
The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
The therapeutic potential of deubiquitinating enzyme inhibitors.
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma]
[New treatments of malignant lymphoma--a review].
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells.]
[Targeted therapy].
[The modulating effect of proapoptotic protein Bax on the resistance of malignant lymphoma cells to tumor necrosis factor related apoptosis inducing ligand-induced apoptosis]
[The proteasome?-?structural aspects and inhibitors: a second life for a validated drug target].
Lymphoma, B-Cell
BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells.
Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.
Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons.
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Proteasome inhibitors in the treatment of B-cell malignancies.
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Lymphoma, Follicular
Follicular lymphoma: expanding therapeutic options.
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Treatment of follicular non-Hodgkin's lymphoma: the old and the new.
Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.
Lymphoma, Large B-Cell, Diffuse
Blocking Autophagy Prevents Bortezomib-Induced NF-?B Activation by Reducing I-?B? Degradation in Lymphoma Cells.
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Proteasome inhibitors in the treatment of B-cell malignancies.
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
[Dynamics of the Functional Activity and Expression of Proteasome Subunits during Cellular Adaptation to Heat Shock].
Lymphoma, Large-Cell, Anaplastic
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Corrigendum to <'The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis'> [Cellular Signalling 59 (2019) 76-84].
The ?-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Lymphoma, Mantle-Cell
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Boronic Esters in Asymmetric Synthesis.
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I?B? kinase downregulation.
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Comparative mechanisms of action of proteasome inhibitors.
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Deubiquitinating enzymes as Therapeutic Targets in Cancer.
Development of Proteasome Inhibitors as Therapeutic Drugs.
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Differential impact of bortezomib on HL-60 and K562 cells.
Dissecting bortezomib: development, application, adverse effects and future direction.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Effects of proteasome inhibitors on bone cancer.
Effects of the proteasome inhibitor bortezomib in combination with chemotherapy for the treatment of mantle cell lymphoma: a meta-analysis
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
From Bortezomib to Other Inhibitors of the Proteasome and Beyond.
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Identification of proteasome inhibitors using analysis of gene expression profiles.
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib.
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Mantle cell lymphoma and its management: where are we now?
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Mechanisms of proteasome inhibitor action and resistance in cancer.
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Molecular pathways: targeting proteasomal protein degradation in cancer.
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
New proteasome inhibitors in myeloma.
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Novel proteasome inhibitors to overcome bortezomib resistance.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Patented small molecule inhibitors in the ubiquitin proteasome system.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Proteasome Inhibitor Drugs.
Proteasome inhibitors in cancer therapy.
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Proteasome inhibitors in mantle cell lymphoma.
Proteasome inhibitors in the treatment of B-cell malignancies.
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Proteasome inhibitors: structure and function.
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
Rational approaches to design of therapeutics targeting molecular markers.
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment.
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
SCF E3 Ubiquitin Ligases as Anticancer Targets.
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Targeting the ubiquitin E1 as a novel anti-cancer strategy.
Targeting the ubiquitin proteasome system in haematological malignancies.
Targeting ubiquitin specific proteases for drug discovery.
The 26S proteasome complex: An attractive target for cancer therapy.
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
The epigenetics of mantle cell lymphoma.
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
The immunoproteasome as a target in hematologic malignancies.
The Immunoproteasome: An Emerging Therapeutic Target.
The molecular mechanisms of acquired proteasome inhibitor resistance.
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
The proteasome and its inhibitors in immune regulation and immune disorders.
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
The role of the proteasome in AML.
The therapeutic potential of deubiquitinating enzyme inhibitors.
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Lymphoma, Non-Hodgkin
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Boron chemicals in diagnosis and therapeutics.
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Bortezomib.
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Proteasome inhibitors in non-Hodgkin's lymphoma.
Proteasome inhibitors: antitumor effects and beyond.
Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
The Proteasome and Proteasome Inhibitors in Cancer Therapy.
The proteasome and proteasome inhibitors in cancer therapy.
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
The resistance mechanisms of proteasome inhibitor bortezomib.
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
The ubiquitin proteasome pathway from bench to bedside.
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Lymphoma, Primary Effusion
Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
Lymphoma, T-Cell
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC Dependent Cell Death in T-Cell and Hodgkin Lymphoma.
Lymphoma, T-Cell, Cutaneous
cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas.
Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Proteasome inhibition as a novel mechanism of the proapoptotic activity of ?-secretase inhibitor I in cutaneous T-cell lymphoma.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Peripheral
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Lymphopenia
Differential expression of genes associated with T lymphocytes function in septic patients with hypoxemia challenge.
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Lymphoproliferative Disorders
Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.
The role of aberrant proteolysis in lymphomagenesis.
Machado-Joseph Disease
Molecular clearance of ataxin-3 is regulated by a mammalian E4.
Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Macular Degeneration
Increased 26S proteasome non-ATPase regulatory subunit 1 in the aqueous humor of patients with age-related macular degeneration.
Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs.
Transformation of the proteasome with age-related macular degeneration.
Malaria
20S proteasomes secreted by the malaria parasite promote its growth.
A Proteasome Mutation Sensitizes P. falciparum Cam3.II K13C580Y Parasites to DHA and OZ439.
Analysis of the Plasmodium falciparum proteasome using Blue Native PAGE and label-free quantitative mass spectrometry.
Antimalarials: Novel proteasome inhibitor combats malaria.
Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome.
Characterization of the 26S proteasome network in Plasmodium falciparum.
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
Genetic differentiation at the 3'UTR of PROS-Ag25: a cDNA homologue of Drosophila melanogaster proteasome subunit PROS-Dm25 in the malaria vector Anopheles gambiae.
Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria.
Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors.
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Malaria parasites regulate intra-erythrocytic development duration via serpentine receptor 10 to coordinate with host rhythms.
Mammalian Deubiquitinating Enzyme Inhibitors Display in Vitro and in Vivo Activity against Malaria Parasites and Potentiate Artemisinin Action.
Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins.
Polymorphisms of transporter associated with antigen processing type 1 (TAP1), proteasome subunit beta type 9 (PSMB9) and their common promoter in African children with different manifestations of malaria.
Proteasome inhibitors block development of Plasmodium spp.
Proteasome inhibitors in development for malaria.
Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites.
Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Targeting SUMOylation in Plasmodium as a Potential Target for Malaria Therapy.
The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
The prokaryotic ClpQ protease plays a key role in growth and development of mitochondria in Plasmodium falciparum.
The proteasome as a target to combat malaria: hits and misses.
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target.
The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.
The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?
Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast.
Threonine peptidases as drug targets against malaria.
Transcriptional analysis identifies potential biomarkers and molecular regulators in acute malaria infection.
Ubiquitin Proteasome System as a Potential Drug Target for Malaria.
Validation of Babesia proteasome as a drug target.
Malaria, Cerebral
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Malnutrition
Processes underlying the nutritional programming of embryonic development by iron deficiency in the rat.
Proteasome production in human muscle during nutritional inhibition of myofibrillar protein degradation.
Mania
Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorder.
Marek Disease
Marek's disease virus Meq oncoprotein interacts with chicken HDAC 1 and 2 and mediates their degradation via proteasome dependent pathway.
Mastocytoma
Genistein-induced apoptosis of p815 mastocytoma cells is mediated by Bax and augmented by a proteasome inhibitor, lactacystin.
Proteasome-driven turnover of tryptophan hydroxylase is triggered by phosphorylation in RBL2H3 cells, a serotonin producing mast cell line.
Medulloblastoma
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-?B signaling, and synergizes with an ERK inhibitor.
Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Cytogenetic and molecular biological characterization of an adult medulloblastoma.
Exploring the role and clinical implications of proteasome inhibition in medulloblastoma.
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
Melanoma
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.
ABT-737 synergizes with Bortezomib to kill melanoma cells.
Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28.
Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.
An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines.
Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21(WAF1) in human melanoma cells.
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model.
Bortezomib enhances the antitumor effects of interferon-? gene transfer on melanoma cells.
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells.
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein.
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells.
Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.
Depigmentation of ?-melanocyte-stimulating hormone-treated melanoma cells by ?-mangostin is mediated by selective autophagy.
Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription.
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope.
Expression of heme oxygenase-1 in response to proteasomal inhibition.
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism.
Identification of key candidate genes involved in melanoma metastasis.
IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome.
IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase.
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Imidazole inhibits B16 melanoma cell migration via degradation of beta-catenin.
Immunoproteasomes edit tumors, which then escapes immune recognition.
Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis.
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Lactacystin inhibits cathepsin A activity in melanoma cell lines.
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex.
Mechanisms of apoptosis induced by anticancer compounds in melanoma cells.
Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals.
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Molecularly targeted therapy for melanoma: current reality and future options.
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.
Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2.
New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy.
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine.
Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.
Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death.
Proteasome inhibition blocks NF-?B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Proteasome inhibitors against amelanotic melanoma.
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells.
Regulation of BRCA1 by protein degradation.
Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Retraction: Proteasome Inhibition Blocks NF-?B and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs.
Selective growth inhibition of human malignant melanoma cells by syringic acid-derived proteasome inhibitors.
Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells.
Targeting PSMD14 inhibits melanoma growth through SMAD3 stabilization.
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
The prognostic value of the proteasome activator subunit gene family in skin cutaneous melanoma.
The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.
The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.
The Zinc-finger AN1-type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
West Nile Virus NS1 Antagonizes Interferon Beta Production by Targeting RIG-I and MDA5.
Melanoma, Amelanotic
Increased level of p27 subunit of proteasomes and its co-localization with tyrosinase in amelanotic melanoma cells indicate its direct role in the regulation of melanin biosynthesis.
Proteasome inhibitors against amelanotic melanoma.
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity.
Melanoma, Experimental
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
CtBP2 downregulation during neural crest specification induces expression of Mitf and REST, resulting in melanocyte differentiation and sympathoadrenal lineage suppression.
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade).
Memory Disorders
Age-related memory deficits are associated with changes in protein degradation in brain regions critical for trace fear conditioning.
Alzheimer-associated mutant ubiquitin impairs spatial reference memory.
Meningioma
Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Meningitis
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Meningoencephalitis
Proteasome serves as pivotal regulator in Angiostrongylus cantonensis-induced eosinophilic meningoencephalitis.
Mental Retardation, X-Linked
UBE2A, which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-linked mental retardation syndrome.
Mesothelioma
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Correction: Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo.
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells.
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Mesothelioma, Malignant
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Metabolic Diseases
Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein.
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
Metabolic Syndrome
Effect of pioglitazone on the expression of ubiquitin proteasome system and autophagic proteins in rat pancreas with metabolic syndrome.
Exercise training prevents the perivascular adipose tissue-induced aortic dysfunction with metabolic syndrome.
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
The 1316T>C missenses mutation in MTHFR contributes to MTHFR deficiency by targeting MTHFR to proteasome degradation.
Microcephaly
Biallelic variants in PSMB1 encoding the proteasome subunit ?6 cause impairment of proteasome function, microcephaly, intellectual disability, developmental delay and short stature.
Microscopic Polyangiitis
Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.
Mitochondrial Diseases
The ubiquitin-proteasome system and its crosstalk with mitochondria as therapeutic targets in medicine.
Mixed Connective Tissue Disease
Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.
Monoclonal Gammopathy of Undetermined Significance
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.
Motor Neuron Disease
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome.
Clinicopathological correlations in behavioural variant frontotemporal dementia.
The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions.
The Ubiquitin Proteasome System Is a Key Regulator of Pluripotent Stem Cell Survival and Motor Neuron Differentiation.
Mouth Diseases
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Mouth Neoplasms
A novel transcript variant of proteasome activator 28?: Identification and function in oral cancer cells.
Gene expression profiling predicts the development of oral cancer.
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
The significance of PA28? and U2AF1 in oral mucosal carcinogenesis.
Movement Disorders
Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease?
Mucopolysaccharidoses
Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein.
Mucopolysaccharidosis III
Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB.
Multiple Myeloma
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
(Immuno)proteasomes as therapeutic target in acute leukemia.
?-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
?-Lactone derivatives and their anticancer activities: A short review.
A case of bortezomib (Velcade)-induced Stevens-Johnson syndrome confirmed by patch test.
A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment.
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model.
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, ?-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.
A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
A metabolic switch in proteasome inhibitor resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib.
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
A novel RP2 missense mutation Q158P identified in an X-linked retinitis pigmentosa family impaired RP2 protein stability.
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
A phase 0 analysis of ixazomib in patients with glioblastoma.
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma.
A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
A Practical Review of Proteasome Pharmacology.
A practical review on carfilzomib in multiple myeloma.
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
A review of the proteasome inhibitor bortezomib in multiple myeloma.
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-?B Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor ?B pathways.
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Activity-based imaging probes of the proteasome.
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
Acute pancreatitis caused by bortezomib.
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Advances in and applications of proteasome inhibitors.
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Advances in the biology and treatment of myeloma bone disease.
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro.
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
An inhibitor of proteasome ?2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
An inhibitor of ubiquitin conjugation and aggresome formation.
An NMR Study of the Bortezomib Degradation under Clinical Use Conditions.
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
An oral proteasome inhibitor for multiple myeloma.
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
An update in treatment options for multiple myeloma in nontransplant eligible patients.
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ?3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Anti-Inflammatory and Immunomodulatory Effects of Bortezomib in Various in vivo Models.
Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.
Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells.
Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-?B and MAPK signaling in rats.
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl?dependent mechanisms.
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.
Association of response endpoints with survival outcomes in multiple myeloma.
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide a.
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Belantamab Mafodotin: First Approval.
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers.
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-?B signaling.
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma.
Black tea polyphenols inhibit tumor proteasome activity.
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Boosting Immunity against Multiple Myeloma.
Boron chemicals in diagnosis and therapeutics.
Boronic Esters in Asymmetric Synthesis.
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.
Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Bortezomib alters sour taste sensitivity in mice.
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.
Bortezomib and bilateral herpes zoster.
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Bortezomib and Waldenstrom's macroglobulinemia.
Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition.
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Bortezomib for the treatment of mantle cell lymphoma: an update.
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bortezomib Improved the Joint Manifestations of Rheumatoid Arthritis in Three Patients.
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Bortezomib in kidney transplantation.
Bortezomib in multiple myeloma.
Bortezomib in multiple myeloma: a practice guideline.
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late?
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Bortezomib induces autophagic death in proliferating human endothelial cells.
Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Bortezomib Partially Improves Laminin ?2 Chain-Deficient Muscular Dystrophy.
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
Bortezomib protects against dextran sulfate sodium?induced ulcerative colitis in mice.
Bortezomib resistance in a myeloma cell line is associated to PSM?5 overexpression and polyploidy.
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RAR?/STAT1 axis.
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.
Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients.
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.
Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
Bortezomib treatment for multiple myeloma.
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.
Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
Bortezomib-induced acute pancreatitis: Case report and review of the literature.
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Bortezomib-induced bronchiolitis obliterans organizing pneumonia.
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Bortezomib-induced histiocytoid Sweet syndrome.
Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy.
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats.
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice.
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.
Bortezomib-induced Severe Congestive Heart Failure.
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.
Bortezomib-induced skin eruption.
Bortezomib-Induced Sweet's Syndrome Confirmed by Rechallenge.
Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review?.
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Bortezomib: a new player in pre- and post-transplant desensitization?
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Bortezomib: the evidence of its clinical impact in multiple myeloma.
Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
BSc2118 is a Novel Proteasome Inhibitor with Activity against Multiple Myeloma.
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.
CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma.
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Cardiotoxicity with carfilzomib at doses greater than 27?mg/m(2): A case series.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Cardiovascular adverse events in multiple myeloma patients.
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.
Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
Carfilzomib for the treatment of multiple myeloma.
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
Carfilzomib induced cardiotoxicity in a multiple myeloma patient.
Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report.
Carfilzomib-induced thrombotic microangiopathy: A case based review.
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
Carfilzomib.
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.
Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma.
Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Carfilzomib: a Tale of a Heartbreaking Moment. Case Report and Concise Review of the Literature.
Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Catechol Containing Polyelectrolyte Complex Nanoparticles as Local Drug Delivery System for Bortezomib at Bone Substitute Materials.
CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341.
CD38-Directed Therapies for Management of Multiple Myeloma.
Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity.
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1.
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Characteristics, pathogenesis, and novel treatments for multiple myeloma.
Characterization of noncompetitive regulators of proteasome activity.
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Chimeric antigen receptor T cell therapies for multiple myeloma.
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NF?B recruitment to IL-1? and TNF? gene promoters in human macrophages.
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients.
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network.
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Clinical development of novel proteasome inhibitors for cancer treatment.
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Clinical significance of cancer-related fatigue in multiple myeloma patients.
Clinical translation in multiple myeloma: from bench to bedside.
Clinical update: novel targets in gynecologic malignancies.
Clinical use of proteasome inhibitors in the treatment of multiple myeloma.
Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells.
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response.
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents".
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Comparative mechanisms of action of proteasome inhibitors.
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Controversies in multiple myeloma: to transplant or not?
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China.
Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis.
Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.
Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice.
Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.
Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome.
Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib.
CSNK1?1 mediates malignant plasma cell survival.
Cullin-RING ligases (CRLs) as attractive anti-cancer targets.
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Current antibody-based therapies for the treatment of multiple myeloma.
Current approaches for the treatment of multiple myeloma.
Current approaches to the initial treatment of symptomatic multiple myeloma.
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Current role of radiation therapy for multiple myeloma.
Current standards for first-line therapy of multiple myeloma.
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Current treatment of refractory and relapsed multiple myeloma.
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation - A Retrospective Analysis.
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
DANFIN functions as an inhibitor of transcription factor NF-?B and potentiates the antitumor effect of bortezomib in multiple myeloma.
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Daratumumab for the treatment of AL amyloidosis.
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Daratumumab: First Global Approval.
Dealing with neuropathy in plasma-cell dyscrasias.
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from ?-amino acid as proteasome inhibitors.
Design, Synthesis and Biological Evaluation of Peptidyl Epoxyketone Proteasome Inhibitors Composed of ?-amino Acids.
Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma.
Deubiquitinating enzymes as Therapeutic Targets in Cancer.
Development and characterization of liposomal formulation of bortezomib.
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Development of ?-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination.
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Development of Proteasome Inhibitors as Therapeutic Drugs.
Development of proteasome inhibitors in oncology and autoimmune diseases.
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in China.
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Differential impact of bortezomib on HL-60 and K562 cells.
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Discovery and development of second-generation proteasome inhibitors.
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Discovery of Natural Product Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Discovery, Development, and clinical applications of bortezomib.
Dissecting bortezomib: development, application, adverse effects and future direction.
Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.
DKK1 Activates Non-canonical NF-kB Signaling via IL-6 Induced CKAP4 receptor in Multiple Myeloma.
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Downregulation of PA28? induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf.
Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Economic and clinical impact of multiple myeloma to managed care.
Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Effect of Bortezomib Regimens and Daratumumab Monotherapy on Cellular Immunity in Multiple Myeloma Patients.
Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Effects of bortezomib on the immune system: a focus on immune regulation.
Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
Effects of proteasome inhibitors on bone cancer.
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.
Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Efficacy of Proteasome Inhibitor-Based Maintenance following Autologous Transplantation in Multiple Myeloma: a systematic review and meta-analysis.
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models.
Elderly patients with multiple myeloma: towards a frailty approach?
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.
Elotuzumab as a novel anti-myeloma immunotherapy.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Emerging agents and regimens for multiple myeloma.
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Emerging drug development technologies targeting ubiquitination for cancer therapeutics.
Emerging role of novel combinations for induction therapy in multiple myeloma.
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
Emerging Therapies in Multiple Myeloma.
Emerging therapies targeting the ubiquitin proteasome system in cancer.
Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement.
Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma.
Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma.
Expanding role of bortezomib in multiple myeloma: nursing implications.
Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
First proteasome inhibitor approved for multiple myeloma.
Focal adhesion kinase as a therapeutic target of bortezomib.
Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
From Bortezomib to Other Inhibitors of the Proteasome and Beyond.
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Frontline therapy for newly diagnosed patients with multiple myeloma.
Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in Multiple Myeloma.
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Genome-wide approaches to systematically identify substrates of the ubiquitin-proteasome pathway.
Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: Multiple, diverse signals converging on a few key downstream regulators.
Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Have drug combinations supplanted stem cell transplantation in myeloma?
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS.
High-risk Multiple Myeloma: Definition and Management.
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
How I manage the toxicities of myeloma drugs.
How I treat the young patient with multiple myeloma.
How I treat: New agents in myeloma.
How is patient care for multiple myeloma advancing?
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.
Identification of a new series of amides as non-covalent proteasome inhibitors.
Identification of a p53-based portable degron based on the MDM2-p53 binding region.
Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe.
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
Identification of proteasome inhibitors using analysis of gene expression profiles.
Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors.
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.
Immunomodulatory drugs in multiple myeloma.
Immunomodulatory drugs in the treatment of multiple myeloma.
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases.
Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.
Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease.
Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.
Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.
Improved SILAC Quantification with Data-Independent Acquisition to Investigate Bortezomib-Induced Protein Degradation.
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma.
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells.
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis.
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.
Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells.
Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients.
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown.
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Inhibiting the proteasome reduces molecular and biological impacts of the natural product insecticide, spinosad.
Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.
Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
Inhibition of HIF1?-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma.
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Inhibition of the ?-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.
Inhibition of the Human Proteasome by Imidazoline Scaffolds.
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Inhibition of the neuronal NF?B pathway attenuates bortezomib-induced neuropathy in a mouse model.
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Inhibition of the Ubiquitin-Proteasome System by Natural Products for Cancer Therapy.
Inhibitors of the AAA+ Chaperone p97.
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies.
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method.
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Investigational agent MLN9708/2238 targets tumor suppressor microRNA-33b in MM cells.
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies.
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Isatuximab: A Review of Its Use in Multiple Myeloma.
Isatuximab: First Approval.
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells.
Ixazomib enhances parathyroid hormone-induced ?-catenin/T-cell factor signaling by dissociating ?-catenin from the parathyroid hormone receptor.
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Ixazomib for the treatment of multiple myeloma.
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Ixazomib inhibits myeloma cell proliferation by targeting UBE2K.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice.
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Ixazomib-induced cutaneous necrotizing vasculitis.
Ixazomib: a novel drug for multiple myeloma.
Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma.
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
Kyprolis gains accelerated approval for multiple myeloma.
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib.
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.
Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Management of Carfilzomib-Associated Cardiac Adverse Events.
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Marizomib for central nervous system-multiple myeloma.
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor?+?dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy.
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma.
Mechanisms of proteasome inhibitor action and resistance in cancer.
Melphalan and its role in the management of patients with multiple myeloma.
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Methods for measuring proteasome activity: current limitations and future developments.
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells.
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients.
Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Molecular pathways: targeting proteasomal protein degradation in cancer.
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Monoclonal antibodies in multiple myeloma.
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
Monoclonal antibody therapy in multiple myeloma.
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Multiple Myeloma Gets Three New Drugs.
Multiple myeloma maintenance therapy: A review of the pharmacologic treatment.
Multiple myeloma: lusting for NF-kappaB.
Multiple myeloma: new uses for available agents, excitement for the future.
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
Nadir lymphocytopenia as a risk factor of bloodstream infection during molecular targeting pharmacotherapy in multiple myeloma.
Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway.
Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development.
Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors.
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
Neurotoxicity induced by antineoplastic proteasome inhibitors.
New developments in post-transplant maintenance treatment of multiple myeloma.
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
New drugs in early development for treating multiple myeloma: all that glitters is not gold.
New drugs in multiple myeloma - role of carfilzomib and pomalidomide.
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.
New insights into therapeutic targets in myeloma.
New orally active proteasome inhibitors in multiple myeloma.
New prognostic biomarkers in multiple myeloma.
New proteasome inhibitors in myeloma.
New proteasome inhibitors in the treatment of multiple myeloma.
New Targets and New Agents in High-Risk Multiple Myeloma.
New treatments for myeloma.
Next-generation proteasome inhibitor approved in multiple myeloma.
Next-generation proteasome inhibitors for cancer therapy.
NF-kappa B as a therapeutic target in multiple myeloma.
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Non-Covalent Proteasome Inhibitors.
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects.
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo.
Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents.
Novel Agents in Multiple Myeloma.
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
Novel approaches to treatment of double-refractory multiple myeloma.
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Novel generation of agents with proven clinical activity in multiple myeloma.
Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Novel proteasome inhibitors to overcome bortezomib resistance.
Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Oculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report.
Old and new generation proteasome inhibitors in multiple myeloma.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Oral ixazomib maintenance therapy in multiple myeloma.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Oral proteasome inhibitor maintenance for multiple myeloma.
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Oxidative deboronation of the Peptide boronic Acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome p450 reaction.
Oxidative stress and proteasome inhibitors in multiple myeloma.
Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment.
Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
Pancreatic Involvement by Plasma Cell Neoplasms.
Panobinostat for the treatment of multiple myeloma: the evidence to date.
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Part II: role of maintenance therapy in transplant-ineligible patients.
Patented small molecule inhibitors in the ubiquitin proteasome system.
Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG?132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Peripheral Artery Disease and Stroke.
Perspectives in the treatment of multiple myeloma.
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution and Excretion of Carfilzomib in Rats.
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma; NPI 0052 101 Part 1.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-?B signaling pathway.
PKC? Regulates Death Receptor 5 Expression Induced by PS-341 through ATF4- ATF3/CHOP axis in Human Lung Cancer Cells.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity.
Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
PO-45 - The role of microvesicles in multiple myeloma progression.
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Pomalidomide for multiple myeloma.
Pomalidomide for the management of refractory multiple myeloma.
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients.
Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting ?2 and ?5 subunits.
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Pre-salvage ISS and Other Important Outcome Associations in CD34 Selected Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Preclinical data with bortezomib in lung cancer.
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant.
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells.
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Profiling proteasome activity in tissue with fluorescent probes.
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Progress and Paradigms in Multiple Myeloma.
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Prolonged endoplasmic reticulum stress promotes mislocalization of immunoglobulins to the cytoplasm.
Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma.
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum.
Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
Proteasome function is required for platelet production.
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Proteasome inhibition and its therapeutic potential in multiple myeloma.
Proteasome inhibition and multiple myeloma.
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Proteasome inhibition as novel treatment strategy in leukaemia.
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.
Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Proteasome inhibition for antibody-mediated allograft rejection.
Proteasome inhibition for the treatment of glioblastoma.
Proteasome inhibition for treatment of multiple myeloma: clinical update.
Proteasome inhibition in cancer therapy.
Proteasome inhibition in multiple myeloma.
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Proteasome inhibition in multiple myeloma: lessons for other cancers.
Proteasome inhibition in multiple myeloma: therapeutic implication.
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Proteasome inhibition: a new approach for the treatment of malignancies.
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Proteasome inhibition: novel therapy for multiple myeloma.
Proteasome inhibitor associated thrombotic microangiopathy.
Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Proteasome inhibitor drugs on the rise.
Proteasome Inhibitor Drugs.
Proteasome inhibitor for treatment of multiple myeloma.
Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Proteasome Inhibitor Induces Apoptosis through Induction of Endoplasmic Reticulum Stress.
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Proteasome inhibitor therapy in multiple myeloma.
Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
Proteasome Inhibitors as a Potential Cause of Heart Failure.
Proteasome inhibitors as therapeutics.
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Proteasome inhibitors for multiple myeloma.
Proteasome inhibitors for the treatment of multiple myeloma.
Proteasome Inhibitors for the Treatment of Multiple Myeloma.
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Proteasome inhibitors in acute leukemia.
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Proteasome inhibitors in cancer therapy.
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Proteasome inhibitors in first-line treatment of transplant-ineligible multiple myeloma patients.
Proteasome inhibitors in mantle cell lymphoma.
Proteasome inhibitors in multiple myeloma.
Proteasome inhibitors in multiple myeloma: 10 years later.
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Proteasome inhibitors in the treatment of B-cell malignancies.
Proteasome inhibitors in the treatment of multiple myeloma.
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Proteasome inhibitors.
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Proteasome inhibitors: antitumor effects and beyond.
Proteasome inhibitors: Dozens of molecules and still counting.
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Proteasome inhibitors: poisons and remedies.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Proteasome inhibitors: structure and function.
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
Proteasome regulators: activators and inhibitors.
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Proteasome-associated deubiquitinases and cancer.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Proteostenosis and plasma cell pathophysiology.
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway.
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.
Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-?B pathway.
Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway.
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma - Polish retrospective multicenter analysis.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Real-World Treatment of Patients With Relapsed/Refractory Myeloma.
Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment.
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Recent updates on CAR T clinical trials for multiple myeloma.
Recommendations on the management of multiple myeloma in 2020.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Reduced response of IRE1?/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.
Refractory primary Sjögren syndrome successfully treated with bortezomib.
Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: Survival outcomes and factors influencing them.
Relapsed refractory multiple myeloma: a comprehensive overview.
Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for fas-mediated apoptosis in human leukemic cells.
Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells.
Revealing targeted therapy for human cancer by gene module maps.
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma.
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Role of carfilzomib in the treatment of multiple myeloma.
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-?B, Hypertrophic Gene Expression and Oxidative Stress.
Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-?B signaling pathway.
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Safety of ixazomib for the treatment of multiple myeloma.
Safety of proteasome inhibitors for treatment of multiple myeloma.
SCF E3 Ubiquitin Ligases as Anticancer Targets.
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Second generation proteasome inhibitors in multiple myeloma.
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Sequence analysis of ?-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Sequencing bortezomib with chemotherapy and targeted agents.
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma.
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-?B Through the Modulation of I?B? Sumoylation.
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma.
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Small Molecule Inhibitors of the Proteasome's Regulatory Particle.
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
Small-molecule inhibitors of proteasome activity.
Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.
Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells.
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78.
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.
Structure-based design of ?1i or ?5i specific inhibitors of human immunoproteasomes.
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD(®) immunomodulatory drug pomalidomide.
Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro.
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma.
Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Targeted Therapies for Multiple Myeloma.
Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Targeted treatments for multiple myeloma: specific role of carfilzomib.
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice.
Targeting Deubiquitinases in Cancer.
Targeting E3 ubiquitin ligases for cancer therapy.
Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors.
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.
Targeting proteasomes as therapy in multiple myeloma.
Targeting proteasomes in infectious organisms to combat disease.
Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma.
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress?mediated cell death in multiple myeloma cells.
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Targeting the proteasome pathway.
Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy.
Targeting the ubiquitin E1 as a novel anti-cancer strategy.
Targeting the ubiquitin proteasome system in haematological malignancies.
Targeting the ubiquitin+proteasome system in solid tumors.
Targeting the ubiquitin-proteasome pathway in cancer therapy.
Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors.
Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Targeting the UPS as therapy in multiple myeloma.
Targeting ubiquitin specific proteases for drug discovery.
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
The 26S proteasome complex: An attractive target for cancer therapy.
The Actions and Mechanisms of P2X7R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain.
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
The aggresome pathway as a target for therapy in hematologic malignancies.
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
The Diagnosis and Treatment of Multiple Myeloma.
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells.
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma.
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
The G-Allele of the PSMA6 -8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
The Holy Grail: Solid Tumor Efficacy by Proteasome Inhibition.
The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
The immunoproteasome as a target in hematologic malignancies.
The immunoproteasome as a therapeutic target for hematological malignancies.
The Immunoproteasome: An Emerging Therapeutic Target.
The immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapies.
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium.
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.
The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
The molecular mechanisms of acquired proteasome inhibitor resistance.
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
The next generation of novel therapies for the management of relapsed multiple myeloma.
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.
The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
The persisting challenge of selective and specific proteasome inhibition.
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
The power of proteasome inhibition in multiple myeloma.
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
The proteasome and its inhibitors in immune regulation and immune disorders.
The Proteasome and Proteasome Inhibitors in Cancer Therapy.
The proteasome and proteasome inhibitors in cancer therapy.
The proteasome and proteasome inhibitors in multiple myeloma.
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
The proteasome in health and disease.
The proteasome in terminal plasma cell differentiation.
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-?1.
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection.
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis.
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
The proteasome inhibitor bortezomib is a potent inducer of zinc-finger AN1-type domain 2a gene expression: role of HSF1/HSF2 heterocomplexes.
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
The proteasome inhibitor PS-341 (Bortezomib) induces calpain-dependent I{kappa}B{alpha} degradation.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
The Proteasome Inhibitor, Bortezomib, Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
The proteasome: a novel therapeutic target in haematopoietic malignancy.
The proteasome: a worthwhile target for the treatment of solid tumours?
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
The resistance mechanisms of proteasome inhibitor bortezomib.
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib.
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
The role of carfilzomib in relapsed/refractory multiple myeloma.
The role of cystatin C as a proteasome inhibitor in multiple myeloma.
The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma.
The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents.
The role of proteasome in malignant diseases.
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
The role of the proteasome in AML.
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
The start of a new wave: developments in proteasome inhibition in multiple myeloma.
The therapeutic potential of deubiquitinating enzyme inhibitors.
The therapeutic potential of microbial proteasome inhibitors.
The ubiquitin proteasome pathway from bench to bedside.
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance.
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.
The UPS: a promising target for breast cancer treatment.
The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
The use of novel agents in multiple myeloma patients with hepatic impairment.
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice.
Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
Thiasyrbactins Induce Cell Death via Proteasome Inhibition in Multiple Myeloma Cells.
Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes.
Thrombotic microangiopathy associated with proteasome inhibitors.
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics.
To b(ortezomib) or not to be: the stroma's the thing.
Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice.
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Transcriptome sequencing (RNA-seq) analysis of the effects of metal nanoparticle exposure on the transcriptome of Chlamydomonas reinhardtii.
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
Treatment of Relapsed/Refractory Multiple Myeloma.
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model.
Treatment Options for Triple-class Refractory Multiple Myeloma.
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013.
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.
Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding.
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy.
Ubiquitylation and cancer development.
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.
Update on proteasome inhibitors in multiple myeloma.
Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Upregulated expression and function of the ?4?1 integrin in multiple myeloma cells resistant to bortezomib.
Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors.
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: A single-center experience.
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy.
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Vision Statement for Multiple Myeloma: Future Directions.
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
Why bortezomib cannot go with 'green'?
Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma.
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes.
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I?B? and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
YWHAE/14-3-3? expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma.
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-?B in multiple myeloma.
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004]
[Aggravated post-herpetic neuralgia due to bortezomib]
[Antibody therapy for multiple myeloma: novel approaches and future perspectives].
[Autologous peripheral blood stem cell transplantation for double-refractory myeloma with K-RAS and N-RAS mutations].
[Bortezomib-induced acute neutrophilic dermatosis.]
[CAR Technology and Its Application in Treatment of Multiple Myeloma].
[Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].
[Classification and synthesis of ubiquitin-proteasome inhibitor].
[Current status and future prospects of immunotherapy for multiple myeloma].
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man.]
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
[Effects of Proteasome Inhibitor PS-341 on the Multiple Cytokine Expressions of Mesenchymal Stem Cells from Bone Marrow in Patients with Multiple Myeloma.]
[Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma]
[Hypercalcemia of malignancy: clinical features, diagnosis and treatment]
[In Process Citation]
[Lung injury associated with bortezomib therapy in Japan].
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]
[Macrocalyxin A induces apoptosis of multiple Myeloma U266 cells through inhibiting the proteasome].
[Management of multiple myeloma in the relapsed/refractory patient].
[Management of proteasome inhibitor-induced peripheral neuropathy].
[Mania Associated with the Use of Bortezomib and Dexamethasone].
[Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
[Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
[Multiple myeloma and other plasma cell dyscrasias].
[Multiple myeloma: a focus on drugs under development].
[Multiple myeloma: update on pathophysiology and management].
[Multiple myeloma].
[New treatment of multiple myeloma.]
[Plasma cells].
[Pomalidomide for multiple myeloma].
[Prognostic significance of sequencing-based MRD detection in multiple myeloma].
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy]
[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma]
[Proteasome inhibitor induces apoptosis and influences the expression of notch 1 and NF-kappaB in multiple myeloma RPMI8226 cells]
[Proteasome inhibitors for multiple myeloma]
[Proteasome inhibitors in cancer therapy].
[Proteasome inhibitors in treatment of multiple myeloma].
[Proteasome inhibitors]
[Proteasome inhibitors].
[Proteasome inhibitor].
[Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile].
[Role of bortezomib in the treatment of multiple myeloma]
[Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma]
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
[Study on natural products for drug development].
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
[The place of immunotherapy in plasma cell myeloma treatment].
[The proteasome?-?structural aspects and inhibitors: a second life for a validated drug target].
[Treatment of newly diagnosed multiple myeloma in transplant-eligible patients].
[Treatment strategy for untreated transplantation-ineligible multiple myeloma patients].
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]
[Triplets therapy for the patients of multiple myeloma].
[Use of proteasome inhibitors in the treatment of patients with multiple myeloma]
Multiple Sclerosis
Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis.
Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis.
Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism.
Detection of antibodies to the 20s proteasome by ELISA.
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon-? therapy in Latvians.
Glatiramer acetate and nanny proteins restrict access of the multiple sclerosis autoantigen myelin basic protein to the 26S proteasome.
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population.
Proteasome antibodies in paraneoplastic cerebellar degeneration.
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
The proteasome is a major autoantigen in multiple sclerosis.
Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Proteasome antibodies in patients with cancer or multiple sclerosis.
Multiple System Atrophy
Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human ?-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
Murine Acquired Immunodeficiency Syndrome
Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects IkappaBalpha turnover.
Muscle Weakness
Effect of Proteasome Inhibitors on Endotoxin Induced Diaphragm Dysfunction.
Muscular Atrophy
Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy.
Altered proteasome function and subunit composition in aged muscle.
Angiotensin (1-7) Decreases Myostatin-Induced NF-?B Signaling and Skeletal Muscle Atrophy.
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle.
Caloric restriction optimizes the proteasome pathway with aging in rat plantaris muscle: implications for sarcopenia.
Calpain and capase-3 play required roles in immobilization-induced limb muscle atrophy.
Changes in 20S proteasome activity during ageing of the LOU rat.
Characterization of the Ubiquitin Specific Protease (USP) family members in the fast and slow muscle fibers from Chinese perch (Siniperca chuatsi).
Chemotherapy-induced muscle wasting: association with NF-?B and cancer cachexia.
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Coordinate expression of the 19S regulatory complex and evidence for ubiquitin-dependent telethonin degradation in the unloaded soleus muscle.
Daily variations in dietary lysine content alter the expression of genes related to proteolysis in chicken pectoralis major muscle.
Denervation-Induced Activation of the Standard Proteasome and Immunoproteasome.
Deubiquitinases in skeletal muscle atrophy.
Deubiquitinating enzymes in skeletal muscle atrophy-An essential role for USP19.
Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro.
Down-regulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia.
Dynamics of autophagy and ubiquitin proteasome system coordination and interplay in skeletal muscle atrophy.
Effect of different dietary protein composition on skeletal muscle atrophy by suspension hypokinesia/hypodynamia in rats.
Effect of flywheel-based resistance exercise on processes contributing to muscle atrophy during unloading in adult rats.
Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.
High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis.
High Fat With High Sucrose Diet Leads to Obesity and Induces Myodegeneration.
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
HMGB1 release and redox regulation accompany regeneration and remodeling of skeletal muscle.
Implication of altered ubiquitin-proteasome system and ER stress in the muscle atrophy of diabetic rats.
Indoxyl sulfate induces myotube atrophy by ROS-ERK and JNK-MAFbx cascades.
Inducible Rpt3, a Proteasome Component, Knockout in Adult Skeletal Muscle Results in Muscle Atrophy.
Inhibition of the proteasome partially attenuates atrophy in botulinum neurotoxin treated skeletal muscle.
Insulin signaling and skeletal muscle atrophy and autophagy in transition dairy cows either overfed energy or fed a controlled energy diet prepartum.
Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions.
Ketone Bodies Attenuate Wasting in Models of Atrophy.
Lack of ?2 -adrenoceptors aggravates heart failure-induced skeletal muscle myopathy in mice.
Maintenance of muscle mass and load-induced growth in Muscle RING Finger 1 null mice with age.
Mechanisms That Activate 26S Proteasomes and Enhance Protein Degradation.
Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway.
Molecular characterization of the MuRF genes in rainbow trout: Potential role in muscle degradation.
Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization.
Overexpression of the Mitochondrial T3 Receptor Induces Skeletal Muscle Atrophy during Aging.
Overexpression of the mitochondrial T3 receptor induces skeletal muscle atrophy during aging.
Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.
PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation.
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.
Polyubiquitin in crustacean striated muscle: increased expression and conjugation during molt-induced claw muscle atrophy.
Prevention of muscle disuse atrophy by MG132 proteasome inhibitor.
Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6.
Proteasome function is required to maintain muscle cellular architecture.
PSMB8 encoding the ?5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.
Psychological stress and aging: role of glucocorticoids (GCs).
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Skeletal muscle atrophy: From mechanisms to treatments.
The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy.
The dependency of autophagy and ubiquitin proteasome system during skeletal muscle atrophy.
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
The Proteasome Inhibitor MG132 Reduces Immobilization-Induced Skeletal Muscle Atrophy in Mice.
The Ubr2 gene is expressed in skeletal muscle atrophying as a result of hind limb suspension, but not Merg1a expression alone.
The Ubr2 Gene is Expressed in Skeletal Muscle Atrophying as a Result of Hind Limb Suspension, but not Merg1a Expression Alone.
Tourniquet-induced ischaemia during total knee arthroplasty results in higher proteolytic activities within vastus medialis cells: a randomized clinical trial.
Transcriptomic analysis of the hepatic response to stress in the red cusk-eel (Genypterus chilensis): Insights into lipid metabolism, oxidative stress and liver steatosis.
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Ventilator-induced diaphragm dysfunction: the clinical relevance of animal models.
Vitamin D Deficiency Induced Muscle Wasting Occurs through the Ubiquitin Proteasome Pathway and Is Partially Corrected by Calcium in Male Rats.
Vitamin D treatment protects against and reverses oxidative stress induced muscle proteolysis.
[Effect of Buyang Huanwu decoction on NF-?B/MuRFl expression in rats with denervated tibial muscle atrophy].
[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease.]
Muscular Atrophy, Spinal
CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Lysine-Less Variants of Spinal Muscular Atrophy SMN and SMN?7 Proteins Are Degraded by the Proteasome Pathway.
The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein.
Muscular Diseases
Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders.
Impaired muscle morphology in a Drosophila model of myosin storage myopathy was supressed by overexpression of an E3 ubiquitin ligase.
Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation.
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.
Proteasome dysfunction induces muscle growth defects and protein aggregation.
Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle.
Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm.
Muscular Disorders, Atrophic
Prevention of muscle disuse atrophy by MG132 proteasome inhibitor.
Muscular Dystrophies
Bortezomib Partially Improves Laminin ?2 Chain-Deficient Muscular Dystrophy.
Effect of calpain and proteasome inhibition on Ca2+-dependent proteolysis and muscle histopathology in the mdx mouse.
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease.
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Proteasome expression in the skeletal muscles of patients with muscular dystrophy.
Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Muscular Dystrophy, Duchenne
Immunoproteasome in animal models of Duchenne muscular dystrophy.
Modulation of Protein Quality Control and Proteasome to Autophagy Switch in Immortalized Myoblasts from Duchenne Muscular Dystrophy Patients.
Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment.
Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.
The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy.
Muscular Dystrophy, Oculopharyngeal
A Novel Feed-Forward Loop between ARIH2 E3-Ligase and PABPN1 Regulates Aging-Associated Muscle Degeneration.
Musculoskeletal Pain
Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
Myasthenia Gravis
Clinical and scientific aspects of acetylcholine receptor myasthenia gravis.
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.
Mycoses
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.
Mycosis Fungoides
miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Myelodysplastic Syndromes
Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Myocardial Infarction
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population.
Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition.
Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.
Genetics of Proteasome Diseases.
Impact of proteasome inhibitor MG-132 on expression of NF-?B, IL-1? and histological remodeling after myocardial infarction.
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: A pathological study of 1503 consecutive autopsy cases.
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Proteasome inhibition during myocardial infarction.
Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.
The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients.
The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population.
The G-Allele of the PSMA6 -8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
UBE2D3 contributes to myocardial ischemia-reperfusion injury by regulating autophagy in dependence of p62/SQSTM1.
Ubiquitin?proteasomes are the dominant mediators of the regulatory effect of microRNA?1 on cardiac remodeling after myocardial infarction.
Validation of the association between the gene encoding proteasome subunit alpha type 6 and myocardial infarction in a Japanese population.
Myocardial Ischemia
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice.
Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.
Proteasome inhibitors in myocardial ischemia, some concerns.
Proteasome mediates removal of proteins oxidized during myocardial ischemia.
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation.
The ubiquitin proteasome system and myocardial ischemia.
The Ubiquitin Proteasome System in Myocardial Ischemia and Preconditioning.
The ubiquitin-proteasome system and cardiovascular disease.
Myocardial Reperfusion Injury
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation.
Myocarditis
Concepts in cardiac oncology.
Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection.
ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
PA28 modulates antigen processing and viral replication during coxsackievirus B3 infection.
Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus-and Cytokine-Mediated Damage of Heart Tissue During Myocarditis.
Proteasome activator REGgamma enhances coxsackieviral infection by facilitating p53 degradation.
Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes.
The role of the proteasome in heart disease.
The ubiquitin-proteasome pathway in viral infections.
Myopathies, Structural, Congenital
Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways.
Myositis
AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis.
Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: A potential therapeutic target.
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type.
In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis.
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation.
Inclusion-body myositis. A myodegenerative conformational disorder associated with A|gb, protein misfolding, and proteasome inhibition.
Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFN?.
Myositis, Inclusion Body
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation.
Myxoma
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
Nasal Polyps
Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts.
Nasopharyngeal Carcinoma
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Proteasome inhibitors decrease paclitaxel?induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.
Nasopharyngeal Neoplasms
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Proteasome inhibitors decrease paclitaxel?induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.
Nematode Infections
Cowpea-Meloidogyne incognita interaction: Root proteomic analysis during early stages of nematode infection.
Neoplasm Metastasis
A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways.
Activity and subunit composition of proteasomes in head and cervical squamous cell carcinomas.
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of ?-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis.
Clinical update: proteasome inhibitors in solid tumors.
Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry.
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Depletion of the proteasome subunit PSMA7 inhibits colorectal cancer cell tumorigenicity and migration.
Deubiquitinase USP29 promotes gastric cancer cell migration by cooperating with phosphatase SCP1 to stabilize Snail protein.
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Discovery, Development, and clinical applications of bortezomib.
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer.
Green tea polyphenols as proteasome inhibitors: implication in chemoprevention.
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Immunological differences between primary and metastatic breast cancer.
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis.
JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Lysosomal Degradation of CD44 Mediates Ceramide Nanoliposome-induced Anoikis and Diminshed Extravasation in Metastatic Carcinoma Cells.
Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis.
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells.
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer.
The "Sharp" blade against HIF-mediated metastasis.
The case for therapeutic proteostasis modulators.
The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells.
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer.
The proteasome: a novel target for cancer chemotherapy.
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
[High expression of proteasome subunit PSMA7 in colorectal cancer is significantly correlated with liver metastasis]
Neoplasm, Residual
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
New Targets and New Agents in High-Risk Multiple Myeloma.
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Neoplasms
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
17-AAG Enhances PS-341-Induced Lung Cancer Cell Death by Blocking the NF-?B and PI3K/Akt Pathways.
2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.
20S proteasome inhibitory activity of flavonoids isolated from Spatholobus suberectus.
26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.
26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors.
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
3,4,5-tricaffeoylquinic acid attenuates proteasome inhibition-mediated programmed cell death in differentiated PC12 cells.
3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins.
?-Boswellic acid, a bioactive substance used in food supplements, inhibits protein synthesis by targeting the ribosomal machinery.
?-Catenin/TCF4 Complex-Mediated Induction of the NRF3 (NFE2L3) Gene in Cancer Cells.
?-Keto phenylamides as P1'-extended proteasome inhibitors.
?-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
?-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients.
?TrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit.
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation.
A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
A FRET-based approach for identification of proteasome catalytic subunit composition.
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells.
A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.
A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types.
A Key Role for the Ubiquitin Ligase UBR4 in Myofiber Hypertrophy in Drosophila and Mice.
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor.
A microRNA-mediated decrease in eukaryotic initiation factor 2? promotes cell survival during PS-341 treatment.
A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis.
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.
A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells.
A new target for proteasome inhibitors: FoxM1.
A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis.
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
A novel bullet hits the proteasome.
A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.
A novel FoxM1-PSMB4 axis contributes to proliferation and progression of cervical cancer.
A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS.
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs).
A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer.
A Peptidomimetic Fluorescent Probe to Detect the Trypsin ?2 Subunit of the Human 20S Proteasome.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers.
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
A Practical Review of Proteasome Pharmacology.
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.
A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.
A synthetic oxygen sensor for plants based on animal hypoxia signalling.
A systematic review of herbal medicines for the treatment of cancer cachexia in animal models.
A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors.
A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.
AACR Special Conference in cancer research: ubiquitination in normal and cancer cells.
Aberrant C-terminal domain of polymerase ? targets the functional enzyme to the proteosomal degradation pathway.
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line.
Abrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene.
Absence of Bax switched MG132-induced apoptosis to non-apoptotic cell death that could be suppressed by transcriptional or translational inhibition.
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells.
Activated Rac1 regulates the degradation of I?B? and the nuclear translocation of STAT3-NF?B complexes in starved cancer cells.
Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF).
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-?B Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells.
Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Activity and subunit composition of proteasomes in head and cervical squamous cell carcinomas.
Activity Enhancement of the Synthetic Syrbactin Proteasome Inhibitor Hybrid and Biological Evaluation in Tumor Cells.
Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells.
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation.
Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition.
Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency.
ADRM1 as a therapeutic target in hepatocellular carcinoma.
ADRM1-amplified metastasis gene in gastric cancer.
Advancing the Role of Gamma-Tocotrienol as Proteasomes Inhibitor: A Quantitative Proteomic Analysis of MDA-MB-231 Human Breast Cancer Cells.
Affinity Maturation of Macrocyclic Peptide Modulators of Lys48-linked Diubiquitin by a Twofold Strategy.
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity.
Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin.
Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
Amino acid response by Halofuginone in Cancer cells triggers autophagy through proteasome degradation of mTOR.
Amino acid starvation sensitizes cancer cells to proteasome inhibition.
Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
An antibody-based amperometric biosensor for 20S proteasome activity and inhibitor screening.
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
An extracellular proteasome releases endostatin from human collagen XVIII.
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
An inhibitor of ubiquitin conjugation and aggresome formation.
An interaction map of proteasome subunits.
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
An Overview of Bortezomib-Induced Neurotoxicity.
An Overview on the Histogenesis and Morphogenesis of Salivary Gland Neoplasms and Evolving Diagnostic Approaches.
Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.
Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Analysis of the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes.
Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.
Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors.
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Anthracyclines, proteasome activity and multi-drug-resistance.
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
Anticancer activity and computational modeling of ternary copper (II) complexes with 3-indolecarboxylic acid and 1,10-phenanthroline.
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Antifungal compounds with anticancer potential from Trichoderma sp. P8BDA1F1, an endophytic fungus from Begonia venosa.
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Antimyeloma activity of heat shock protein-90 inhibition.
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi's sarcoma.
Antiprotease therapy in cancer: hot or not?
Antiproteasomal agents in rectal cancer.
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs.
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Antitumor pharmacology -- quo vadis?
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
Antitumorigenic effect of proteasome inhibitors on insulinoma cells.
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-? from degradation and induce apoptosis in prostate cancer cells.
Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells.
Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2.
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Apoptosis induction of 2'-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells.
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21(WAF1) in human melanoma cells.
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Approaches to discovering drugs that regulate E3 ubiquitin ligases.
Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment.
Arene-Ru(II) Complexes of Curcumin Exert Antitumor Activity via Proteasome Inhibition and Apoptosis Induction.
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Aromatic monophenols from cinnamon bark act as proteasome inhibitors by upregulating ER stress, suppressing FoxM1 expression, and inducing apoptosis in prostate cancer cells.
Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.
Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the Proteasome Inhibitor PS-341 in Human Lung Cancer Cells.
Association of growth factors, HIF-1 and NF-?B expression with proteasomes in endometrial cancer.
Association of Metals and Proteasome Activity in Erythrocytes of Prostate Cancer Patients and Controls.
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors.
Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.
Baceridin, a Cyclic Hexapeptide from an Epiphytic Bacillus Strain, Inhibits the Proteasome.
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide a.
BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome.
BAG3 down-modulation sensitizes HPV18(+) HeLa cells to PEITC-induced apoptosis and restores p53.
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
Baicalein attenuates proteasome inhibition-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways.
Baicalin and Scutellarin Are Proteasome Inhibitors that Specifically Target Chymotrypsin-like Catalytic Activity.
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.
BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition?
Bax?2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.
Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids.
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR).
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Biochemical analysis of the native TRAIL death-inducing signaling complex.
Biochemical mechanisms of cellular catabolism.
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-?B signaling.
Black tea polyphenols inhibit tumor proteasome activity.
Bladder cancer detection using a peptide substrate of the 20S proteasome.
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Blocking Cancer Growth with Less POMP or Proteasomes.
Blocking protein quality control to counter hereditary cancers.
Bone marrow microenvironment and the identification of new targets for myeloma therapy.
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
Borneol and Luteolin from Chrysanthemum morifolium Regulate Ubiquitin Signal Degradation.
Bortezomib (millennium pharmaceuticals).
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.
Bortezomib Alone and in Combination with Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death in Vitro and in Female Nude Mice.
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma.
Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Bortezomib as a potential treatment for prostate cancer.
Bortezomib as an antitumor agent.
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells.
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk.
Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation.
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Bortezomib in the treatment of cancer.
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma.
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Bortezomib induction of C/EBP{beta} mediates Epstein-Barr virus lytic activation in Burkitt's lymphoma.
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma.
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.
Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation.
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo.
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Bortezomib treatment and regulatory T-cell depletion enhance the anti-tumor effects of adoptively infused NK cells.
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome.
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
Bortezomib-Encapsulated CuS/Carbon Dot Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway.
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats.
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
Bortezomib: a novel therapy approved for multiple myeloma.
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
Bowman-Birk inhibitors, proteasome peptidase activities and colorectal pre neoplasias induced by 1,2-dimethylhydrazine in Swiss mice.
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3? dependent mechanism.
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells.
BU-32: a novel proteasome inhibitor for breast cancer.
C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1? through the Oxygen-Dependent Degradation Pathway.
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Cadmium Induced p53-Dependent Activation of Stress Signaling, Accumulation of Ubiquitinated Proteins, and Apoptosis in Mouse Embryonic Fibroblast Cells.
Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Caffeic acid phenethyl ester potentiates gastric cancer cell sensitivity to doxorubicin and cisplatin by decreasing proteasome function.
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells.
Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome.
Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.
Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function.
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
Cancer vulnerabilities unveiled by genomic loss.
Cancer: Opening the door to a new class of proteasome inhibitors.
Candidate Genes and MiRNAs Linked to the Inverse Relationship Between Cancer and Alzheimer's Disease: Insights From Data Mining and Enrichment Analysis.
Capsaicin, a Component of Red Peppers, Inhibits the Growth of Androgen-Independent, p53 Mutant Prostate Cancer Cells.
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
Cardiotoxicity of cancer chemotherapy in clinical practice.
Carfilzomib boosted combination therapy for relapsed multiple myeloma.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.
Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells.
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Carfilzomib reverses pulmonary arterial hypertension.
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia.
Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3.
Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Caspase-mediated specific cleavage of human histone deacetylase 4.
Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells.
Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341.
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
CDC4 Gene Expression as Potential Biomarker for Targeted Therapy in Prostate Cancer.
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells.
Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity.
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.
Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format.
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Cezanne (OTUD7B) regulates HIF-1? homeostasis in a proteasome-independent manner.
Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Changes in proteasome structure and function caused by HAMLET in tumor cells.
Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.
Characterization and differential expression of a newly identified phosphorylated isoform of the human 20S proteasome beta7 subunit in tumor vs. normal cell lines.
Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition.
Characterization of the 20S proteasome in human glioblastomas.
Characterizing the Dynamics of Proteasome Complexes by Proteomics Approaches.
Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.
CHIP and BAP1 Act in Concert to Regulate INO80 Ubiquitination and Stability for DNA Replication.
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Chlamydia trachomatis Infection Impairs MHC-I Intracellular Trafficking and Antigen Cross-Presentation by Dendritic Cells.
Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-?B signaling.
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Circadian modulation of proteasome activity and accumulation of oxidized protein in human embryonic kidney HEK 293 cells and primary dermal fibroblasts.
Circulating 20S proteasome in patients with non-metastasized breast cancer.
Cisplatin-induced cell death in Saccharomyces cerevisiae is programmed and rescued by proteasome inhibition.
CITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition.
Clinical and Marketed Proteasome Inhibitors for Cancer Treatment.
Clinical development of novel proteasome inhibitors for cancer treatment.
Clinical translation of nuclear export inhibitors in cancer.
Clinical update: novel targets in gynecologic malignancies.
Clinical update: proteasome inhibitors in solid tumors.
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages.
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update.
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.
cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas.
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Cobalt oxide nanoparticle-synergized protein degradation and phototherapy for enhanced anticancer therapeutics.
Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes.
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention.
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1? production.
Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial.
Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line.
Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells.
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Comparative mechanisms of action of proteasome inhibitors.
Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry.
Comparative proteomics of ovarian epithelial tumors.
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Comparative study of proteasome inhibitory, synergistic antibacterial, synergistic anticandidal, and antioxidant activities of gold nanoparticles biosynthesized using fruit waste materials.
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Comprehensive Profiling of Protein Ubiquitination for Drug Discovery.
Computational inference of cancer-specific vulnerabilities in clinical samples.
Concomitant differentiation and partial proteasome inhibition trigger apoptosis in neuroblastoma cells.
Conjugated linoleic acid synthesis-related protein proteasome subunit ? 5 (PSMA5) is increased by vaccenic acid treatment in goat mammary tissue.
Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation.
Contemporary drug therapies for multiple myeloma.
Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation.
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
Controlled Access of p53 to the Nucleus Regulates Its Proteasomal Degradation by MDM2.
Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.
Copper compounds in anticancer strategies.
Copper in diseases and treatments, and copper-based anticancer strategies.
Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study.
Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer.
Core and specific network markers of carcinogenesis from multiple cancer samples.
Correction to "The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from 'Indian winter cherry'".
Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?
Could Dysregulation of UPS be a Common Underlying Mechanism for Cancer and Neurodegeneration? Lessons from UCHL1.
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells.
Crosstalk between autophagy and proteasome protein degradation systems: possible implications for cancer therapy.
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome.
CTGF associated with oncogenic activities and drug resistance in glioblastoma multiforme (GBM).
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Cupriphilic compounds to aid in proteasome inhibition.
Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects.
Curcumin inhibits HIV-1 by promoting Tat protein degradation.
Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Current and emerging treatments for multiple myeloma.
Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.
Current status of bortezomib in the treatment of multiple myeloma.
Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Cyclohelminthol X, a Hexa-Substituted Spirocyclopropane from Helminthosporium velutinum yone96: Structural Elucidation, Electronic Circular Dichroism Analysis, and Biological Properties.
Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp.
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
Defining targets of modulation of human tumor cell response to cisplatin.
Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells.
Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice.
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.
Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway.
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Design, Synthesis and Evaluation of Substituted Aryl-2-Nitrovinyl Derivatives as Small Molecules Proteasome Inhibitors.
Design, synthesis, and evaluation of cystargolide-based ?-lactones as potent proteasome inhibitors.
Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.
Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation.
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation.
Deubiquitinase inhibition as a cancer therapeutic strategy.
Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-?B inhibition and p53 reactivation in human lung cancer cells.
Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Developing novel strategies to target B-cell malignancies.
Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma.
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Development of ?-Hairpin Peptides for the Measurement of SCF-Family E3 Ligase Activity in Vitro via Ornithine Ubiquitination.
Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor.
Development of inhibitors in the ubiquitination cascade.
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib.
Development of proteasome inhibitors as research tools and cancer drugs.
Development of Proteasome Inhibitors as Therapeutic Drugs.
Development of proteasome inhibitors in oncology and autoimmune diseases.
Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.
Development of the proteasome inhibitor Velcade (Bortezomib).
Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells.
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Differential impact of bortezomib on HL-60 and K562 cells.
Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study.
Differential protein expression in honeybee (Apis mellifera L.) larvae: underlying caste differentiation.
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Differential regulation of the REG?-proteasome pathway by p53/TGF-? signalling and mutant p53 in cancer cells.
Dimerized Linear Mimics of a Natural Cyclopeptide (TMC-95A) Are Potent Noncovalent Inhibitors of the Eukaryotic 20S Proteasome.
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor.
Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Discovery and development of second-generation proteasome inhibitors.
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Discovery of a Small Molecule Probe of Rpn-6, an Essential Subunit of the 26S Proteasome.
Discovery of Natural Product Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Discovery of PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Discovery, Development, and clinical applications of bortezomib.
Disrupted eNOS activity and expression account for vasodilator dysfunction in different stage of sepsis.
Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme.
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
Dithiocarbamate-Based Coordination Compounds As Potent Proteasome Inhibitors in Human Cancer Cells.
Divergent effect of proteasome inhibition on interleukin-1beta and tumor necrosis factor alpha signaling in human astroglial cells.
DNA damage emergency: cellular garbage disposal to the rescue?
DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors.
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.
Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to HSP90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels.
Down-regulating Proteolysis to Enhance Anticancer Activity of Peptide Nanofibers.
Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.
Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262.
Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines.
Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.
Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.
Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines.
Downregulation of TNF receptor-associated protein-2/p97 in renal cell carcinoma.
Drug Combinations with Proteasome Inhibitors in Antitumor Therapy.
Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.
Drug discovery and assay development in the ubiquitin-proteasome system.
Drug discovery in the ubiquitin-proteasome system.
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.
Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells.
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Dynamic interplay between breast cancer cells and normal endothelium mediates the expression of matrix macromolecules, proteasome activity and functional properties of endothelial cells.
Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.
Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.
E-cad-Fc-Matrix Enhances Cancer Stem-Like Properties and Induces Mesenchymal Features in Colon Cancer Cells.
E1 Enzymes as Therapeutic Targets in Cancer.
E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIP S.
E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway.
Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells.
Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Effect of cancer cachexia on the activity of tripeptidyl-peptidase II in skeletal muscle.
Effect of Neoadjuvant Chemoradiation Therapy on Proteasome Pool in Rectal Cancer.
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells.
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.
Effects of a proteasome inhibitor on the NF-?B signalling pathway in experimental osteoarthritis.
Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells.
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Effects of bortezomib on mouse preimplantation embryo development in vitro.
Effects of ELF magnetic fields on protein expression profile of human breast cancer cell MCF7.
Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone.
Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats.
Effects of proteasome inhibitors on bone cancer.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.
Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia.
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Effects of thymoquinone on isolated and cellular proteasomes.
Effects of tumor necrosis factor-alpha on the 26S proteasome and 19S regulator in skeletal muscle of severely scalded mice.
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.
EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Ehrlichia chaffeensis TRP32 interacts with host cell targets that influence intracellular survival.
Electrostatic Map Of Proteasome ?-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding.
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway.
Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients.
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.
Emerging drug development technologies targeting ubiquitination for cancer therapeutics.
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Emerging Therapies for the Treatment of Relapsed or Refractory Multiple Myeloma.
Emerging therapies targeting the ubiquitin proteasome system in cancer.
Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis.
Endoplasmic reticulum proteostasis: a key checkpoint in cancer.
Endpoint of cancer treatment: targeted therapies.
Engineered protein nanoparticles for in vivo tumor detection.
Engineering anticancer T cells for extended functional longevity.
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-?B in vitro and in vivo.
Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Enhanced Glioblastoma Targeting Ability of Carfilzomib Enabled by a DA7R-Modified Lipid Nanodisk.
Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
Enhanced O-GlcNAcylation Mediates Cytoprotection under Proteasome Impairment by Promoting Proteasome Turnover in Cancer Cells.
Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells.
Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug-Resistant Model and Genome-Wide siRNA Screening.
Enhancement of TNF-alpha-mediated cell death in vascular smooth muscle cells through cytochrome c-independent pathway by the proteasome inhibitor.
Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma.
Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation.
Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.
Eponemycin exerts its antitumor effect through the inhibition of proteasome function.
Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis.
Essential amino acid mixtures drive cancer cells to apoptosis through proteasome inhibition and autophagy activation.
Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis.
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.
Etiology and management of hypertension in patients with cancer.
Evaluation of copper-dependent proteasome-inhibitory and apoptosis-inducing activities of novel pyrrolidine dithiocarbamate analogues.
Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors.
Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology.
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.
Evidence for anti-apoptotic roles of proteasome activator 28? via inhibiting caspase activity.
Evidence for the mode of action of the highly cytotoxic Streptomyces polyketide kendomycin.
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins.
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.
Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.
Exploring the binding affinity of novel syringic acid analogues and critical determinants of selectivity as potent proteasome inhibitors.
Exploring the proteasome system: A novel concept of proteasome inhibition and regulation.
Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-?B Pathway in Preclinical Models of Pediatric High-Grade Glioma.
Expression Atlas of the Deubiquitinating Enzymes in the Adult Mouse Retina, Their Evolutionary Diversification and Phenotypic Roles.
Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers.
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Expression of proteasomal proteins in ten different tumor cell lines.
Expression of Proteasome Activator REG? in Human Laryngeal Carcinoma and Associations with Tumor Suppressor Proteins.
Expression of Proteasome Subunit ?5t in Thymic Epithelial Tumors.
Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle.
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Feasibility of Repurposing Clioquinol for Cancer Therapy.
Feedback regulation of proteasome gene expression and its implications in cancer therapy.
Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells.
Fetal growth plate: a developmental model of cellular adaptation to hypoxia.
Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors.
Fibrosis and hypoxia-inducible factor-1?-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.
Fish Oil Diet during Pre-mating, Gestation, and Lactation in Adult Offspring Rats on Cancer Cachexia Prevention.
Flavanonol taxifolin attenuates proteasome inhibition-induced apoptosis in differentiated PC12 cells by suppressing cell death process.
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Fluorescence-based proteasome activity profiling.
Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time.
Foe to Friend: Supramolecular Nanomedicines Consisting of Natural Polyphenols and Bortezomib.
Food Shortage Causes Differential Effects on Body Composition and Tissue-Specific Gene Expression in Salmon Modified for Increased Growth Hormone Production.
Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions.
FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
Friend or foe? The proteasome in combined cancer therapy.
From Bortezomib to Other Inhibitors of the Proteasome and Beyond.
Function and mechanism of F-box proteins in gastric cancer (Review).
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
Functioning of Proteasomes in Lymphogenic Metastasizing of Non-Small-Cell Lung Cancer.
Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
GADD34 Facilitates Cell Death Resulting from Proteasome Inhibition.
Gambogic acid enhances proteasome inhibitor-induced anticancer activity.
Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo.
Ganetespib for small cell lung cancer.
Gankyrin activates the hedgehog signalling to drive metastasis in osteosarcoma.
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.
Gankyrin, the 26 S proteasome, the cell cycle and cancer.
Gap junctions sensitize cancer cells to proteasome inhibitor MG132-induced apoptosis.
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
Generation and identification of a conditional knockout allele for the PSMD11 gene in mice.
Genetic and epigenetic changes in stomach cancer.
Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.
Genetics of Proteasome Diseases.
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Genome-wide analysis of differentially expressed genes during the early stages of tomato infection by a potyvirus.
Genome-wide identification of molecular pathways and biomarkers in response to arsenic exposure in zebrafish liver.
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
Getting to the root of the problem: the causes of relapse in multiple myeloma.
Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction.
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Gold complexes as prospective metal-based anticancer drugs.
Green tea polyphenols as a natural tumour cell proteasome inhibitor.
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Growth factor regulation of a 26S proteasomal subunit in breast cancer.
GRP-78 secreted by tumor cells blocks the anti-angiogenic activity of bortezomib.
GSK-3? signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1.
Harnessing Proteasome Dynamics and Allostery in Drug Design.
Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
HAUSP, a deubiquitinating enzyme for p53, is polyubiquitinated, polyneddylated, and dimerized.
HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2.
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.
Heat shock protein and proteasome targeting agents.
Heat shock proteins and proteasomal degradation in normal and tumor cells.
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
HERC1 Regulates Breast Cancer Cells Migration and Invasion.
Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA).
High-resolution cryo-EM proteasome structures in drug development.
Highly Multiplexed Quantitative Mass Spectrometry Analysis of Ubiquitylomes.
Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells.
Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer.
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
HLA-B27 and genetic predisposing factors in spondyloarthropathies.
Homogeneous, bioluminescent proteasome assays.
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
Host-Viral Interactions Revealed among Shared Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19 Pathogenesis.
HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells.
HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.
HSP70 Inhibition by the Small-Molecule 2-Phenylethynesulfonamide Impairs Protein Clearance Pathways in Tumor Cells.
Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis.
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer.
Hydrazino-aza and N-azapeptoids with therapeutic potential as anticancer agents.
Hypoxia enhances the senescence effect of bortezomib--the proteasome inhibitor--on human skin fibroblasts.
Hypoxia-induced autophagy: a new player in cancer immunotherapy?
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
Hypoxic resistance to articular chondrocyte apoptosis--a possible mechanism of maintaining homeostasis of normal articular cartilage.
Identification and Application of NEDD8 E1 Inhibitors.
Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle.
Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Identification of a ?1/?2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening.
Identification of a new series of amides as non-covalent proteasome inhibitors.
Identification of a p53-based portable degron based on the MDM2-p53 binding region.
Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53.
Identification of factors that function in Drosophila salivary gland cell death during development using proteomics.
Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
Identification of proteasome inhibitors using analysis of gene expression profiles.
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.
IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.
IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Image-based screening for the identification of novel proteasome inhibitors.
Imaging 26S proteasome activity and inhibition in living mice.
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.
Immune mechanism of the antitumor effects generated by bortezomib.
Immunocytochemical localization of multicatalytic protease complex (proteasome) during generation of murine IL-2-activated natural killer (A-NK) cells.
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity.
Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Immunoproteasome in cancer and neuropathologies: a new therapeutic target?
Immunoproteasome Inhibitor-Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation.
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade).
Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study.
Impaired bortezomib binding to mutant ?5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B: cells and dendritic cells.
Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells: A NOVEL ANTIPROLIFERATIVE AGENT WITH A POTENTIAL THERAPEUTIC IMPLICATION.
Implication of 14-3-3? and 14-3-3?/? in proteasome inhibition-induced apoptosis of glioma cells.
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins.
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-?B and the proteasome.
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes.
In situ photoaffinity labeling of proteasome with photoactive adriamycin analogue.
In vitro and in vivo anticancer activity of copper(I) complexes with homoscorpionate tridentate tris(pyrazolyl)borate and auxiliary monodentate phosphine ligands.
In Vitro and In Vivo Antitumor Activities and DNA Binding Mode of Five Coordinated Cyclometalated Organoplatinum(II) Complexes Containing Biphosphine Ligands.
In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
In vivo imaging, tracking, and targeting of cancer stem cells.
In Vivo Inhibition of Proteasome Activity and Tumour Growth by Murraya koenigii Leaf Extract in Breast Cancer Xenografts and by its active flavonoids in breast cancer cells.
In vivo modulation of ubiquitin chains by N-methylated non-proteinogenic cyclic peptides.
In vivo pharmacodynamic imaging of proteasome inhibition.
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
Inactivation of the 20S proteasome in Streptomyces lividans and its influence on the production of heterologous proteins.
Inactivation of USP14 Perturbs Ubiquitin Homeostasis and Delays the Cell Cycle in Mouse Embryonic Fibroblasts and in Fruit Fly Drosophila.
Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Increased Expression of Atrogenes and TWEAK Family Members after Severe Burn Injury in Nonburned Human Skeletal Muscle.
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss.
Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.
Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor.
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2).
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
Indolo-Phakellins as ?5-Specific Noncovalent Proteasome Inhibitors.
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation.
Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound.
Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells.
Induction of BAG2 protein during proteasome inhibitor-induced apoptosis in thyroid carcinoma cells.
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Induction of tumor cell apoptosis by taurine Schiff base copper complex is associated with the inhibition of proteasomal activity.
Inflammaging and Skeletal Muscle: Can Protein Intake Make a Difference?
Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.
Influence of proteasome inhibitors on apoptosis.
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells.
Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
Inhibition of metalloproteinase and proteasome activities in colon cancer cells by citrus peel extracts.
Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.
Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts.
Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death.
Inhibition of Proteasome Activity Induces Aggregation of IFIT2 in the Centrosome and Enhances IFIT2-Induced Cell Apoptosis.
Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death.
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Inhibition of proteasome reveals basal mitochondrial ubiquitination.
Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?
Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.
Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.
Inhibition of the proteasome activity by graphene oxide contributes to its cytotoxicity.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells.
Inhibition of the ubiquitin-proteasome system induces stress granule formation.
Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'.
Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes.
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency.
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Inhibition on Proteasome ?1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Inhibitors of the AAA+ Chaperone p97.
Inhibitors of the Immunoproteasome: Current Status and Future Directions.
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.
Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection.
Insulin-degrading enzyme (IDE): a novel heat shock-like protein.
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.
Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes.
Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.
Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein.
Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
Intersection of nuclear receptors and the proteasome on the epigenetic landscape.
Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Investigating the Effects of RBBP6 Gene Expression on Telomerase Activity in Cervical Cancer Cells.
Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal ?2 Subunits.
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Isolation and structure determination of a proteasome inhibitory metabolite from a culture of Scytonema hofmanni.
Isolation, Structure, and Biological Activities of Fellutamides C and D from an Undescribed Metulocladosporiella (Chaetothyriales) Using the Genome-Wide Candida albicans Fitness Test.
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70.
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Ketone Bodies Attenuate Wasting in Models of Atrophy.
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Knockdown of Adhesion-Regulating Molecule 1 Inhibits Proliferation in HL60 Cells.
Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.
Knockdown of REG? inhibits proliferation by inducing apoptosis and cell cycle arrest in prostate cancer.
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
KRIBB53 binds to OCT4 and enhances its degradation through the proteasome, causing apoptotic cell death of OCT4-positive testicular germ cell tumors.
L-glutamine Schiff base copper complex as a proteasome inhibitor and an apoptosis inducer in human cancer cells.
L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats.
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research.
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system.
Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
Left Ventricular Dysfunction in Cancer Treatment: Is it Relevant?
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload.
Lessons learned from art pardee in cell cycle, science, and life.
Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
Limiting the power of p53 through the ubiquitin proteasome pathway.
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability.
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
Long-term incubation with proteasome inhibitors(PIs) induces I?B? degradation via the lysosomal pathway in a I?B kinase (IKK)-dependent and IKK-independent manners.
Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition.
Loss of skeletal muscle in cancer: biochemical mechanisms.
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.
Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (?5i) Delivering Efficacy in Multiple Myeloma Models.
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
MAGE-A antigens as targets for cancer immunotherapy.
MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation.
Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines.
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF?B Activation in Breast Cancer.
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Marizomib, a potent second generation proteasome inhibitor from natural origin.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
Matrix Metalloproteinase-11 Promotes Early Mouse Mammary Gland Tumor Growth through Metabolic Reprogramming and Increased IGF1/AKT/FoxO1 Signaling Pathway, Enhanced ER Stress and Alteration in Mitochondrial UPR.
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
MDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells.
MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress.
Measurement of active site ionization equilibria in the 670 kDa proteasome core particle using methyl-TROSY NMR.
Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Mechanism of muscle protein degradation induced by a cancer cachectic factor.
Mechanism of non-steroidal anti-inflammatory drug-gastropathy.
Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
Mechanisms of endogenous MHC class II presentation by tumor cells.
Mechanisms of proteasome inhibitor action and resistance in cancer.
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors.
Mechanistic insights into the impact of Cold Atmospheric Pressure Plasma on human epithelial cell lines.
Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas.
Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors.
Metal complexes as inhibitors of the 26S proteasome in tumor cells.
Metal ionophores - An emerging class of anticancer drugs.
Metal-based 2,3-indolinedione derivatives as proteasome inhibitors and inducers of apoptosis in human cancer cells.
Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors.
Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.
Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2.
MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo.
MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.
MG132, a proteasome inhibitor, induces apoptosis in tumor cells.
MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.
Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts.
Microangiopathy in Cancer: Causes, Consequences, and Management.
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Mining the cinnabaramide biosynthetic pathway to generate novel proteasome inhibitors.
Misfolded proteins: from little villains to little helpers in the fight against cancer.
Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
Mitochondrial Malfunctioning, Proteasome Arrest and Apoptosis in Cancer Cells by Focused Intracellular Generation of Oxygen Radicals.
Mitochondrial metabolism promotes adaptation to proteotoxic stress.
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Model of translational cancer research in multiple myeloma.
Modeling tumor progression via the comparison of stage-specific graphs.
Modulation of proteasome activity by curcumin and didemethylcurcumin.
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein.
Modulatory effects of bortezomib on host immune cell functions.
Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein.
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.
Molecular cancer therapeutics: recent progress and targets in drug resistance.
Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications.
Molecular discoveries alter our view of inflammatory bowel disease. A review from scientific, clinical, and laboratory perspectives.
Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
Molecular mechanisms involved in NSAID-induced gastropathy.
Molecular pathways: targeting proteasomal protein degradation in cancer.
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Molecular study on copper-mediated tumor proteasome inhibition and cell death.
Molecularly targeted therapies in multiple myeloma.
Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.
Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.
Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.
mTORC1 signaling activates NRF1 to increase cellular proteasome levels.
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Multi-omics analysis identifies potential mechanisms of AURKB in mediating poor outcome of lung adenocarcinoma.
Multi-output model with Box-Jenkins operators of linear indices to predict multi-target inhibitors of ubiquitin-proteasome pathway.
Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins.
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Multiple myeloma: lusting for NF-kappaB.
Multiple Myeloma: New Insights and Therapeutic Approaches.
Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.
Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study.
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.
MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.
N-?-acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28?.
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
Natural products from thioester reductase containing biosynthetic pathways.
Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2.
NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration.
Neurotoxicity induced by antineoplastic proteasome inhibitors.
Neutrophil-Derived IL-1? Impairs the Efficacy of NF-?B Inhibitors against Lung Cancer.
New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome.
New advances in drug discovery.
New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy.
New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells.
New insights into therapeutic targets in myeloma.
New Peptide-Based Pharmacophore Activates 20S Proteasome.
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.
New proteasome inhibitors in myeloma.
New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.
New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors.
New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.
Next-generation proteasome blockers promise safer cancer therapy.
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Next-generation proteasome inhibitors for cancer therapy.
NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
NF-kB signaling mediates acquired resistance after PARP inhibition.
NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression.
Nigrostriatal pathway degeneration in rats after intraperitoneal administration of proteasome inhibitor MG-132.
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Nitrile-Containing Fischerindoles from the Cultured Cyanobacterium Fischerella sp.
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
NOD mice are defective in proteasome production and activation of NF-kappaB.
Non-Covalent Proteasome Inhibitors.
Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.
Non?covalent proteasome inhibitor PI?1840 induces apoptosis and autophagy in osteosarcoma cells.
Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo.
Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.
Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells.
Novel agents in indolent lymphomas.
Novel biologically based therapies for myeloma.
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells.
Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
Novel generation of agents with proven clinical activity in multiple myeloma.
Novel green synthesis of gold nanoparticles using Citrullus lanatus rind and investigation of proteasome inhibitory activity, antibacterial, and antioxidant potential.
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
Novel lenalidomide-based combinations for treatment of multiple myeloma.
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.
Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Novel phosphorylation and ubiquitination sites regulate ROS-dependent degradation of anti-apoptotic c-FLIP protein.
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Novel proteasome inhibitors to overcome bortezomib resistance.
Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines.
Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening.
Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
Novel treatment strategies for soft tissue sarcoma.
Nrf1-mediated transcriptional regulation of the proteasome requires a functional TIP60 complex.
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
NRF3-POMP-20S proteasome assembly axis promotes cancer development via ubiquitin-independent proteolysis of p53 and Rb.
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma.
Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment.
Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma.
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.
O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?
O-GlcNAcylation protein disruption by Thiamet G promotes changes on the GBM U87-MG cells secretome molecular signature.
O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1.
Of Mice and Men: Proteasome'S Role in LPS-INDUCED Inflammation and Tolerance.
Omega-3 Polyunsaturated Fatty Acids Delay the Progression of Endotoxic Shock-Induced Myocardial Dysfunction.
On and off: proteasome and TGF-beta signaling.
On the involvement of calpains in the degradation of the tumor suppressor protein p53.
On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants.
Oncogenic addiction to high 26S proteasome level.
Oncogenic RAS-induced CK1? drives nuclear FOXO proteolysis.
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy.
ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
Opposing effects of bortezomib-induced nuclear factor-?B inhibition on chemical lung carcinogenesis.
Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Optimization of in vitro measurement of proteasome activity in mammalian cells using fluorogenic substrates.
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
OVA12 promotes tumor growth by regulating p53 expression in human cancer cells.
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Overcoming bortezomib resistance in multiple myeloma.
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition.
Overexpression of PSMA7 predicts poor prognosis in patients with gastric cancer.
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Overview of targeted therapies in oncology.
Overview on Anticancer Drug Design and Development.
Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment.
Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha.
Oxygen levels do not determine radiation survival of breast cancer stem cells.
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.
P53 and the proteasome regulate androgen receptor activity.
P53 facilitates degradation of human T-cell leukaemia virus type I Tax-binding protein through a proteasome-dependent pathway.
p53 mutations promote proteasomal activity.
p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts.
p53-dependent induction of apoptosis by proteasome inhibitors.
p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells.
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Pain Management in Patients with Multiple Myeloma: An Update.
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Paradoxical inhibition of cellular protein expression by proteasome inhibitors.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Partial proteasome inhibition in human fibroblasts triggers accelerated M1 senescence or M2 crisis depending on p53 and Rb status.
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.
Patented small molecule inhibitors in the ubiquitin proteasome system.
Pathogenesis of cancer cachexia.
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
Pathway-specific differences between tumor cell lines and normal and tumor tissue cells.
Pattern of MHC class I and immune proteasome expression in Walker 256 tumor during growth and regression in Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis.
Pattern of proteasome expression in Walker 256 tumor cells after their transplantation into the Brattleboro rats with genetic defect of vasopressin synthesis.
Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.
Peptide-Based Proteasome Inhibitors in Anticancer Drug Design.
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib.
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness.
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies.
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Phosphonic Analogs of Alanine as Acylpeptide Hydrolase Inhibitors.
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Pipecolic esters as minimized templates for proteasome inhibition.
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors.
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system.
Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies.
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition.
Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function.
PO-45 - The role of microvesicles in multiple myeloma progression.
Poly C Binding Protein 1 Regulates p62/SQSTM1 mRNA Stability and Autophagic Degradation to Repress Tumor Progression.
Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Polyamine depletion reduces TNFalpha/MG132-induced apoptosis in bone marrow stromal cells.
Polyamines as clinical laboratory tools.
Polyamines Counteract Carbonate-Driven Proteasome Stalling in Alkaline Conditions.
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.
Positioning of proteasome inhibitors in therapy of solid malignancies.
Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells.
Post-translationally modified S12, absent in transformed breast epithelial cells, is not associated with the 26S proteasome and is induced by proteasome inhibitor.
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Potent antitumor agent proteasome inhibitors: a novel trigger for Bcl2 phosphorylation to induce apoptosis.
Potential for proteasome inhibition in the treatment of cancer.
Potential Marker Pathways in the Endometrium That May Cause Recurrent Implantation Failure.
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer.
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts.
Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia.
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Primary study on the lesions and specific proteins in BEAS-2B cells induced with the 2009 A (H1N1) influenza virus.
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells.
Pro-apoptotic action of protein-carbohydrate fraction isolated from coelomic fluid of the earthworm Dendrobaena veneta against human colon adenocarcinoma cells.
Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors.
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Prodrugs of Fluoro-Substituted Benzoates of EGC as Tumor Cellular Proteasome Inhibitors and Apoptosis Inducers.
Production of spliced peptides by the proteasome.
Productively combining proteasome inhibition with the immunotherapy of cancer.
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Profiling proteasome activity in tissue with fluorescent probes.
Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.
Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon.
Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH2-terminal kinase signaling.
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
Prosomes (proteasomes) changes during differentiation are related to the type of inducer.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells.
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking.
Proteasomal insensitivity of apoptin in tumor cells.
Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus-and Cytokine-Mediated Damage of Heart Tissue During Myocarditis.
Proteasomal regulation of caspase-8 in cancer cell apoptosis.
Proteasomal Regulation of Mammalian SPT16 in Controlling Transcription.
Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum.
Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis.
Proteasome activity and their subunit composition in endometrial cancer tissue: correlations with clinical morphological parameters.
Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.
Proteasome activity is required for the initiation of precancerous pancreatic lesions.
Proteasome and cancer.
Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.
Proteasome and NF-kappaB inhibiting phaeophytins from the green alga Cladophora fascicularis.
Proteasome antibodies in paraneoplastic cerebellar degeneration.
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome as an emerging therapeutic target in cancer.
Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Proteasome Dependent Actin Remodeling Facilitates Antigen Extraction at the Immune Synapse of B Cells.
Proteasome deubiquitinases as novel targets for cancer therapy.
Proteasome dysfunction in cardiomyopathies.
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1.
Proteasome dysregulation in human cancer: implications for clinical therapies.
Proteasome expression and activity in cancer and cancer stem cells.
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Proteasome functioning in breast cancer: connection with clinical-pathological factors.
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Proteasome inhibition as a new strategy in cancer therapy and chemoprevention .
Proteasome inhibition as a novel mechanism of the proapoptotic activity of ?-secretase inhibitor I in cutaneous T-cell lymphoma.
Proteasome inhibition as a novel therapeutic target in human cancer.
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors.
Proteasome inhibition as novel treatment strategy in leukaemia.
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.
Proteasome inhibition blocks NF-?B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity.
Proteasome inhibition can impair caspase-8 Activation upon sub-maximal Stimulation of apoptotic tumour necrosis factor-related apoptosis inducing ligand (TRAIL) signalling.
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells.
Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.
Proteasome inhibition in cancer therapy.
Proteasome inhibition in cancer: development of PS-341.
Proteasome inhibition in multiple myeloma: lessons for other cancers.
Proteasome inhibition in multiple myeloma: therapeutic implication.
Proteasome inhibition in the treatment of cancer.
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Proteasome Inhibition Induces a p38 MAPK Pathway-Dependent Antiapoptotic Program via Nrf2 in Thyroid Cancer Cells.
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction.
Proteasome inhibition leads to NF-kappaB-independent IL-8 transactivation in human endothelial cells through induction of AP-1.
Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells.
Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response.
Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27.
Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage.
Proteasome inhibition profoundly affects activated human B cells.
Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts.
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling.
Proteasome inhibition therapies in childhood cancer.
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol.
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas.
Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3?.
Proteasome inhibition: a new anti-inflammatory strategy.
Proteasome inhibition: a new approach for the treatment of malignancies.
Proteasome inhibition: a new strategy in cancer treatment.
Proteasome inhibition: a new therapeutic strategy to cancer treatment.
Proteasome inhibition: a novel approach to cancer therapy.
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Proteasome inhibition: mechanism of action.
Proteasome inhibition: novel therapy for multiple myeloma.
Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.
Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis.
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-?B Signaling.
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Proteasome Inhibitor Induces Apoptosis through Induction of Endoplasmic Reticulum Stress.
Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts.
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells.
Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat.
Proteasome inhibitor MG-132 induces MCPIP1 expression.
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Proteasome inhibitor MG132 enhances cisplatin-induced apoptosis in osteosarcoma cells and inhibits tumor growth.
Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells.
Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-kappaB Activity.
Proteasome inhibitor MG132 inhibits the process of renal interstitial fibrosis.
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp.
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
Proteasome inhibitor patents (2010 - present).
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells.
Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.
Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-?B and CHOP expression.
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status.
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.
Proteasome Inhibitor-Loaded Micelles Enhance Antitumor Activity Through Macrophage Reprogramming by NF-?B Inhibition.
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis.
Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
Proteasome inhibitors as new anticancer drugs.
Proteasome inhibitors as potential novel anticancer agents.
Proteasome inhibitors as therapeutic agents: current and future strategies.
Proteasome inhibitors as therapeutics.
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Proteasome inhibitors differentially affect heat shock protein response in cancer cells.
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Proteasome inhibitors for cancer therapy.
Proteasome Inhibitors In Cancer Therapy And Their Relation To Redox Regulation.
Proteasome inhibitors in cancer therapy.
Proteasome Inhibitors in Cancer Therapy.
Proteasome inhibitors in cancer therapy.
Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Proteasome inhibitors in cancer therapy: lessons from the first decade.
Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
Proteasome inhibitors in glioblastoma.
Proteasome inhibitors in multiple myeloma.
Proteasome inhibitors in pediatric cancer treatment.
Proteasome inhibitors in the treatment of B-cell malignancies.
Proteasome inhibitors in the treatment of cancer.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells.
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants.
Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability.
Proteasome inhibitors induce p53-independent apoptosis in human cancer cells.
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Proteasome inhibitors mechanism; source for design of newer therapeutic agents.
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.
Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells.
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Proteasome Inhibitors Sensitize Colon Carcinoma Cells to TRAIL-Induced Apoptosis via Enhanced Release of Smac/DIABLO from the Mitochondria.
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKC?-dependent downregulation of AKT and XIAP expressions.
Proteasome inhibitors suppress the protein expression of mutant p53.
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Proteasome inhibitors therapeutic strategies for cancer.
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Proteasome inhibitors with photocontrolled activity.
Proteasome Inhibitors-Mediated TRAIL Resensitization and Bik Accumulation.
Proteasome inhibitors.
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Proteasome inhibitors: an expanding army attacking a unique target.
Proteasome inhibitors: antitumor effects and beyond.
Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell malignancies.
Proteasome inhibitors: from research tools to drug candidates.
Proteasome inhibitors: poisons and remedies.
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.
Proteasome inhibitory activity of thiazole antibiotics.
Proteasome inhibitory, antioxidant, and synergistic antibacterial and anticandidal activity of green biosynthesized magnetic Fe3O4 nanoparticles using the aqueous extract of corn (Zea mays L.) ear leaves.
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Proteasome modulators: essential chemical genetic tools for understanding human diseases.
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Proteasome proteolysis supports stimulated platelet function and thrombosis.
Proteasome regulation of ULBP1 transcription.
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors.
Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity.
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
Proteasome Ubiquitin Receptor hRpn13 and its Interacting Deubiquitinating Enzyme Uch37 are Required for Proper Cell Cycle Progression.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Proteasome-associated deubiquitinases and cancer.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis.
Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.
Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation.
Proteasome: an emerging target for cancer therapy.
Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer.
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?
Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo.
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Protein breakdown in cancer cachexia.
Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.
Protein ubiquitylation in pancreatic cancer.
Proteolytic dynamics of human 20S thymoproteasome.
Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study.
Proteomic analysis of affinity-purified extracellular proteasomes reveals exclusively 20S complexes.
Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches.
Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System.
Proteomic analysis of tumor tissue in CT-26 implanted BALB/C mouse after treatment with ascorbic acid.
Proteomic analysis uncovers common effects of IFN-? and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 ? Protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level.
Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Proteomics to study the diversity and dynamics of proteasome complexes: from fundamentals to the clinic.
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
PSMA7 inhibits the tumorigenicity of A549 human lung adenocarcinoma cells.
PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
PSMB5 plays a dual role in cancer development and immunosuppression.
PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma.
PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.
PSMD9 expression predicts radiotherapy response in breast cancer.
PSME3 Promotes TGFB1 Secretion by Pancreatic Cancer Cells to Induce Pancreatic Stellate Cell Proliferation.
PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity.
Pyrrolidine Dithiocarbamate Facilitates Arsenic Trioxide Against Pancreatic Cancer via Perturbing Ubiquitin-Proteasome Pathway.
Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity.
Quantitative analysis of a ubiquitin-dependent substrate using capillary electrophoresis with dual laser-induced fluorescence.
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.
Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity.
Radioimmunotherapy with antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6.
Radioresistance of prostate cancer cells with low proteasome activity.
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Radix Tetrastigma Hemsleyani Flavone Suppresses Cutaneous Squamous Cell Carcinoma A431 Cells via Proteasome Inhibition.
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response.
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of Paclitaxel and bortezomib using an adaptive dose-finding approach.
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Recent advances in antimultiple myeloma drug development.
Recent advances in proteasome inhibitor-based cancer therapies.
Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome.
Recent advances in the identification and development of 20S proteasome inhibitors.
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Recent Trends in the Design, Synthesis and Biological Exploration of ?-Lactams.
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells.
Reducing treatment toxicity in Waldenström macroglobulinemia.
REG? accelerates melanoma formation by regulating Wnt/?-catenin signalling pathway.
REG? deficiency promotes premature aging via the casein kinase 1 pathway.
REG? deficiency suppresses tumor progression via stabilizing CK1? in renal cell carcinoma.
REGgamma is associated with multiple oncogenic pathways in human cancers.
Regulation of apoptosis by the ubiquitin and proteasome pathway.
Regulation of apoptosis proteins in cancer cells by ubiquitin.
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Regulation of catechol-O-methyltransferase expression in human myometrial cells.
Regulation of CD95 (Fas/APO-1)-induced apoptosis in human chondrocytes.
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells.
Regulation of FOXO protein stability via ubiquitination and proteasome degradation.
Regulation of NRF1, a master transcription factor of proteasome genes: implications for cancer and neurodegeneration.
Regulation of p53 and Rb links the alternative NF-?B pathway to EZH2 expression and cell senescence.
Regulation of proteasome assembly and activity in health and disease.
Regulation of Protein Degradation by Proteasomes in Cancer.
Regulation of PSMB5 and ?-Subunits of Mammalian Proteasome by Constitutively Activated STAT3: Potential Role in Bortezomib Mediated Anticancer Therapy.
Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Regulation of synovial cell apoptosis by proteasome inhibitor.
Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation.
Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target.
Regulation of the stability of cell surface E-cadherin by the proteasome.
Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.
Renal gene expression in embryonic and newborn diabetic mice.
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition.
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity.
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells.
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
REST-dependent expression of TRF2 renders non-neuronal cancer cells resistant to DNA damage during oxidative stress.
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Retinoblastoma protein co-purifies with proteasomal insulin-degrading enzyme: implications for cell proliferation control.
Retroviruses have differing requirements for proteasome function in the budding process.
Revealing targeted therapy for human cancer by gene module maps.
Reversal of Sjogren's-like syndrome in non-obese diabetic mice.
Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3?/hypoxia-inducible factor-1?.
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.
Review. The endoplasmic reticulum: a target for new anticancer drugs.
Revisiting the role of the immunoproteasome in the activation of the canonical NF-?B pathway.
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.
Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells.
RNA-Seq Reveals Spliceosome and Proteasome Genes as Most Consistent Transcripts in Human Cancer Cells.
Role of a 19S Proteasome Subunit- PSMD10Gankyrin in Neurogenesis of Human Neuronal Progenitor Cells.
Role of ginsenoside Rd in inhibiting 26S proteasome activity.
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Role of oncogenic REG? in cancer.
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Role of proteasomes in disease.
Role of S-nitrosylation in apoptosis resistance and carcinogenesis.
Role of the bone marrow microenvironment in multiple myeloma.
Role of the proteasome in the downregulation of transcription factors NFkappaB and C/EBP in macrophages from tumor hosts.
Roles of CNC Transcription Factors NRF1 and NRF2 in Cancer.
Roles of estrogen receptor and p21WAF1 in bortezomib-induced growth inhibition in human breast cancer cells.
Roles of heat shock factor 1 and 2 in response to proteasome inhibition: consequence on p53 stability.
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors.
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Ruthenium(ii) and palladium(ii) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies.
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells.
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
Salinosporamide Natural Products: Potent 20?S Proteasome Inhibitors as Promising Cancer Chemotherapeutics.
Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome.
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
Sanggenon C decreases tumor cell viability associated with proteasome inhibition.
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo.
Scaled-down purification protocol to access proteomic analysis of 20S proteasome from human tissue samples: comparison of normal and tumor colorectal cells.
SCF ubiquitin ligase-targeted therapies.
SCF ubiquitin ligases in the maintenance of genome stability.
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Schiff base Cu(II) complexes as inhibitors of proteasome in human cancer cells.
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Screening of tissue microarrays for ubiquitin proteasome system components in tumors.
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs).
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks.
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors.
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site.
Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy.
Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples.
Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-?B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Sem1 is a functional component of the nuclear pore complex-associated messenger RNA export machinery.
Sem1: A versatile "molecular glue"?
Sensitivity of proteasome to its inhibitors increases during cAMP-induced differentiation of neuroblastoma cells in culture and causes decreased viability.
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Sensitizing tumor cells to immune-mediated cytotoxicity.
Separation, identification and characterization of stress degradation products of bortezomib using HPLC and LC-MS.
Sequence analysis of ?-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Serendipity in discovery of proteasome inhibitors.
SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival.
Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance.
Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest.
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition.
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression.
Silencing Hsp25/Hsp27 gene expression augments proteasome activity and increases CD8+ T-cell-mediated tumor killing and memory responses.
Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration.
Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity.
Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Single-cell imaging of the heat-shock response in colon cancer cells suggests that magnitude and length rather than time of onset determines resistance to apoptosis.
Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells.
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy.
Small heat shock proteins and the ubiquitin-proteasome system in malignant tumors.
Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.
Small-molecule inhibitors of proteasome activity.
Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib.
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids.
Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
SPOP and cancer: a systematic review.
Stability of the HTLV-1 Antisense-Derived Protein, HBZ, Is Regulated by the E3 Ubiquitin-Protein Ligase, UBR5.
STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
STD and TRNOESY NMR studies for the epitope mapping of the phosphorylation motif of the oncogenic protein beta-catenin recognized by a selective monoclonal antibody.
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Stress signals utilize multiple pathways to stabilize p53.
Structural characterization of functionalized gold nanoparticles for drug delivery in cancer therapy: a NMR based approach.
Structural plasticity of the proteasome and its function in antigen processing.
Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome.
Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents.
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells.
Studies of phosphoproteomic changes induced by NPM-ALK highlight deregulation of TNF/Fas/TRAIL signaling pathway in ALK-positive anaplastic large cell lymphoma.
Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach.
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Sulforaphane activates heat shock response and enhances proteasome activity through upregulation of HSP27.
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage.
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor.
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors.
Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.
Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
Synergistic induction of apoptosis of rheumatoid arthritis synovial cells by H(2)O(2) and N-acetyl-leucyl-leucyl-norleucinal.
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors.
Synthesis and activity of proteasome inhibitors.
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.
Synthesis and biological properties of C-terminal vinyl ketone pseudotripeptides.
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Synthesis and Pharmacology of Proteasome Inhibitors.
Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.
Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization.
Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan-Based Peptides as 20S Proteasome Inhibitors.
Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity.
Synthesis, radiosynthesis, and biological evaluation of new proteasome inhibitors in a tumor targeting approach.
Synthetic analogs of green tea polyphenols as proteasome inhibitors.
Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers.
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer.
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis.
Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide Conjugation.
Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression.
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Targeted Therapy for EBV-associated B-cell Neoplasms.
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.
Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies.
Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Targeting Deubiquitinases in Cancer.
Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therap.
Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Targeting malignancies with disulfiram (antabuse): multidrug resistance, angiogenesis, and proteasome.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Targeting mitotic exit in solid tumors.
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.
Targeting proteasome inhibition in hematologic malignancies.
Targeting proteasomes with natural occurring compounds in cancer treatment.
Targeting senescence pathways to reverse drug resistance in cancer.
Targeting the Bone Marrow Microenvironment.
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules.
Targeting the ubiquitin proteasome system in haematological malignancies.
Targeting the Ubiquitin Proteasome System: beyond proteasome inhibition.
Targeting the ubiquitin+proteasome system in solid tumors.
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
Targeting the ubiquitin-proteasome pathway in breast cancer.
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy.
Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
Targeting the UPS as therapy in multiple myeloma.
Targeting TRAIL death receptors.
Targeting tumor proteasome with traditional Chinese medicine.
Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization.
Targeting tumour-supportive cellular machineries in anticancer drug development.
Targeting ubiquitin specific proteases for drug discovery.
Targeting Ubiquitin-Proteasome System With Copper Complexes for Cancer Therapy.
Temporal Quantitative Proteomics Reveals Proteomic and Phosphoproteomic Alterations Associated with Adaptive Response to Hypoxia in Melanoma Cells.
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}.
The 'cancer cachectic factor'.
The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28?? and equally degrade FAT10.
The 26S proteasome - from basic mechanisms to drug targeting.
The 26S proteasome complex: An attractive target for cancer therapy.
The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis.
The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.
The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance.
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
The capture proteasome assay: A method to measure proteasome activity in vitro.
The case for therapeutic proteostasis modulators.
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: a proteomic approach.
The chemotherapeutic agent bortezomib induces the formation of stress granules.
The cilia-regulated proteasome and its role in the development of ciliopathies and cancer.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15.
The cytotoxic concentration of rosmarinic acid increases MG132-induced cytotoxicity, proteasome inhibition, autophagy, cellular stresses, and apoptosis in HepG2 cells.
The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2.
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
The effect of proteasome inhibition on the generation of the human leukocyte antigen peptidome.
The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
The ERG1a potassium channel increases basal intracellular calcium concentration and calpain activity in skeletal muscle cells.
The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells.
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer.
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
The Holy Grail: Solid Tumor Efficacy by Proteasome Inhibition.
The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers.
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
The Importance of Ubiquitin E3 Ligases, SCF and APC/C, in Human Cancers.
The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
The integrated stress response and proteotoxicity in cancer therapy.
The JAMM motif of human deubiquitinase Poh1 is essential for cell viability.
The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome.
The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma.
The Molecular Motor F-ATP Synthase Is Targeted by the Tumoricidal Protein HAMLET.
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.
The oncogenic role of REG ? is exerted by activating the Wnt/?-catenin signaling pathway in osteosarcoma.
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.
The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma.
The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.
The potential of proteasome inhibition in the treatment of colon cancer.
The potential of proteasome inhibitors in cancer therapy.
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation.
The proteasome and its inhibitors in immune regulation and immune disorders.
The Proteasome and Myeloma-Associated Bone Disease.
The Proteasome and Proteasome Inhibitors in Cancer Therapy.
The proteasome and proteasome inhibitors in cancer therapy.
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
The proteasome as a novel target for the treatment of breast cancer.
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
The proteasome as a target for cancer therapy.
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5.
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
The proteasome in cancer biology and treatment.
The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL-Mediated Apoptosis.
The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-? gene.
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats.
The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.
The Proteasome Inhibitor MG-132 Induces AIF Nuclear Translocation Through Down-Regulation of ERK and Akt/mTOR Pathway.
The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation.
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells.
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
The proteasome inhibitor PS-341 (Bortezomib) induces calpain-dependent I{kappa}B{alpha} degradation.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
The proteasome inhibitor PS-341 in cancer therapy.
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
The proteasome is involved in determining differential utilization of double-strand break repair pathways.
The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NF?B) activation.
The proteasome, a new target for cancer therapy.
The proteasome.
The proteasome: a molecular target for cancer therapy.
The proteasome: a new target for novel drug therapies.
The proteasome: a novel target for anticancer therapy.
The proteasome: a novel target for cancer chemotherapy.
The proteasome: a novel therapeutic target in haematopoietic malignancy.
The proteasome: a worthwhile target for the treatment of solid tumours?
The proteasome: structure, function, and role in the cell.
The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells.
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
The resistance mechanisms of proteasome inhibitor bortezomib.
The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis.
The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells.
The role of bortezomib in the treatment of lymphoma.
The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells.
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
The role of proteasome inhibitors in solid tumors.
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
The role of the proteasome activator PA28 in MHC class I antigen processing.
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design.
The role of the ubiquitin/proteasome system in cellular responses to radiation.
The role of ubiquitination in tumorigenesis and targeted drug discovery.
The significance of PA28? and U2AF1 in oral mucosal carcinogenesis.
The Significance of Ubiquitin Proteasome Pathway in Cancer Development.
The stress-inducible transcription factor ATF4 accumulates at specific rRNA-processing nucleolar regions after proteasome inhibition.
The Tao of myeloma.
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
The therapeutic potential of deubiquitinating enzyme inhibitors.
The therapeutic potential of microbial proteasome inhibitors.
The toxicology of Clioquinol.
The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers.
The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction.
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
The Tumor Suppressor SCRIB is a Negative Modulator of the Wnt/?-Catenin Signaling Pathway.
The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of Bid.
The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis.
The ubiquitin proteasome system - Implications for cell cycle control and the targeted treatment of cancer.
The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
The Ubiquitin Proteasome System as a source of drug targets for cancer therapy.
The Ubiquitin Proteasome System in Genome Stability and Cancer.
The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options.
The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
The ubiquitin-proteasome pathway and its role in cancer.
The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.
The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib.
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance.
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.
The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice.
The UPS: a promising target for breast cancer treatment.
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
The use of mass spectrometry to identify antigens from proteasome processing.
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
The X-Linked Tumor Suppressor TSPX Interacts and Promotes Degradation of the Hepatitis B Viral Protein HBx via the Proteasome Pathway.
Therapeutic anti-cancer targets upstream of the proteasome.
Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.
Therapeutic targeting of cancer cell cycle using proteasome inhibitors.
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Therapy of human papillomavirus-related disease.
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
Thiostrepton, a natural compound that triggers heat shock response and apoptosis in human cancer cells: a proteomics investigation.
Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice.
Thymoquinone: An edible redox-active quinone for the pharmacotherapy of neurodegenerative conditions and glial brain tumors. A short review.
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.
Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein.
Titania-Coated Gold Nano-Bipyramids for Blocking Autophagy Flux and Sensitizing Cancer Cells to Proteasome Inhibitor-Induced Death.
TNF-NF-kappaB signaling mediates excessive somnolence in hemiparkinsonian rats.
Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
TRAIL and Bortezomib: Killing Cancer with Two Stones.
Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.
Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.
Transcriptional upregulation of BAG3 upon proteasome inhibition.
Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation.
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Trash Talk: Mammalian Proteasome Regulation at the Transcriptional Level.
Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes.
Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Treatment of cutaneous lymphomas: today and tomorrow.
Treatment Options for Triple-class Refractory Multiple Myeloma.
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
Trial Watch: Proteasomal inhibitors for anticancer therapy.
TRIB2 and the ubiquitin proteasome system in cancer.
TRIB3 destabilizes tumor suppressor PPAR? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14.
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression.
tRNA Fragments Show Intertwining with mRNAs of Specific Repeat Content and Have Links to Disparities.
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency.
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Tumor cells can evade dependence on autophagy through adaptation.
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors.
Tumor necrosis factor alpha stimulates p62 accumulation and enhances proteasome activity independently of ROS.
Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses Against Short-Lived Proteins Through a P62-Dependent Mechanism.
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis.
Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3.
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Tuning the proteasome to brighten the end of the journey.
Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.
Ubiquitin ligases and medulloblastoma: genetic markers of the four consensus subgroups identified through transcriptome datasets.
Ubiquitin proteasome inhibition and cancer therapy.
Ubiquitin proteasome pathway: implications and advances in cancer therapy.
Ubiquitin-independent degradation of proteins by the proteasome.
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.
Ubiquitin-proteasome pathway and prostate cancer.
Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Ubiquitin-Proteasome System Regulation of an Evolutionarily Conserved RNA Polymerase II-Associated Factor 1 Involved in Pancreatic Oncogenesis.
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Ubiquitylation and cancer development.
Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of Histone deacetylase inhibitors on ras-transformed thyroid cells.
Up-regulation of PSMB4 is associated with neuronal apoptosis after neuroinflammation induced by lipopolysaccharide.
Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation.
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines.
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors.
Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Upregulation of Rpn10 promotes tumor progression via activation of the NF-?B pathway in clear cell renal cell carcinoma.
Uraemic serum induces dysfunction of vascular endothelial cells: role of ubiquitin-proteasome pathway.
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates.
Utilization of Lipid-Based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Utilization of [11C]phosgene for radiosynthesis of N-(2-{3-[3,5-bis(trifluoromethyl)]phenyl[11C]ureido}ethyl)glycyrrhetinamide, an inhibitory agent for proteasome and kinase in tumors.
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.
Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Vascular effects of cancer treatments.
VCP and PSMF1: Antagonistic regulators of proteasome activity.
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation.
Viruses and the 26S proteasome: hacking into destruction.
Vision Statement for Multiple Myeloma: Future Directions.
Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
WDR23 regulates NRF2 independently of KEAP1.
Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.
Wheat sprout extract induces changes on 20S proteasomes functionality.
Wheat sprout extract-induced apoptosis in human cancer cells by proteasomes modulation.
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy.
Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-?B in multiple myeloma.
Zinc Protoporphyrin Suppresses ?-Catenin Protein Expression in Human Cancer Cells: The Potential Involvement of Lysosome-Mediated Degradation.
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004]
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
[Biosensors as a tool to use in the experiments on blood and selected blood proteins].
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
[Classification and synthesis of ubiquitin-proteasome inhibitor].
[Detection for therapeutic targets specifically expressed in myeloma side population cells].
[Diagnostics of thyroid cancer: limitations of the existing methods and perspectives for future developments].
[Effects of proteasome inhibitors on leukemias]
[Features of the immune proteasome expression in ascite Zajdela hepatoma after implantation into Brattleboro rats with the hereditary defect of arginine-vasopressin synthesis].
[Hypercalcemia of malignancy: clinical features, diagnosis and treatment]
[In Process Citation]
[Intracellular processing of viral and tumor antigens by proteasomes]
[Mechanism of G2/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132]
[Multiple myeloma: past, present and future--editorial]
[P28GANK is a novel marker for prognosis and therapeutic target in gastric cancer].
[Proteasome activity in tumors of female reproductive system].
[Proteasome and calpain activities in colon cancer: the relation with metastasis and prognosis].
[Proteasome and proteolysis]
[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]
[Proteasome inhibitors--new option in the treatment of tumor diseases]
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer]
[Proteasome inhibitors]
[Proteasome inhibitors].
[Proteasome inhibitor]
[Proteasome inhibitor].
[Proteomic analysis of G2/M arrest of HL-60 cells induced by MG132]
[Regulation of insulin-like growth factors and NF-kappaB by proteasome system in endometrial cancer].
[Targeted drugs in radiation therapy]
[The role of proteasome in pathophysiology of cancer cachexia]
[The ubiquitin system for intracellular protein degradation--involvement in human pathologies and therapeutic implications]
Neoplasms, Germ Cell and Embryonal
KRIBB53 binds to OCT4 and enhances its degradation through the proteasome, causing apoptotic cell death of OCT4-positive testicular germ cell tumors.
Neoplasms, Glandular and Epithelial
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Neoplasms, Plasma Cell
Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.
FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impair clearing of protein aggregates and autophagy.
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Neoplasms, Squamous Cell
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
Nephritis
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
The ubiquitin-proteasome pathway and IgA nephropathy: a novel link?
Ubiquitin C-Terminal Hydrolase L1 is required for regulated protein degradation through the ubiquitin proteasome system in kidney.
Nephrotic Syndrome
A case of nephrotic syndrome, showing evidence of response to saquinavir.
Use of Bortezomib in Heavy-Chain Deposition Disease: A Report of 3 Cases.
Nervous System Diseases
Copper: from neurotransmission to neuroproteostasis.
Downregulation of UBE2Q1 is associated with neuronal apoptosis in rat brain cortex following traumatic brain injury.
Multicatalytic proteinase is associated with characteristic oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy.
Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies.
Proteasome Assay in Cell Lysates.
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes.
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy.
Neuralgia
A role of the ubiquitin-proteasome system in neuropathic pain.
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients.
Control of chronic pain by the ubiquitin proteasome system in the spinal cord.
Interplay between the Endogenous Opioid System and Proteasome Complex: Beyond Signaling.
Pain Management in Patients with Multiple Myeloma: An Update.
Neurilemmoma
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.
Neuroblastoma
6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation.
?-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
A Central Role for Phosphorylated p38? in Linking Proteasome Inhibition-Induced Apoptosis and Autophagy.
A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells.
Adaptive changes in autophagy after UPS impairment in Parkinson's disease.
Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations.
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes.
Amyloid-? Secretion, Generation, and Lysosomal Sequestration in Response to Proteasome Inhibition: Involvement of Autophagy.
Apigenin Reduces Proteasome Inhibition-Induced Neuronal Apoptosis by Suppressing the Cell Death Process.
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures.
Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.
Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells.
Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4.
Characterization of the protein ubiquitination response induced by Doxorubicin.
Cobalt chloride affects the death of SH-SY5Y cells induced by inhibition of ubiquitin proteasome system. Role of heat shock protein 70 and caspase 3.
Cocaine and ethanol target 26S proteasome activity and gene expression in neuroblastoma cells.
Concomitant differentiation and partial proteasome inhibition trigger apoptosis in neuroblastoma cells.
Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice.
Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination.
Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson's Disease.
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Effect of cisplatin on proteasome activity.
Fas expression promotes proteasomal activity in toxin-induced parkinsonism.
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
gp130 cytokines stimulate proteasomal degradation of tyrosine hydroxylase via extracellular signal regulated kinases 1 and 2.
Heparan sulfate degradation products can associate with oxidized proteins and proteasomes.
HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
Identifying altered gene expression in neuroblastoma cells preceding apoptosis.
In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome.
Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway.
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease.
Insulin-degrading enzyme (IDE): a novel heat shock-like protein.
Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death.
Lig-8, a bioactive lignophenol derivative from bamboo lignin, protects against neuronal damage in vitro and in vivo.
Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects.
N-Acetyl Cysteine Blunts Proteotoxicity in a Heat Shock Protein-Dependent Manner.
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Novel covalent modifications of alpha-synuclein during the recovery from proteasomal dysfunction.
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.
p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells.
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.
Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells.
Proteasomal regulation of caspase-8 in cancer cell apoptosis.
Proteasome activation and nNOS down-regulation in neuroblastoma cells expressing a Cu,Zn superoxide dismutase mutant involved in familial ALS.
Proteasome activity is critical for the cAMP-induced differentiation of neuroblastoma cells.
Proteasome inhibition and Tau proteolysis: an unexpected regulation.
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines.
Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons.
Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.
Proteasome subunit and opioid receptor gene expression down-regulation induced by paraquat and maneb in human neuroblastoma SH-SY5Y cells.
Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site.
Protein repertoire impact of Ubiquitin-Proteasome System impairment: insight into the protective role of beta-estradiol.
Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system.
Proteomic signature of neuroblastoma cells UKF-NB-4 reveals key role of lysosomal sequestration and the proteasome complex in acquiring chemoresistance to cisplatin.
Proteomics identify nuclear export as a targetable pathway in neuroblastoma: Comment on "XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of I?B".
Reciprocal Effects of alpha-Synuclein Overexpression and Proteasome Inhibition in Neuronal Cells and Tissue.
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells.
Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.
Sarco(endo)plasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, which negatively regulates its expression.
Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries.
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Sensitivity of proteasome to its inhibitors increases during cAMP-induced differentiation of neuroblastoma cells in culture and causes decreased viability.
Sepiapterin attenuates 1-methyl-4-phenylpyridinium-induced apoptosis in neuroblastoma cells transfected with neuronal NOS: role of tetrahydrobiopterin, nitric oxide, and proteasome activation.
Short Chemical Ischemia Triggers Phosphorylation of eIF2? and Death of SH-SY5Y Cells but not Proteasome Stress and Heat Shock Protein Response in both SH-SY5Y and T98G Cells.
SIRT2 interferes with autophagy-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition.
Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells.
Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect.
Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity And Induces Tumor Cell Death.
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor.
Tau is not normally degraded by the proteasome.
TCF11/Nrf1-mediated induction of proteasome expression prevents cytotoxicity by Rotenone.
The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.
The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells.
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
The Extent of Neurodegeneration and Neuroprotection in Two Chemical In Vitro Models Related to Parkinson's Disease is Critically Dependent on Cell Culture Conditions.
The proteasome activator PA200 regulates expression of genes involved in cell survival upon selective mitochondrial inhibition in neuroblastoma cells.
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration.
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB.
Neurodegenerative Diseases
20S proteasome mediated degradation of DHFR: implications in neurodegenerative disorders.
A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs).
A Practical Review of Proteasome Pharmacology.
A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.
Accumulation of phosphorylated neurofilaments and increase in apoptosis-specific protein and phosphorylated c-Jun induced by proteasome inhibitors.
Adaptive autophagy in Alexander disease-affected astrocytes.
Affinity Purification of Mammalian 26S Proteasomes Using an Ubiquitin-Like Domain.
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model.
An antibody-based amperometric biosensor for 20S proteasome activity and inhibitor screening.
Annexin A3 is associated with cell death in lactacystin-mediated neuronal injury.
Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by PINK1 mutation.
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Archaeal Unfoldase Counteracts Protein Misfolding Retinopathy in Mice.
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Are expanded polyglutamine proteins a proteasome substrate?
Assessment of proteasome impairment and accumulation/aggregation of ubiquitinated proteins in neuronal cultures.
Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.
Binding of amyloid beta protein to the 20 S proteasome.
Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.
c-Jun N-terminal kinase pathway mediates Lactacystin-induced cell death in a neuronal differentiated Neuro2a cell line.
Celastrol causes apoptosis and cell cycle arrest in rat glioma cells.
Cell-Clearing Systems Bridging Repeat Expansion Proteotoxicity and Neuromuscular Junction Alterations in ALS and SBMA.
Chaperone-mediated 26S Proteasome Remodeling Facilitates Free K63 Ubiquitin Chain Production and Aggresome Clearance.
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Clustering of heat-shock factors.
Comprehensive Analysis of Proteasomal Complexes in Mouse Brain Regions Detects ENO2 as a Potential Partner of the Proteasome in the Striatum.
Comprehensive Profiling of Protein Ubiquitination for Drug Discovery.
Continued 26S proteasome dysfunction in mouse brain cortical neurons impairs autophagy and the Keap1-Nrf2 oxidative defence pathway.
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome - insights into the enzyme activation mechanism.
Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition.
D: -Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.
Different action mechanisms of low- and high-level quercetin in the brains of adult zebrafish (Danio rerio).
Differential effect of calmodulin antagonists on MG132-induced mitochondrial dysfunction and cell death in PC12 cells.
Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity.
Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.
Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.
Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
Dynamic Expression Changes in the Transcriptome of the Prefrontal Cortex after Repeated Exposure to Cocaine in Mice.
Dysfunction of the unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition.
Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons.
Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function.
Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae.
Enhanced proteasome degradation extends Caenorhabditis elegans lifespan and alleviates aggregation-related pathologies.
Enhancement of proteasome activity by a small-molecule inhibitor of USP14.
Evaluating age-associated phenotypes in a mouse model of protein dyshomeostasis.
Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.
Failure of ubiquitin proteasome system: risk for neurodegenerative diseases.
Fast axonal transport of the proteasome complex depends on membrane interaction and molecular motor function.
Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers.
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.
Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Giant axonal neuropathy.
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death.
Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly.
Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
Impaired proteasome function in Alzheimer's disease.
Impairment of protein degradation and proteasome function in hereditary neuropathies.
Implications of Valosin-containing Protein in Promoting Autophagy to Prevent Tau Aggregation.
In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.
Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.
Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease.
Inhibition of proteasome activity by anthocyanins and anthocyanidins.
Interaction of amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with proteins involved in metabolic and protein degradation pathways.
K63-linked ubiquitination and neurodegeneration.
Lactacystin Stimulates Stellation of Cultured Rat Cortical Astrocytes.
Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.
Linkage between the proteasome pathway and neurodegenerative diseases and aging.
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Measurement of the Multiple Activities of 26S Proteasomes.
Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system.
Mechanistic and thermodynamic characterization of oxathiazolones as potent and selective covalent immunoproteasome inhibitors.
Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection.
Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.
Methylmercury can induce Parkinson's-like neurotoxicity similar to 1-methyl-4- phenylpyridinium: a genomic and proteomic analysis on MN9D dopaminergic neuron cells.
Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates.
Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.
Modulation of proteasome activity by curcumin and didemethylcurcumin.
Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.
Mutant ubiquitin UBB+1 induces mitochondrial fusion by destabilizing mitochondrial fission-specific proteins and confers resistance to oxidative stress-induced cell death in astrocytic cells.
N-Acyldopamine induces aggresome formation without proteasome inhibition and enhances protein aggregation via p62/SQSTM1 expression.
Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons.
New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder.
Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress: Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.
Oxidative protein damage and the proteasome.
Oxidative stress-induced ubiquitination of RCAN1 mediated by SCFbeta-TrCP ubiquitin ligase.
Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases.
Patented small molecule inhibitors in the ubiquitin proteasome system.
Peptidase activities of the 20/26S proteasome and a novel protease in human brain.
Peptide-Based Proteasome Inhibitors in Anticancer Drug Design.
Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: Involvement of proteasome activation.
Polyphenolic flavonoid (Myricetin) upregulated proteasomal degradation mechanisms: Eliminates neurodegenerative proteins aggregation.
Positive correlation between proteasome activity and polyphenols in the telencephalon of adult female mice.
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome.
Precise assembly and regulation of 26S proteasome and correlation between proteasome dysfunction and neurodegenerative diseases.
Prion-like mechanisms in epileptogenesis.
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells.
Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
Proteasome Activation by Small Molecules.
Proteasome activation delays aging and protects against proteotoxicity in neurodegenerative disease.
Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders.
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration.
Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture.
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis.
Proteasome inhibition induces stress kinase dependent transport deficits--implications for Alzheimer's disease.
Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid.
Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism.
Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells.
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Proteasome Subunits Involved in Neurodegenerative Diseases.
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Protein misfolding in neurodegenerative diseases: implications and strategies.
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system.
Protein repertoire impact of Ubiquitin-Proteasome System impairment: insight into the protective role of beta-estradiol.
Proteolytic stress causes heat shock protein induction, tau ubiquitination, and the recruitment of ubiquitin to tau-positive aggregates in oligodendrocytes in culture.
Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system.
Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord.
Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases.
Removing protein aggregates: the role of proteolysis in neurodegeneration.
Reporter-Based Screens for the Ubiquitin/Proteasome System.
Restructured endoplasmic reticulum generated by mutant amyotrophic lateral sclerosis-linked VAPB is cleared by the proteasome.
Resveratrol attenuates oxidative stress and improves behaviour in 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice.
Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway.
Roles of the proteasome in neurodegenerative disease: refining the hypothesis.
Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples.
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
Synthesis and activity of isoxazoline vinyl ester pseudopeptides as proteasome inhibitors.
Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.
Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.
The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
The proteasome in health and disease.
The proteasome: a central regulator of inflammation and macrophage function.
The Role of HSP70 and Its Co-chaperones in Protein Misfolding, Aggregation and Disease.
The role of the ubiquitin proteasome system in synapse remodeling and neurodegenerative diseases.
The roles of the proteasome pathway in signal transduction and neurodegenerative diseases.
The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases.
The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases.
The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim?
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.
The ubiquitin proteasome system in synaptic and axonal degeneration: a new twist to an old cycle.
The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review.
Transcriptional regulation of human USP24 gene expression by NF-kappa B.
Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.
Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies.
Ubiquitin-Proteasome System in Neurodegenerative Disorders.
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Ubiquitin-Synaptobrevin Fusion Protein Causes Degeneration of Presynaptic Motor Terminals in Mice.
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes.
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
Neuroendocrine Tumors
Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Neurofibrosarcoma
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Amphetamine toxicities: classical and emerging mechanisms.
Bassoon proteinopathy drives neurodegeneration in multiple sclerosis.
BV-2 stimulation by lactacystin results in a strong inflammatory reaction and apoptotic neuronal death in SH-SY5Y cells.
Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis.
Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
Investigations into the Role of 26S Proteasome Non-ATPase Regulatory Subunit 13 in Neuroinflammation.
Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus.
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
LPS-induced down-regulation of NO-sensitive guanylyl cyclase in astrocytes occurs by proteasomal degradation in clastosomes.
Neuroinflammation alters cellular proteostasis by producing endoplasmic reticulum stress, autophagy activation and disrupting ERAD activation.
Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.
Reactive glia show increased immunoproteasome activity in Alzheimer's disease.
REG? controls Th17 cell differentiation and autoimmune inflammation by regulating dendritic cells.
Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Neurologic Manifestations
Neuropathy Associated with Systemic Amyloidosis.
Neuromuscular Diseases
Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases.
Neuronal Ceroid-Lipofuscinoses
Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome dependent manner.
Neutropenia
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Nevus
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
Nocardia Infections
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Non-alcoholic Fatty Liver Disease
Moderate chronic ethanol consumption exerts beneficial effects on nonalcoholic fatty liver in mice fed a high-fat diet: possible role of higher formation of triglycerides enriched in monounsaturated fatty acids.
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Serum ubiquitin levels in patients with nonalcoholic steatohepatitis.
non-chaperonin molecular chaperone atpase deficiency
[Mechanism of heat shock protein 90 for regulating 26S proteasome in hyperthermia].
Obesity
"Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy".
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Defective regulation of the ubiquitin/proteasome system in the hypothalamus of obese male mice.
Detecting the genetic link between Alzheimer's disease and obesity using bioinformatics analysis of GWAS data.
High Fat With High Sucrose Diet Leads to Obesity and Induces Myodegeneration.
Landscape of heart proteome changes in a diet-induced obesity model.
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome.
Proteasome activity correlates with male BMI and contributes to the differentiation of adipocyte in hADSC.
PROTEASOME DYSFUNCTION ASSOCIATED TO OXIDATIVE STRESS AND PROTEOTOXICITY IN ADIPOCYTES COMPROMISE INSULIN SENSITIVITY IN HUMAN OBESITY.
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPAR? binodal complementary modules.
Proteasome Subunits mRNA Expressions Correlate With Male BMI: Implications for a Role in Obesity.
Skeletal muscle myotubes in severe obesity exhibit altered ubiquitin-proteasome and autophagic/lysosomal proteolytic flux.
The roles of ubiquitin and 26S proteasome in human obesity.
Obesity, Morbid
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Oncogene Addiction
Oncogenic addiction to high 26S proteasome level.
Opportunistic Infections
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors.
Optic Atrophy, Autosomal Dominant
Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells.
Optic Neuritis
Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis.
Osteitis Deformans
Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta.
Osteoarthritis
Effects of a proteasome inhibitor on the NF-?B signalling pathway in experimental osteoarthritis.
Hypoxic resistance to articular chondrocyte apoptosis--a possible mechanism of maintaining homeostasis of normal articular cartilage.
Local induction of heat shock protein 70 (Hsp70) by proteasome inhibition confers chondroprotection during surgically induced osteoarthritis in the rat knee.
Protection against murine osteoarthritis by inhibition of the 26S proteasome and lysine-48 linked ubiquitination.
Suppression of pain and joint destruction by inhibition of the proteasome system in experimental osteoarthritis.
Osteolysis
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Effects of proteasome inhibitors on cytokines, metalloproteinases and their inhibitors and collagen type-I expression in periprosthetic tissues and fibroblasts from loose arthroplasty endoprostheses.
Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.
Nanosized Alumina Particle and Proteasome Inhibitor Bortezomib Prevented inflammation and Osteolysis Induced by Titanium Particle via Autophagy and NF-?B Signaling.
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo.
Osteonecrosis
Bioinformatics analysis of microRNA linked to ubiquitin proteasome system in traumatic osteonecrosis of the femoral head.
Osteoporosis
Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.
Osteoporosis, Postmenopausal
Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.
Osteosarcoma
A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma.
A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
Adenylate cyclase regulation via proteasome-mediated modulation of Galphas levels.
alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity.
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation.
APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome.
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma.
Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2?/ATF4/CHOP axis.
Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Identification of cellular proteins interacting with equine infectious anemia virus S2 protein.
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb.
Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells.
Non?covalent proteasome inhibitor PI?1840 induces apoptosis and autophagy in osteosarcoma cells.
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
Proteasome inhibitor MG132 enhances cisplatin-induced apoptosis in osteosarcoma cells and inhibits tumor growth.
Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells.
Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR.
Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Significance of NF-kappaB signaling and PARP1 activity in the TNF-induced inhibition of PHEX gene expression in human osteoblasts.
The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RAR?.
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cells.
[Cytotoxic effect of cisplatin with proteasome inhibitor on osteosarcoma cells]
Osteosclerosis
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Ovarian Cysts
Proteasome Activity and C-Reactive Protein Concentration in the Course of Inflammatory Reaction in Relation to the Type of Abdominal Operation and the Surgical Technique Used.
Ovarian Neoplasms
Autophagy-independent enhancing effects of Beclin 1 on cytotoxicity of ovarian cancer cells mediated by proteasome inhibitors.
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Bim protein degradation contributes to cisplatin resistance.
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.
Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting.
Expression profiles and prognostic values of BolA family members in ovarian cancer.
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
New agents for the treatment of ovarian cancer: the next generation.
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Proteasome antibodies in patients with cancer or multiple sclerosis.
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Proteasome inhibition increases recruitment of I?B kinase ? (IKK?), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition.
PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Specific MALDI Imaging and Profiling for Biomarker Hunting and Validation: Fragment of the 11S Proteasome Activator Complex, Reg Alpha Fragment, Is a New Potential Ovary Cancer Biomarker.
STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.
Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341.
The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.
[Association of intracellular proteinase activities with the content of locomotor proteins in tissues of primary tumors and metastasis in ovarian cancer].
[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]
Pancreatic Neoplasms
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells.
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Development of the proteasome inhibitor Velcade (Bortezomib).
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.
Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines.
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells.
Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Lysosomal Degradation of CD44 Mediates Ceramide Nanoliposome-induced Anoikis and Diminshed Extravasation in Metastatic Carcinoma Cells.
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
New Difluoro Knoevenagel Condensates of Curcumin, Their Schiff Bases and Copper Complexes as Proteasome Inhibitors and Apoptosis Inducers in Cancer Cells.
Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines.
Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis.
Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers.
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer.
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-kappaB Activity.
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.
Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6.
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells.
The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer.
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Pancreatitis
Bortezomib-induced acute pancreatitis: Case report and review of the literature.
CaMKII/proteasome/cytosolic calcium/cathepsin B axis was present in tryspin activation induced by nicardipine.
Chymotrypsin-like activity in rat tissues in experimental acute pancreatitis.
Dynamic changes of proteasome and protective effect of bortezomib, a proteasome inhibitor, in mice with acute pancreatitis.
Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats.
The Potential Effect of Proteasome Inhibitor PS-341 on Severe Acute Pancreatitis Detected by Positron Emission Tomography in ICR Mice.
The proteasome inhibitor MG132 protects against acute pancreatitis.
Therapeutic proteasome inhibition in experimental acute pancreatitis.
[Effect of MG-132 upon the expression of intercellular adhesion molecule-1 in cerulein-induced acute pancreatitis in mice]
[Protective effect of proteasome inhibitor MG-132 in rats with severe acute pancreatitis and lung injury]
Papilloma
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Molecular mechanism of curcumin action in signaling pathways: Review of the latest research.
REG? is critical for skin carcinogenesis by modulating the Wnt/?-catenin pathway.
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]
Paralysis
18?-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures.
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Diaphragm muscle fiber function and structure in humans with hemidiaphragm paralysis.
The A? Containing Brain Extracts Having Different Effects in Alzheimer's Disease Transgenic Caenorhabditis elegans and Mice.
Paraneoplastic Cerebellar Degeneration
Proteasome antibodies in paraneoplastic cerebellar degeneration.
Paraproteinemias
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
Current Controversies in the Management of Myeloma Bone Disease.
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
The proteasome in terminal plasma cell differentiation.
Parasitic Diseases
Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.
The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni.
Paresthesia
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Parkinson Disease
A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration.
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis.
Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin.
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Analysis of gene expression in neural cells subject to chronic proteasome inhibition.
Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells.
Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.
Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.
Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.
Brain proteasomal function in sporadic Parkinson's disease and related disorders.
c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration.
Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression.
Characterization of chronic low-level proteasome inhibition on neural homeostasis.
Characterization of proteasome inhibition on astrocytes cell cycle.
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration.
Co-expression network-based analysis of hippocampal expression data associated with Alzheimer's disease using a novel algorithm.
Compensatory role of the Nrf2-ARE pathway against paraquat toxicity: Relevance of 26S proteasome activity.
Complex interactions in Parkinson's disease: a two-phased approach.
Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer's patients.
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.
Cysteine cathepsins are essential in lysosomal degradation of ?-synuclein.
Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies.
Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson's Disease.
Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry.
Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Dopaminergic Neuroprotection via Nrf2-ARE Pathway Activation: Identification of an Activator from Green Perilla Leaves.
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats.
Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection.
Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.
Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown.
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin.
GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.
Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation.
Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease.
Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association.
Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson's disease.
Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats.
Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease.
Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.
Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis.
Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Lack of nigrostriatal pathology in a rat model of proteasome inhibition.
Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death.
Lactacystin Stimulates Stellation of Cultured Rat Cortical Astrocytes.
Long-term heat shock proteins (HSPs) induction by carbenoxolone improves hallmark features of Parkinson's disease in a rotenone-based model.
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
Loss of TDP-43 Inhibits Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 Aggresome Formation in an HDAC6-Dependent Manner.
Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease.
Mechanisms of rotenone-induced proteasome inhibition.
Mitochondrial accumulation of polyubiquitinated proteins and differential regulation of apoptosis by polyubiquitination sites Lys-48 and -63.
Mitochondrial Dysfunction Precedes Other Sub-Cellular Abnormalities in an In Vitro Model Linked with Cell Death in Parkinson's Disease.
Modeling proteasome dynamics in Parkinson's disease.
Morphological and Metabolic Changes in the Nigro-Striatal Pathway of Synthetic Proteasome Inhibitor (PSI)-Treated Rats: A MRI and MRS Study.
N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
N-Acetylcysteine in Combination with IGF-1 Enhances Neuroprotection against Proteasome Dysfunction-Induced Neurotoxicity in SH-SY5Y Cells.
Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease?
Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1? and BDNF/CREB pathways.
Neurotoxin-induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response.
Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated ?-synuclein.
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Nuclear localization of the 20S proteasome subunit in Parkinson's disease.
Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients.
Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition.
p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells.
Pathological proteins in Parkinson's disease: focus on the proteasome.
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease.
Posttranslational Modifications and Clearing of ?-Synuclein Aggregates in Yeast.
Proteasome Assay in Cell Lysates.
Proteasome dysfunction in aged human alpha-synuclein transgenic mice.
Proteasome function and pathological proteins in the pathogenesis of Parkinson's disease.
Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover.
Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells.
Proteasome inhibition and Parkinson's disease modeling.
Proteasome inhibition and Tau proteolysis: an unexpected regulation.
Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures.
Proteasome inhibitor lactacystin induces cholinergic degeneration.
Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.
Proteasome inhibitor-induced model of Parkinson's disease.
Proteomic Study of a Parkinson's Disease Model of Undifferentiated SH-SY5Y Cells Induced by a Proteasome Inhibitor.
Recent progress of imaging agents for Parkinson's disease.
Reciprocal Upshot of Nitric Oxide, Endoplasmic Reticulum Stress, and Ubiquitin Proteasome System in Parkinson's Disease Pathology.
Reduced protein stability of human DJ-1/PARK7 L166P, linked to autosomal recessive Parkinson disease, is due to direct endoproteolytic cleavage by the proteasome.
Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.
Resveratrol attenuates oxidative stress and improves behaviour in 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice.
Retraction. Proteasome inhibitor-induced model of Parkinson's disease (Ann Neurol 2006;60:243-247).
Role of the ubiquitin proteasome system in Parkinson's disease.
Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders.
Rpt2 proteasome subunit reduction causes Parkinson's disease like symptoms in Drosophila.
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.
Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis.
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
TCF11/Nrf1-mediated induction of proteasome expression prevents cytotoxicity by Rotenone.
Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson's disease.
The Extent of Neurodegeneration and Neuroprotection in Two Chemical In Vitro Models Related to Parkinson's Disease is Critically Dependent on Cell Culture Conditions.
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.
The parkinsonism-associated protein FBXO7 cooperates with the BAG6 complex in proteasome function and controls the subcellular localization of the complex.
The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
The Proteasome Inhibition Model of Parkinson's Disease.
The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
Thyroarytenoid Muscle Gene Expression in a Rat Model of Early-Onset Parkinson's Disease.
Transcriptional regulation of human USP24 gene expression by NF-kappa B.
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease.
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients.
Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?
UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin.
Using the attract method to identify core pathways in juvenile idiopathic arthritis.
Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.
[Effect of Electroacupuncture on 26 S Proteasome and Nuclear Factor kappa B in Substantia Nigra of Rats with Rotenone-induced Parkinson's Disease].
[Proteasomal inhibitor lactacystin induces cell apoptosis and caspase 3 activation in PC12 cells]
[Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity].
[Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Parkinsonian Disorders
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Are ubiquitination pathways central to Parkinson's disease?
Clinicopathological correlations in behavioural variant frontotemporal dementia.
D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly.
Guanosine improves motor behavior, reduces apoptosis, and stimulates neurogenesis in rats with parkinsonism.
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
L-dopa impairs proteasome activity in Parkinsonism through D1 dopamine receptor.
Nocardia asteroides strain GUH-2 induces proteasome inhibition and apoptotic death of cultured cells.
Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.
The parkinsonism-associated protein FBXO7 cooperates with the BAG6 complex in proteasome function and controls the subcellular localization of the complex.
Ubiquitin, proteasome and parkin.
[Impairment of the ubiquitin-proteasome system and neurodegeneration]
Pelizaeus-Merzbacher Disease
Myelin under stress.
peptide-n4-(n-acetyl-beta-glucosaminyl)asparagine amidase deficiency
Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency.
Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.
Loss of peptide:N-glycanase causes proteasome dysfunction mediated by a sugar-recognizing ubiquitin ligase.
Peri-Implantitis
Identification of key genes and pathways for peri-implantitis through the analysis of gene expression data.
Periodontitis
The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats.
Peripheral Nervous System Diseases
?-Keto phenylamides as P1'-extended proteasome inhibitors.
A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors.
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons.
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis.
Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro.
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.
Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Iatrogenic neuropathies.
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.
Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy.
Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.
Neurotoxicity induced by antineoplastic proteasome inhibitors.
Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Pain Management in Patients with Multiple Myeloma: An Update.
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
PMP22 accumulation in aggresomes: implications for CMT1A pathology.
Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia.
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.
Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib.
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD(®) immunomodulatory drug pomalidomide.
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
The Actions and Mechanisms of P2X7R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain.
The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy.
The start of a new wave: developments in proteasome inhibition in multiple myeloma.
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Utilization of iPSC-derived human neurons for high-throughput drug-induced peripheral neuropathy screening.
[POEMS syndrome: Diagnosis, stratification, treatments].
Peritonitis
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Persistent Infection
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity.
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
Pestivirus Infections
The structure of classical swine fever virus N(pro): a novel cysteine Autoprotease and zinc-binding protein involved in subversion of type I interferon induction.
Pheochromocytoma
Bortezomib Alone and in Combination with Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death in Vitro and in Female Nude Mice.
Lig-8, a highly bioactive lignophenol derivative from bamboo lignin, exhibits multifaceted neuroprotective activity.
Proteasome Inhibitors: A Potential Medical Therapy for Malignant Pheochromocytoma.
Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein.
Pick Disease of the Brain
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Pituitary Neoplasms
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition.
Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells.
Plant Diseases
The Chinese wild grapevine (Vitis pseudoreticulata) E3 ubiquitin ligase Erysiphe necator-induced RING finger protein 1 (EIRP1) activates plant defense responses by inducing proteolysis of the VpWRKY11 transcription factor.
Plasmacytoma
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy.
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Wheat sprout extract-induced apoptosis in human cancer cells by proteasomes modulation.
Pleural Effusion
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity.
Pneumonia
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
Pneumonia, Pneumococcal
Proteasome ?5i Subunit Deficiency Affects Opsonin Synthesis and Aggravates Pneumococcal Pneumonia.
Pneumonia, Ventilator-Associated
Proteasomes in Human Bronchoalveolar Lavage Fluid After Burn and Inhalation Injury.
POEMS Syndrome
[Progress in Treatment of POEMS Syndrome--Review].
Polycystic Kidney, Autosomal Dominant
MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
Polyneuropathies
A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Porcine Reproductive and Respiratory Syndrome
The ubiquitin proteasome system is necessary for efficient proliferation of porcine reproductive and respiratory syndrome virus.
Porphyria, Erythropoietic
Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
Poxviridae Infections
Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.
Pre-Eclampsia
Altered expression of COP9 signalosome proteins in preeclampsia.
Altered expression of p97/Valosin containing protein and impaired autophagy in preeclamptic human placenta.
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Genome-wide hypermethylation coupled with promoter hypomethylation in the chorioamniotic membranes of early onset pre-eclampsia.
Increased oxidative stress in pre-eclamptic placenta is associated with altered proteasome activity and protein patterns.
Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
[Microarray analysis of differentially expressed genes in peripheral leucocytes derived from severe preeclampsia and normotensive pregnancies]
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
The mTOR inhibitor RAD001 (Everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia.
Higher ratio immune vs. constitutive proteasome level as novelindicator of sensitivity of pediatric acute leukemia cells to proteasomeinhibitors.
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells.
Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-?B activity.
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B.
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia.
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Premature Birth
Amniotic Fluid Proteasome and Immunoproteasome in the Setting of Intra-Amniotic Infection, Inflammation, and Preterm Birth.
Effect of proteasome pathway on initiation of mouse labor induced by antiprogesterone.
Primary Graft Dysfunction
A novel mechanism for immune regulation after human lung transplantation.
Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
Primary Immunodeficiency Diseases
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
Primary Myelofibrosis
Modern management of myelofibrosis.
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Prion Diseases
Could inhibition of the proteasome cause mad cow disease?
Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations.
Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.
Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction.
Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease.
Interaction between misfolded PrP and the ubiquitin-proteasome system in prion-mediated neurodegeneration.
Mechanistic insights into the cure of prion disease by novel antiprion compounds.
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation.
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice.
Prion-Associated Neurodegeneration Causes Both Endoplasmic Reticulum Stress and Proteasome Impairment in a Murine Model of Spontaneous Disease.
Prions and the proteasome.
Proteasome inhibitors promote the sequestration of PrPSc into aggresomes within the cytosol of prion-infected CAD neuronal cells.
Trafficking, turnover and membrane topology of PrP.
Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.
Prostatic Neoplasms
1,10-Phenanthroline promotes copper complexes into tumor cells and induces apoptosis by inhibiting the proteasome activity.
15,16-Dihydrotanshinone I, a Compound of Salvia miltiorrhiza Bunge, Induces Apoptosis through Inducing Endoplasmic Reticular Stress in Human Prostate Carcinoma Cells.
A differential expression network method identifies ankylosing spondylitis-related genes.
A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.
A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells.
AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer.
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.
Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells.
Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-? from degradation and induce apoptosis in prostate cancer cells.
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Aromatic monophenols from cinnamon bark act as proteasome inhibitors by upregulating ER stress, suppressing FoxM1 expression, and inducing apoptosis in prostate cancer cells.
Association of Metals and Proteasome Activity in Erythrocytes of Prostate Cancer Patients and Controls.
Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.
Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells.
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.
Bortezomib as a potential treatment for prostate cancer.
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
CDC4 Gene Expression as Potential Biomarker for Targeted Therapy in Prostate Cancer.
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.
Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells.
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells.
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
Cotargeting stress-activated hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.
Development of the proteasome inhibitor Velcade (Bortezomib).
Diltiazem Enhances the Apoptotic Effects of Proteasome Inhibitors to Induce Prostate Cancer Cell Death.
Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.
Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology.
Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell.
Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells.
Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis.
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis.
Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Inhibition on Proteasome ?1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.
L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.
Long non-coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer.
Marchantin M: a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells.
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition.
Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome.
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Novel phosphorylation and ubiquitination sites regulate ROS-dependent degradation of anti-apoptotic c-FLIP protein.
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.
P53 and the proteasome regulate androgen receptor activity.
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives.
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy.
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells.
Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
Proteasomal regulation of caspase-8 in cancer cell apoptosis.
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.
Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKK?.
Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells.
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-?B and CHOP expression.
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
Proteasome mediated degradation of Id-1 is associated with TNFalpha-induced apoptosis in prostate cancer cells.
Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.
PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
Radioresistance of prostate cancer cells with low proteasome activity.
Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.
Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition.
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration.
Specific positive and negative effects of FLIP on cell survival in human prostate cancer.
Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors.
Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1?.
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
The NF-?B subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells.
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-?/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer.
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.
The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry".
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress.
Ubiquitin-proteasome pathway and prostate cancer.
Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer]
proteasome endopeptidase complex deficiency
A ubiquitin stress response induces altered proteasome composition.
Analysis of the spontaneous mutator phenotype associated with 20S proteasome deficiency in S. cerevisiae.
Genetic and proteomic analyses of a proteasome-activating nucleotidase A mutant of the haloarchaeon Haloferax volcanii.
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease.
Proteasome nuclear import mediated by Arc3 can influence efficient DNA damage repair and mitosis in Schizosaccharomyces pombe.
Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle.
[Nakajo-Nishimura syndrome].
Protein C Deficiency
[Biosensors as a tool to use in the experiments on blood and selected blood proteins].
Protein Deficiency
Proteasome degradation of protein C and plasmin inhibitor mutants.
The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha.
[Proteasome degradation of protein C and plasmin inhibitor mutants: molecular mechanism of congenital protein deficiency]
Proteinuria
Bortezomib for Reduction of Proteinuria in IgA Nephropathy.
Pseudomonas Infections
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Psoriasis
An ensemble of the iCluster method to analyze longitudinal lncRNA expression data for psoriasis patients.
Anti-20S Proteasome Antibodies in Psoriatic Arthritis.
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Naturally occurring proteasome inhibitors from mate tea (Ilex paraguayensis) serve as models for topical proteasome inhibitors.
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.
Proteasome inhibition: a new anti-inflammatory strategy.
Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated.
Reduced Proteasome Activity and Enhanced Autophagy in Blood Cells of Psoriatic Patients.
The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.
Pterygium
The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved.
UVB-mediated down-regulation of proteasome in cultured human primary pterygium fibroblasts.
Pulmonary Arterial Hypertension
Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.
Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease.
Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.
Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept.
Dissecting the molecular effects of cigarette smoke on proteasome function.
Does oxidative stress modulate limb muscle atrophy in severe copd patients?
Effects of exercise training on quadriceps muscle gene expression in chronic obstructive pulmonary disease.
Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease.
Heightened Endoplasmic Reticulum Stress in COPD Lungs: The Role of Nrf2-Regulated Proteasomal Activity.
Histone 3.3 participates in a self-sustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease.
Involvement of the FoxO1/MuRF1/Atrogin-1 Signaling Pathway in the Oxidative Stress-Induced Atrophy of Cultured Chronic Obstructive Pulmonary Disease Myotubes.
Proteasome activity related with the daily physical activity of COPD patients.
Proteasome function is not impaired in healthy aging of the lung.
Proteasome inhibition improves diaphragm function in an animal model for COPD.
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Role of autophagy in COPD skeletal muscle dysfunction.
Skeletal muscle molecular responses to resistance training and dietary supplementation in COPD.
Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease.]
Pulmonary Emphysema
Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.
Pulmonary Fibrosis
Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation Without Proteasome Inhibition.
Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome.
Regulation of 26S Proteasome Activity in Pulmonary Fibrosis.
Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.
What shall we do with the damaged proteins in lung disease? Ask the proteasome!
Purpura, Thrombocytopenic, Idiopathic
T cell immune abnormalities in immune thrombocytopenia.
Pyoderma Gangrenosum
Monogenic autoinflammatory diseases: concept and clinical manifestations.
Rabies
[A DNA Construct That Encodes the Rabies Virus Consensus Glycoprotein with a Proteasome Degradation Signal Induces Antibody Production with IgG2A Subtype Predominance].
Rectal Neoplasms
Antiproteasomal agents in rectal cancer.
Effect of Neoadjuvant Chemoradiation Therapy on Proteasome Pool in Rectal Cancer.
Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors.
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?
Renal Insufficiency
Emerging roles of proteasomes in ischemia-reperfusion injury of organs.
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Renal Insufficiency, Chronic
Caspase-3 cleaves specific 19S proteasome subunits in skeletal muscle stimulating proteasome activity.
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Differential expression of proteins from cultured endothelial cells exposed to uremic versus normal serum.
Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact.
Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Reperfusion Injury
Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes.
Back to your heart: Ubiquitin proteasome system-regulated signal transduction.
Bicarbonate Increases Ischemia-Reperfusion Damage by Inhibiting Mitophagy.
Effect of a low dose of proteasome inhibitor on cell death and gene expression in neonatal rat cardiomyocyte cultures exposed to anoxia-reoxygenation.
Emerging roles of proteasomes in ischemia-reperfusion injury of organs.
Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.
Inhibition of the proteasome preserves Mitofusin-2 and mitochondrial integrity, protecting cardiomyocytes during ischemia-reperfusion injury.
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury.
Possible involvement of ubiquitin proteasome system and other proteases in acute and delayed aspects of ischemic preconditioning of brain in mice.
Proteasome and Organs Ischemia-Reperfusion Injury.
Proteasome functional insufficiency in cardiac pathogenesis.
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.
Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.
Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Proteasome inhibitors: an expanding army attacking a unique target.
Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?
Proteasome peptidase activities parallel histomorphological and functional consequences of ischemia-reperfusion injury in the lung.
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
Respiratory Distress Syndrome
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
Distinct Proteasome Subpopulations in the Alveolar Space of Patients with the Acute Respiratory Distress Syndrome.
Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome.
Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.
Respiratory Insufficiency
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Retinal Degeneration
Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats.
Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila.
Proteasome overload is a common stress factor in multiple forms of inherited retinal degeneration.
The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration.
Retinitis Pigmentosa
A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system.
Retinoblastoma
APC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathway.
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.
Proteolytic degradation of the retinoblastoma family protein p107: A putative cooperative role of calpain and proteasome.
Retinoblastoma protein regulation by the COP9 signalosome.
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors.
Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.
The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
The Id-protein family in developmental and cancer-associated pathways.
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Rett Syndrome
Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations.
Rhabdomyosarcoma
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro.
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
The effect of the NF-kappa B inhibitors curcumin and lactacystin on myogenic differentiation of rhabdomyosarcoma cells.
The involvement of proteasome in myogenic differentiation of murine myocytes and human rhabdomyosarcoma cells.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Rosacea
Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea.
Sarcoidosis
Alveolar and intraparenchymal proteasome in sarcoidosis.
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome.
mRNA expression profile of bronchoalveolar lavage fluid cells from patients with idiopathic pulmonary fibrosis and sarcoidosis.
New molecular targets for the treatment of sarcoidosis.
Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.
RNA-sequencing Identifies Novel Pathways in Sarcoidosis Monocytes.
Sarcoidosis activates diverse transcriptional programs in bronchoalveolar lavage cells.
The proteasome is a major autoantigen in multiple sclerosis.
Sarcoma
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.
New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and down-regulation of survivin.
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Targeting sarcomas: therapeutic targets and their rational.
Targets for cancer therapy in childhood sarcomas.
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses Against Short-Lived Proteins Through a P62-Dependent Mechanism.
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines.
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Sarcoma, Avian
Distinct protease pathways control cell shape and apoptosis in v-src-transformed quail neuroretina cells.
Enhanced levels of multicatalytic proteinase mRNAs in Rous sarcoma virus transformed cells.
Molecularly targeted therapy for gastrointestinal cancer.
Retroviruses have differing requirements for proteasome function in the budding process.
The role of Src protein in the process formation of PC12 cells induced by the proteasome inhibitor MG-132.
Sarcoma, Ewing
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.
Sarcoma, Kaposi
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.
Sarcoma, Synovial
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
Sarcopenia
Caloric restriction optimizes the proteasome pathway with aging in rat plantaris muscle: implications for sarcopenia.
Effect of Dietary Silk Peptide on Obesity, Hyperglycemia, and Skeletal Muscle Regeneration in High-Fat Diet-Fed Mice.
Meeting Report: American Aging Association 40(th) Annual Meeting, Raleigh, North Carolina, June 3-6, 2011.
Novel intriguing strategies attenuating to sarcopenia.
Sarcopenia in heart failure: mechanisms and therapeutic strategies.
Schistosomiasis
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni.
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes.
Schistosoma mansoni: functional proteasomes are required for development in the vertebrate host.
Scleroderma, Systemic
Is biological therapy in systemic sclerosis the answer?
The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis.
Scrapie
Cellular prion protein (PrPC) protects neuronal cells from the effect of huntingtin aggregation.
Interplay between 20S proteasomes and prion proteins in scrapie disease.
[Scrapie, proteasome and endoplasmic reticulum]
Seizures
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Sepsis
Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis.
Amino acids, independent of insulin, attenuate skeletal muscle autophagy in neonatal pigs during endotoxemia.
Biochemical mechanisms of cellular catabolism.
Calpain activity and muscle wasting in sepsis.
Catabolic response to stress and injury: implications for regulation.
Differential Regulation of the Autophagy and Proteasome Pathways in Skeletal Muscles in Sepsis.
Effect of Proteasome Inhibitors on Endotoxin Induced Diaphragm Dysfunction.
Endotoxin reduces CD95-induced neutrophil apoptosis by cIAP-2-mediated caspase-3 degradation.
Glucocorticoids do not regulate the expression of proteolytic genes in skeletal muscle from Cushing's syndrome patients.
Heightened levels of circulating 20S proteasome in critically ill patients.
Inability to replete white adipose tissue during recovery phase of sepsis is associated with increased autophagy, apoptosis, and proteasome activity.
INHIBITION OF GSK-3? ACTIVITY WITH LITHIUM IN VITRO ATTENUATES SEPSIS-INDUCED CHANGES IN MUSCLE PROTEIN TURNOVER.
Marginal dietary zinc deprivation augments sepsis-induced alterations in skeletal muscle TNF-? but not protein synthesis.
Modulation of inflammatory response in sepsis by proteasome inhibition.
Platelet Proteasome Activity and Metabolism Is Upregulated during Bacterial Sepsis.
Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis.
Protein kinases, TNF-{alpha}, and proteasome contribute in the inhibition of fructose intestinal transport by sepsis in vivo.
Resveratrol Downregulates Biomarkers of Sepsis via Inhibition of Proteasome's Proteases.
Role of proteasomes in disease.
Roles of Toll-Like Receptor 4, I?B Kinase, and the Proteasome in the Intestinal Alterations Caused by Sepsis.
Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo.
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
Temporally Distinct Regulation of Pathways Contributing to Cardiac Proteostasis During the Acute and Recovery Phases of Sepsis.
The case for therapeutic proteostasis modulators.
The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events.
The value of correlation of serum 20S proteasome concentration and percentage of lymphocytic apoptosis in critically ill patients: a prospective observational study.
Tripeptidyl-peptidase II expression and activity are increased in skeletal muscle during sepsis.
[Effect of ubiquitin-proteasome pathway on inflammatory reaction in intestine and its barrier function in rats with postburn sepsis]
[Gene expression of C2 subunit of proteasome in cardiac muscle in burned rats with sepsis]
Sertoli Cell-Only Syndrome
Quantitative proteomic analysis of human testis reveals system-wide molecular and cellular pathways associated with non-obstructive azoospermia.
Severe Acute Respiratory Syndrome
Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus.
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
Severe Fever with Thrombocytopenia Syndrome
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Shock, Septic
A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model.
Lipopolysaccharides Promote S-Nitrosylation and Proteasomal Degradation of Liver Kinase B1 (LKB1) in Macrophages in Vivo.
Proteasome inhibition decreases inflammation in human endothelial cells exposed to lipopolysaccharide.
Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients.
The proteasome: a central regulator of inflammation and macrophage function.
Sjogren's Syndrome
Expression of Proteasomal Immunosubunit {beta}1i Is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sjogren's Syndrome.
Expression of proteasome immunosubunit in labial glands of patients with primary Sjogren's syndrome.
Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sjogren Syndrome.
The proteasome is a major autoantigen in multiple sclerosis.
Skin Diseases
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
CANDLE Syndrome: a report of a novel mutation and review of the literature.
Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related auto-inflammatory disease.
Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.
Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.
Sleep Initiation and Maintenance Disorders
T2D and Depression Risk Gene Proteasome Modulator 9 is Linked to Insomnia.
Small Cell Lung Carcinoma
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines.
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Identification of differentially expressed genes and pathways crosstalk analysis in Rheumatoid and Osteoarthritis using next-generation sequencing and protein-protein networks.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Proteasome inhibitors in lung cancer.
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Spasm
Managing Multiple Myeloma in the Face of Drug-Induced Adverse Drug Reaction.
Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report.
Vascular Spasm: A Newly Unraveled Cause for Cardiovascular Adversity of Proteasome Inhibition.
Spinal Cord Injuries
cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons.
Nanoparticles Exacerbate Both Ubiquitin and Heat Shock Protein Expressions in Spinal Cord Injury: Neuroprotective Effects of the Proteasome Inhibitor Carfilzomib and the Antioxidant Compound H-290/51.
Spinocerebellar Ataxias
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Allosteric regulation of deubiquitylase activity through ubiquitination.
Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.
Delayed spinocerebellar ataxia in transgenic mice expressing mutant ubiquitin.
Molecular clearance of ataxin-3 is regulated by a mammalian E4.
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product.
Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions.
The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Spondylitis, Ankylosing
Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the Ubiquitin Proteasome pathway.
Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis.
Association to HLA-DRB1*08, HLA-DPB1*0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Circulating Proteasomes in the Pathogenesis of Head and Neck Squamous Cell Carcinoma.
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
Proteasome regulation of ULBP1 transcription.
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.
SEC61G identified as a prognostic biomarker of head and neck squamous cell carcinoma.
Targeted therapy in head and neck cancer.
The molecular mechanisms of XBP-1 gene silencing on IRE1?-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]
Starvation
Amino acid starvation sensitizes cancer cells to proteasome inhibition.
AMPK regulates ESCRT-dependent microautophagy of proteasomes concomitant with proteasome storage granule assembly during glucose starvation.
Arabidopsis SINAT Proteins Control Autophagy by Mediating Ubiquitylation and Degradation of ATG13.
Autophagic Degradation of the 26S Proteasome Is Mediated by the Dual ATG8/Ubiquitin Receptor RPN10 in Arabidopsis.
Autophagy regulator Atg9 is degraded by the proteasome.
BNIP3 is degraded by ULK1-dependent autophagy via MTORC1 and AMPK.
Both negative and positive G1 cell cycle regulators undergo proteasome-dependent degradation during sucrose starvation in Arabidopsis.
Changes in the expression and the enzymic properties of the 20S proteasome in sugar-starved maize roots. evidence for an in vivo oxidation of the proteasome.
Decreased heat shock protein 27 expression and altered autophagy in human cells harboring A8344G mitochondrial DNA mutation.
Deficient autophagy in epithelial stem cells drives aging in the freshwater cnidarian Hydra.
Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation.
Eat or be eaten: The autophagic plight of inactive 26S proteasomes.
Effect of starvation on global gene expression and proteolysis in rainbow trout (Oncorhynchus mykiss).
Expression pattern of parkin isoforms in lung adenocarcinomas.
Genome-wide RNAi Screen for Fat Regulatory Genes in C. elegans Identifies a Proteostasis-AMPK Axis Critical for Starvation Survival.
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells.
GOLPH3 silencing inhibits adhesion of glioma U251 cells by regulating ITGB1 degradation under serum starvation.
Growth-dependent change of the 26S proteasome in budding yeast.
Herp depletion protects from protein aggregation by up-regulating autophagy.
Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy.
Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.
Mechanism of endocytic regulation of intestinal tight junction remodeling during nutrient starvation in jejunal IPEC-J2 cells.
Mechanisms of deregulation of IFN regulatory factor-1 in ras-transformed fibroblasts.
Microautophagy regulates proteasome homeostasis.
Modulation of the cell cycle regulating transcription factor E2F1 pathway by the proteasome following amino acid starvation.
NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons.
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome.
PPAR?-Mediated Positive-Feedback Loop Contributes to Cold Exposure Memory.
Proteasomal degradation of Sfp1 contributes to the repression of ribosome biogenesis during starvation and is mediated by the proteasome activator Blm10.
Proteasome 19S RP and translation preinitiation complexes are secreted within exosomes upon serum starvation.
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Proteasome storage granules protect proteasomes from autophagic degradation upon carbon starvation.
Proteomics identifies ubiquitin-proteasome targets and new roles for chromatin-remodeling in the Arabidopsis response to phosphate starvation.
Responses of Saccharomyces cerevisiae to nitrogen starvation in wine alcoholic fermentation.
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
Serum starvation raises turnover of phosphorylated p62/SQSTM1 (Serine 349), reveals expression of proteasome and N-glycanase1 interactive protein RAD23B and sensitizes human synovial fibroblasts to BAY 11-7085-induced cell death.
Spatial Organization of Proteasome Aggregates in the Regulation of Proteasome Homeostasis.
Starvation Induces Proteasome Autophagy with Different Pathways for Core and Regulatory Particles.
Stress induced nuclear granules form in response to accumulation of misfolded proteins in Caenorhabditis elegans.
Stress-induced polyubiquitination of proteasomal ubiquitin receptors targets the proteolytic complex for autophagic degradation.
Synergistic effects of TOR and proteasome pathways on the yeast transcriptome and cell growth.
The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
Tissue-specific changes of multicatalytic proteinase activity in the fasted rat.
To save or degrade: balancing proteasome homeostasis to maximize cell survival.
VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD.
WRKY42 Modulates Phosphate Homeostasis through Regulating Phosphate Translocation and Acquisition in Arabidopsis.
Yeast Dun1 kinase regulates ribonucleotide reductase inhibitor Sml1 in response to iron deficiency.
Status Epilepticus
Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
Stevens-Johnson Syndrome
ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs.
Stomach Neoplasms
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation.
ADRM1-amplified metastasis gene in gastric cancer.
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
ANXA1?derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
Benzoquinones from Cyperus spp. trigger IRE1?-independent and PERK-dependent ER stress in human stomach cancer cells and are novel proteasome inhibitors.
Caffeic acid phenethyl ester potentiates gastric cancer cell sensitivity to doxorubicin and cisplatin by decreasing proteasome function.
Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells.
Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability.
Degradation of retinoid X receptor alpha by TPA through proteasome pathway in gastric cancer cells.
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients.
Inhibition of proteasome function induced apoptosis in gastric cancer.
Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells.
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1.
Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp.
Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia.
The differential proteome profile of stomach cancer: identification of the biomarker candidates.
The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells.
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
[Screening and analysis of associated genes in the carcinogenesis and progression of gastric cancer]
Stroke
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Emerging roles of proteasomes in ischemia-reperfusion injury of organs.
Peripheral Artery Disease and Stroke.
Proteasome Assay in Cell Lysates.
Proteasome inhibitors: from research tools to drug candidates.
Small-molecule inhibitors of proteasome activity.
Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.
The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.
The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response.
The role of the ubiquitin proteasome system in ischemia and ischemic tolerance.
Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.
Supranuclear Palsy, Progressive
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Sweet Syndrome
Bortezomib-induced histiocytoid Sweet syndrome.
Bortezomib-Induced Sweet's Syndrome Confirmed by Rechallenge.
Synovitis
Regulation of synovial cell apoptosis by proteasome inhibitor.
Synucleinopathies
Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells.
In this issue: Proteomics 6/2008.
Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synucleinopathies and other chronic human neurodegenerative disease?
Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Tachycardia
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Tachycardia, Ventricular
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
Taste Disorders
Bortezomib alters sour taste sensitivity in mice.
Tauopathies
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline.
Clinicopathological correlations in behavioural variant frontotemporal dementia.
Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans.
Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.
In this issue: Proteomics 6/2008.
Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
TDP-43 Proteinopathies
Disease-Associated Mutations of TDP-43 Promote Turnover of the Protein Through the Proteasomal Pathway.
Telangiectasis
Human T-lymphotropic virus type 1 p30 interacts with REGgamma and modulates ATM (ataxia telangiectasia mutated) to promote cell survival.
Teratozoospermia
Identification of candidate causal genes and their associated pathogenic mechanisms underlying teratozoospermia based on the spermatozoa transcript profiles.
Testicular Neoplasms
Ubiquitin proteasome system and autophagy associated proteins in human testicular tumors.
Tetanus
[Relationship between hippocampal long term potentiation induction and activity of 26S proteasome]
Thrombocytopenia
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Proteasome function is required for platelet production.
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus.
Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
Regulatory role of proteasome in determination of platelet life span.
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Thrombosis
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats.
Proteasome proteolysis supports stimulated platelet function and thrombosis.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Thrombotic Microangiopathies
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Proteasome inhibitor associated thrombotic microangiopathy.
Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
Thrombotic microangiopathy associated with proteasome inhibitors.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Thymoma
Proteasome subunit ?5t expression in cervical ectopic thymoma.
Thyroid Carcinoma, Anaplastic
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Thyroid Diseases
Large multifunctional proteasome 2 gene Arg60His variant in autoimmune thyroid disease in Shanghai Chinese.
Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.
Thyroid Neoplasms
A systematic analysis of heart transcriptome highlights divergent cardiovascular disease pathways between animal models and humans.
Abnormally high expression of proteasome activator-gamma in thyroid neoplasm.
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Beclin 1 enhances proteasome inhibition-mediated cytotoxicity of thyroid cancer cells in macroautophagy-independent manner.
Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells.
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells.
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells.
Implication of Oxygen-Regulated Protein 150 (ORP150) in Apoptosis Induced by Proteasome Inhibitors in Human Thyroid Cancer Cells.
Induction of BAG2 protein during proteasome inhibitor-induced apoptosis in thyroid carcinoma cells.
Involvement of Nrf2 in proteasome inhibition-mediated induction of ORP150 in thyroid cancer cells.
miR-451a inhibits cancer growth, epithelial-mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8.
Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Proteasome Inhibition Induces a p38 MAPK Pathway-Dependent Antiapoptotic Program via Nrf2 in Thyroid Cancer Cells.
Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Quercetin-Induced Cell Death in Human Papillary Thyroid Cancer (B-CPAP) Cells.
REG? potentiates TGF-?/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells.
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells.
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms.
Thyroiditis
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice.
Thyroiditis, Autoimmune
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis.
Tics
Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
z-Leucinyl-Leucinyl-Norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response.
Tinnitus
Proteasome Activity in the Plasma as a Novel Biomarker in Mild Cognitive Impairment with Chronic Tinnitus.
Tonsillitis
Standard and immunoproteasomes expression in paediatric tonsillectomy patients.
Toxoplasmosis
Toxoplasma gondii infection of activated J774-A1 macrophages causes inducible nitric oxide synthase degradation by the proteasome pathway.
Tremor
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome.
Resveratrol Protects from Toxin-Induced Parkinsonism: Plethora of Proofs Hitherto Petty Translational Value.
Triple Negative Breast Neoplasms
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells.
Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Inhibition of the Proteasome ?2 Site Sensitizes Triple-Negative Breast Cancer Cells to ?5 Inhibitors and Suppresses Nrf1 Activation.
Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.
Lapatinib--induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.
Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Novel Copper Complexes That Inhibit the Proteasome and Trigger Apoptosis in Triple-Negative Breast Cancer Cells.
P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Trypanosomiasis, African
Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis.
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes.
Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.
Trypanocidal effect of alpha',beta'-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity.
Tuberculosis
"Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates.
A luminescence assay for natural product inhibitors of the Mycobacterium tuberculosis proteasome.
An adenosine triphosphate-independent proteasome activator contributes to the virulence of Mycobacterium tuberculosis.
Assembling proteomics data as a prerequisite for the analysis of large scale experiments.
Bacterial proteasome activator bpa (rv3780) is a novel ring-shaped interactor of the mycobacterial proteasome.
Binding-induced folding of prokaryotic ubiquitin-like protein on the Mycobacterium proteasomal ATPase targets substrates for degradation.
Characterization of the proteasome accessory factor (paf) operon in Mycobacterium tuberculosis.
Correction for Bai et al., Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Cytokinins beyond plants: synthesis by Mycobacterium tuberculosis.
Development of potential proteasome inhibitors against Mycobacterium tuberculosis.
Development of Tyrphostin Analogues to Study Inhibition of the Mycobacterium tuberculosis Pup Proteasome System*.
Discovery of new [Formula: see text] proteasome inhibitors using a knowledge-based computational screening approach.
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
Erratum to: Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach.
Fate of Pup inside the Mycobacterium Proteasome Studied by in-Cell NMR.
Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome.
Game of 'Somes: Protein Destruction for Mycobacterium tuberculosis Pathogenesis.
How ATPases unravel a mystery.
Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.
Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome.
Identification of substrates of the Mycobacterium tuberculosis proteasome.
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice.
Induced Folding Under Membrane Mimetic and Acidic Conditions Implies Undiscovered Biological Roles of Prokaryotic Ubiquitin-Like Protein Pup.
Inhibitors selective for mycobacterial versus human proteasomes.
Loss-of-Function Mutations in HspR Rescue the Growth Defect of a Mycobacterium tuberculosis Proteasome Accessory Factor E (pafE) Mutant.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.
Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity.
Mycobacterium tuberculosis proteasomal ATPase Mpa has a ?-grasp domain that hinders docking with the proteasome core protease.
Mycobacterium tuberculosis Proteasome Accessory Factor A (PafA) Can Transfer Prokaryotic Ubiquitin-Like Protein (Pup) between Substrates.
N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.
Novel Proteasome Inhibitors as Potential Drugs to Combat Tuberculosis.
Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.
Phosphorylation regulates mycobacterial proteasome.
Prokaryotic ubiquitin-like protein (Pup), proteasomes and pathogenesis.
Prokaryotic Ubiquitin-Like Protein and Its Ligase/Deligase Enyzmes.
Prokaryotic ubiquitin-like protein pup is intrinsically disordered.
Prokayrotic ubiquitin-like protein (Pup) proteome of Mycobacterium tuberculosis.
Proteasomal Control of Cytokinin Synthesis Protects Mycobacterium tuberculosis against Nitric Oxide.
Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome.
Pup, a prokaryotic ubiquitin-like protein, is an intrinsically disordered protein.
PUPylation provides the punch as Mycobacterium tuberculosis battles the host macrophage.
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.
Structural analysis of Mycobacterium tuberculosis homologues of the eukaryotic proteasome assembly chaperone 2 (PAC2).
Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis.
Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome.
Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
Structural insights on the Mycobacterium tuberculosis proteasomal ATPase Mpa.
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
Survival in Hostile Conditions: Pupylation and the Proteasome in Actinobacterial Stress Response Pathways.
Targeting proteasomes in infectious organisms to combat disease.
The mycobacterial proteasomal ATPase Mpa forms a gapped ring to engage the 20S proteasome.
The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide.
The Mycobacterium tuberculosis proteasome: more than just a barrel-shaped protease.
The Mycobacterium tuberculosis Pup-proteasome system regulates nitrate metabolism through an essential protein quality control pathway.
The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.
The Pup-Proteasome System of Mycobacteria.
The Pup-Proteasome System of Mycobacterium tuberculosis.
Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis.
[Establishment of a Mycobacterium tuberculosis proteasome inhibitor model in vitro].
Tuberous Sclerosis
mTORC1 signaling activates NRF1 to increase cellular proteasome levels.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
ubiquitinyl hydrolase 1 deficiency
Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity.
Uremia
Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
Renal cytoplasmic proteasome proteinase activities are altered in chronic renal failure.
Salmon spawning migration and muscle protein metabolism: the August Krogh principle at work.
The balance between glucocorticoids and insulin regulates muscle proteolysis via the ubiquitin-proteasome pathway.
The search for the uremic toxin: the case for metabolic acidosis.
Ureteral Obstruction
Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo.
Urinary Bladder Neoplasms
Bladder cancer detection using a peptide substrate of the 20S proteasome.
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
Core and specific network markers of carcinogenesis from multiple cancer samples.
Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells.
Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells.
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
[Chymotripsin-like activity and subunit composition of proteasomes in human cancers].
uroporphyrinogen-iii synthase deficiency
Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Urticaria
High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Uterine Cervical Neoplasms
?,?-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.
A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir.
Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8 + T cell immune response and antitumor effects in a preclinical cervical cancer model.
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.
Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry.
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Enhanced Efficacy against Cervical Carcinomas through Polymeric Micelles Physically Incorporating the Proteasome Inhibitor MG132.
Genetic polymorphisms of proteasome subunit genes of the MHC-I antigen-presenting system are associated with cervical cancer in a Chinese Han population.
High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Molecular biology of cervical cancer.
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Proteasome inhibition can impair caspase-8 Activation upon sub-maximal Stimulation of apoptotic tumour necrosis factor-related apoptosis inducing ligand (TRAIL) signalling.
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Proteasome inhibitors induce AMPK activation via CaMKK? in human breast cancer cells.
PSMD9 expression correlates with recurrence after radiotherapy in patients with cervical cancer.
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Suppression of HIF-1? accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer.
The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]
Uveitis
Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
High Levels of Serum Ubiquitin and Proteasome in a Case of HLA-B27 Uveitis.
Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis.
Uveitis, Anterior
Polymorphism in the LMP2 gene influences the relative risk for acute anterior uveitis in unselected patients with ankylosing spondylitis.
Vaccinia
Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides.
Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.
Post-translational regulation of rotavirus protein NSP1 expression in mammalian cells.
Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation.
Varicocele
Functional Analysis of Differentially Expressed Acetylated Spermatozoal Proteins in Infertile Men with Unilateral and Bilateral Varicocele.
Vascular Diseases
Bortezomib Alleviates Experimental Pulmonary Arterial Hypertension.
Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging.
Proteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stress-induced death.
Vascular System Injuries
Caspase-3-dependent apoptosis in vascular smooth muscle cell by proteasome inhibition.
The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection.
The proteasome as a target for prevention of restenosis following vascular injury.
Vasculitis
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
The proteasome is a major autoantigen in multiple sclerosis.
Vasospasm, Intracranial
Proteasome function is required for platelet production.
Venous Thrombosis
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Concepts in cardiac oncology.
Vesicular Stomatitis
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities.
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
The ubiquitin-vacuolar protein sorting system is selectively required during entry of influenza virus into host cells.
Virus Diseases
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
A novel mechanism for immune regulation after human lung transplantation.
Activity-based profiling of the proteasome pathway during hepatitis C virus infection.
Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
Constitutive and interferon-gamma-induced expression of the human proteasome subunit multicatalytic endopeptidase complex-like 1.
Cullin E3 ligases and their rewiring by viral factors.
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
Dynamic interactions between Bombyx mori nucleopolyhedrovirus and its host cells revealed by transcriptome analysis.
Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Grass carp reovirus capsid protein interacts with cellular proteasome subunit beta-type 7: Evidence for the involvement of host proteasome during aquareovirus infection.
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays.
Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection.
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.
Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Inhibition of the host proteasome facilitates papaya ringspot virus accumulation and proteosomal catalytic activity is modulated by viral factor HcPro.
Interaction of the Tobacco mosaic virus replicase protein with a NAC domain transcription factor is associated with the suppression of systemic host defenses.
Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis.
Modification of cytoskeleton and prosome networks in relation to protein synthesis in influenza A virus-infected LLC-MK2 cells.
Plant immunity against viruses: antiviral immune receptors in focus.
Plant Virus Infection and the Ubiquitin Proteasome Machinery: Arms Race along the Endoplasmic Reticulum.
Potential roles of microRNAs and their target genes in human multiple myeloma.
Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Proteasome subunit beta type-8 from sevenband grouper negatively regulates cytokine responses by interfering NF-?B signaling upon nervous necrosis viral infection.
Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage.
PSMB1 Negatively Regulates the Innate Antiviral Immunity by Facilitating Degradation of IKK-?.
Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection.
Rice stripe Tenuivirus nonstructural protein 3 hijacks the 26S proteasome of the small brown planthopper, via direct interaction with regulatory-particle non-ATPase subunit 3.
Roles of the two distinct proteasome pathways in hepatitis C virus infection.
Rotavirus replication requires a functional proteasome for effective assembly of viroplasms.
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
The ER quality control and ER associated degradation machineries are vital for viral pathogenesis.
The immunoproteasome and viral infection: a complex regulator of inflammation.
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection.
The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.
The ubiquitin-proteasome system regulates the accumulation of Turnip yellow mosaic virus RNA-dependent RNA polymerase during viral infection.
TRIM5? Degradation via Autophagy Is Not Required for Retroviral Restriction.
Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells.
Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases.
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.
Vitamin D Deficiency
Vitamin D Deficiency Induced Muscle Wasting Occurs through the Ubiquitin Proteasome Pathway and Is Partially Corrected by Calcium in Male Rats.
Vitiligo
A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.
Waldenstrom Macroglobulinemia
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia.
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
How to Sequence Therapies in Waldenström Macroglobulinemia.
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Ixazomib-induced cutaneous necrotizing vasculitis.
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia.
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Proteasome inhibitors in Waldenström macroglobulinemia.
Proteasome Inhibitors in Waldenström Macroglobulinemia.
Role of proteasome inhibition in Waldenström's macroglobulinemia.
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature.
Wasting Syndrome
Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.
Insulin suppresses the increased activities of lysosomal cathepsins and ubiquitin conjugation system in burn-injured rats.
Mechanisms of skeletal muscle atrophy.
Sex Differences in Muscle Wasting.
West Nile Fever
West Nile virus genome amplification requires the functional activities of the proteasome.
Whooping Cough
Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation.
The pertussis toxin S1 subunit is a thermally unstable protein susceptible to degradation by the 20S proteasome.
Wound Infection
Pseudomonas syringae pv. syringae uses proteasome inhibitor syringolin A to colonize from wound infection sites.
Xeroderma Pigmentosum
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells.
Erythropoietic Defect Associated with Reduced Cell Proliferation in Mice Lacking the 26S Proteasome Shuttling Factor Rad23b.
Regulation of repair by the 26S proteasome.
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-?B and AP-1 signalling.
Yersinia Infections
Yersinia enterocolitica impairs activation of transcription factor NF-kappaB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor alpha production.
Zika Virus Infection
An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication.
NS5-independent Ablation of STAT2 by Zika virus to antagonize interferon signalling.
Quantitative Proteomic Analysis of Mosquito C6/36 Cells Reveals Host Proteins Involved in Zika Virus Infection.
Therapeutic applications of Peptides against Zika Virus: A Review.